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Abstract	
The	IBD	Control	Questionnaire:		the	development	and	psychometric	validation	of	a	
questionnaire	 for	 measuring	 inflammatory	 bowel	 disease	 control	 from	 the	
patient’s	perspective.	
Clare	Ormerod	Introduction:	 	 The	 importance	 of	 patient	 reported	 outcome	 measures	 (PROMs)	 is	increasingly	recognised.		However,	their	use	in	inflammatory	bowel	disease	(IBD)	care	is	not	widespread.		The	aim	of	this	research	was	to	develop	and	validate	a	PROM	for	use	in	day	to	day	clinical	practice.	Methods:	(1)	Questionnaire	development:		Questionnaire	specification	was	determined	by	 a	 multidisciplinary	 steering	 group.	 	 Literature	 review	 of	 existing	 PROMs	 was	undertaken.		Focus	groups	meetings	and	one-to-one	patient	interviews	were	performed.		Participants	 were	 asked	 to	 discuss	 the	 concept	 of	 “control”	 of	 their	 IBD.	 	 Thematic	analysis	of	field	notes	and	transcribed	quotes	was	performed.		A	draft	questionnaire	was	designed	and	a	pilot	study	of	30	patients	was	undertaken.		(2)	Prospective	validation	of	the	IBD	Control	Questionnaire:			Patients	completed	the	IBD-Control	Questionnaire	and	the	following	established	measures:		a	quality	of	life	questionnaire	(UK-IBD-Q),	EuroQol	(EQ-5D)	and	the	Hospital	Anxiety	and	Depression	Score.	 	Disease	activity	indices	were	recorded	 (Harvey-Bradshaw	 Index	 or	 Simple	Clinical	 Colitis	 Activity	 Index).	 	 A	 global	physician	assessment	(blinded	to	questionnaire	score)	was	also	performed.		Data	were	recorded	at	baseline	and	subsequent	hospital	visits.		The	psychometric	properties	of	the	questionnaire	were	determined	as	detailed	below.	Results:		Core	domains	of	“physical”,	“social”,	“emotional”	and	“treatment”	were	identified	on	the	basis	of	literature	review	and	patient	consultation.		The	pre-defined	questionnaire	specification	was	used	 to	guide	 item	selection	 to	 represent	 these	domains.	 	The	 ‘IBD-Control’	questionnaire	comprises	13	items	plus	a	visual	analogue	scale	(VAS)	(0–100).		299	 patients	 returned	 baseline	 surveys	 (Crohn's	 disease,	 n=160;	 ulcerative	 colitis,	n=139)	and	138	attended	for	repeat	visits.	Completion	time	(mean;	SD):	1	min	15	s;	25	s;	Internal	 consistency:	 Cronbach's	 α	 for	 all	 13	 items	 (0.85);	 for	 subgroup	 of	 eight	questions	 (‘IBD-Control-8’;	 0.86).	 Strong	 correlation	 between	 IBD-Control-8	 and	 IBD-Control-VAS	(r=0.81).	Test-retest	reliability	(2	week	repeat):	intra-class	correlation=0.97	for	IBD-Control-8	and	0.96	for	IBD-Control-VAS.	Construct	validity:	Moderate-to-strong	correlations	 between	 IBD-Control-8	 and	 IBD-Control-VAS	 versus	 activity	 indices,	 UK-IBD-Q	 and	 EQ-5D	 (utility)	 with	 r	 values	 0.52–0.86.	Discriminant	 validity	(mean	instrument	scores	for	remission,	mild,	moderate	or	severe):	p<0.001	(analysis	of	variance	(ANOVA)).	Sensitivity	 to	 change:	 Effect	 sizes:	 0.76–1.44.	 	 Sensitivity	 and	 specificity	 to	
identify	quiescent	patients:	 	area	under	the	receiver	operating	characteristic	curve	0.90	IBD	Control	8,	0.86	IBD	Control	VAS.	 	Cut	off	values	 for	 identifying	quiescent	patients:		IBD	Control	8	-	13	points	or	more	90.6%	specificity,	IBD	Control	VAS	–	85	points	or	more	90%	specificity.	Conclusion:		The	IBD	Control	Questionnaire	is	a	valid	patient	reported	measure	of	disease	control.		Its	brevity	and	generic	content	make	it	suited	to	routine	clinical	care.	
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Chapter	1	Introduction	
	The	 need	 to	 measure	 health	 status	 from	 the	 patient’s	 perspective	 is	 becoming	increasingly	recognised.	 	Patient	reported	outcome	measures	are	now	used	to	monitor	quality	of	healthcare	within	 the	National	Health	Service	and	 there	 is	ongoing	work	 to	develop	their	use	further.		Patient	reported	outcome	measures	might	also	play	a	role	in	other	aspects	of	healthcare	such	as	informing	day-to-day	clinical	decision-making[1].		Inflammatory	 bowel	 disease	 (IBD)	 is	 a	 chronic	 disorder	 of	 the	 gastro-intestinal	 tract.		Whilst	a	number	of	patient	reported	outcome	measures	have	been	developed	for	use	in	IBD,	to	date	none	have	become	established	in	routine	clinical	care.	 	This	study	aims	to	develop	and	validate	a	new	patient	 reported	outcome	measure	 for	use	 in	 the	 routine	clinical	care	of	patients	with	inflammatory	bowel	disease.	
	
1.1	 	 Inflammatory	bowel	disease		
1.1.1	 	 Definition		Inflammatory	bowel	disease	is	a	chronic	inflammatory	disorder	of	the	gastro-intestinal	tract	and	comprises	of	two	main	conditions:		ulcerative	colitis	and	Crohn’s	disease.		Ulcerative	colitis	is	defined	as	a	chronic	inflammatory	condition	resulting	in	continuous	mucosal	 inflammation	 of	 the	 colon.	 	 Inflammation	 involves	 the	 rectum	 as	well	 as	 the	remaining	colon	to	a	variable	extent.		Inflammation	is	continuous.		There	is	an	absence	of	granulomata	in	histological	specimens[2].	
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	Crohn’s	disease	is	characterised	by	patchy	inflammation	with	skip	lesions.		It	can	affect	any	part	of	the	gastro-intestinal	tract	and	inflammation	is	transmural.		Crohn’s	disease	is	defined	 by	 location	 as	 well	 as	 behaviour	 (for	 example,	 the	 presence	 of	 fistulating	disease)[3].		A	 small	proportion	of	patients	with	 colitis	 cannot	be	diagnosed	with	either	ulcerative	colitis	or	Crohn’s	colitis	on	the	basis	of	standard	investigation	modalities.	 	These	cases	are	termed	“IBD	unclassified	“	(IBDU)[2].		The	Montreal	classification	of	inflammatory	bowel	disease	aims	to	define	IBD	on	the	basis	of	both	disease	distribution	and	behaviour.		Ulcerative	colitis	is	classified	on	the	basis	of	distribution	(extent):		E1-proctitis	(disease	limited	to	the	rectum),	E2-left	sided	disease	(inflammation	 distal	 to	 the	 splenic	 flexure)	 and	 E3-extensive	 (involvement	 extends	proximal	to	the	splenic	flexure)	(Figure	1).	 	Crohn’s	disease	classification	involves	age,	distribution	and	disease	behaviour	(Figure	2)[2].		Classification	of	IBD	is	of	use	to	guide	clinical	management	and	is	also	of	benefit	in	clinical	trials.				
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Figure	1	The	Montreal	classification	of	ulcerative	colitis[2]	
	 	 Description	 Extent	E1	 Proctitis	 Inflammation	limited	to	rectum		E2	 Left-sided	(distal)	colitis	 Inflammation	 beyond	 rectum,	 but	 distal	 to	 the	splenic	flexure	E3	 Extensive	colitis	 Inflammation	proximal	to	the	splenic	flexure				
Figure	2	The	Montreal	classification	of	Crohn’s	disease[2]	
	 Age	 Location	 Behaviour	A1	less	than	16		 L1	Ileal	 B1	 Non-stricturing,	 non-penetrating	A2	17	to	40		 L2	Colonic	 B2	Penetrating	A3	over	40		 L3	Ileo-colonic	 B3	Stricturing		 L4*	Isolated	upper	GI	disease		 p**		perianal	disease		*L4	is	added	to	L1-L3	if	upper	GI	disease	is	also	present	**p	is	added	to	B1-B3	if	perianal	disease	is	also	present		
1.1.2	 	 Epidemiology		Inflammatory	bowel	disease	is	a	disorder	of	industrialised	countries	and	is	most	common	in	areas	such	as	Northern	Europe,	the	United	Kingdom	and	Northern	America	[4].		The	annual	incidence	of	IBD	in	Europe	per	100	000	population	per	year,	has	been	estimated	at	5.4	for	Crohn’s	disease,	8.2	for	ulcerative	colitis	and	1.7	for	IBDU	(IBD	unclassified)[5].		Within	 industrialised	 countries,	 the	 incidence	 of	 ulcerative	 colitis	 was	 first	 to	 rise,	followed	 by	 Crohn’s	 disease.	 	 The	 incidence	 of	 ulcerative	 colitis	 has	 now	 stabilised,	whereas	that	of	Crohn’s	disease	has	continued	to	rise.		Of	note,	the	incidence	of	Crohn’s	disease	presenting	in	childhood	is	rising	[6].			
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The	 epidemiology	 of	 IBD	 is	 changing	globally.	 	Whilst	 incidence	 and	 prevalence	 have	stabilised	 in	 developed	 areas,	 there	 has	 been	 a	 rise	 in	 cases	 of	 IBD	 in	 developing	countries.		There	seems	to	be	an	increase	in	incidence	of	IBD	as	countries	transition	from	developing	 to	 industrialised	 nations.	 	 This	 phenomenon	 supports	 the	 view	 that	environmental	risk	factors	play	a	key	role	in	the	development	of	IBD	[7].		
1.1.3	 	 Risk	factors	
	A	number	of	risk	factors	for	IBD	have	been	identified.		Smoking	is	a	risk	factor	for	Crohn’s	disease	and	meta-analysis	suggests	a	 two	fold	increase	risk	 in	smokers[8].	 	Moreover,	smoking	will	also	increase	the	risk	of	an	adverse	clinical	course	of	the	disease.		Smokers	are	more	likely	to	have	ileal	disease[9],	less	likely	to	have	an	inflammatory	phenotype[10]	and	more	likely	to	have	recurrent	disease	following	surgery[11].		Smokers	are	also	more	likely	to	need	immunosuppression[12].		In	 contrast	 to	 Crohn’s	 disease,	 smoking	 and	 ulcerative	 colitis	 are	 inversely	associated[13].		The	mechanism	for	this	has	not	been	identified.		Smoking	also	seems	to	be	protective	for	conditions	associated	with	ulcerative	colitis	such	as	primary	sclerosing	cholangitis[14]	and	pouchitis[15].		Previous	appendicectomy	is	also	inversely	related	to	ulcerative	colitis.		A	meta-analysis	has	 shown	 a	 69%	 reduction	 in	 risk	 of	 development	 of	 ulcerative	 colitis	 following	appendicectomy	[16].		Data	are	limited	and	at	times	conflicting.			However,	most	studies	have	suggested	that	appendicectomy	is	protective[17].		
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Previous	 appendicectomy	has	 been	 shown	 to	 increase	 the	 risk	 of	 developing	 Crohn’s	disease.	 	A	large	cohort	study	has	shown	an	increased	risk	of	Crohn’s	disease	with	the	exception	of	children	undergoing	the	procedure	under	the	age	of	10	(in	whom	this	was	a	protective	 factor	 against	 Crohn’s	 disease).	 	 It	 was	 also	 noted	 that	 patients	 requiring	surgery	for	a	perforated	appendix	subsequently	developed	more	severe	Crohn’s[18].		The	mechanism	 by	which	 appendicetomy	 affects	 the	 risk	 of	 ulcerative	 colitis	 and	 Crohn’s	disease	is	not	clear.		There	 is	 some	 evidence	 that	 the	 use	 of	 oral	 contraceptives	 may	 increase	 the	 risk	 of	developing	IBD.		A	metanalysis	has	shown	an	association	between	oral	contraceptive	use	and	ulcerative	 colitis	 and	Crohn’s	disease	 (RR	 for	Crohn’s	disease	1.46	 (95%	CI	1.26-1.70),	RR	for	UC	1.28	(95%	CI	1.06-1.54))[19].		The	mechanism	of	this	association	is	not	known.		There	 have	 been	 many	 observational,	 population	 based	 and	 case	 control	 studies	 on	possible	dietary	risk	factors	for	IBD.		However,	investigation	into	potential	dietary	risk	factors	has	been	limited	by	difficulties	interpreting	results,	possible	recall	bias,	as	well	as	results	not	being	reproducible	in	some	studies	[7].		Several	 case	 controlled	 studies	 have	 reported	 a	 link	 between	 high	 sugar	 intake	 and	IBD[20].		Dietary	fat	has	also	been	linked	to	IBD	in	some	epidemiological	studies	[21,	22].		Overall,	whilst	the	role	of	dietary	antigens	in	IBD	is	likely	clear	dietary	triggers	have	not	been	identified.		
	
 23 
1.1.4	 	 Pathophysiology		The	 pathophysiology	 of	 inflammatory	 bowel	 disease	 is	 complex	 and	 as	 yet,	 not	 fully	understood.	 	The	consensus	view	is	that	IBD	develops	due	to	a	genetically	determined	abnormal	 response	 to	 commensal	 organisms	 within	 the	 gastro-intestinal	 tract.		Furthermore,	 this	 abnormal	 response	 is	 affected	 by	 a	 number	 of	 environmental	triggers[23].		There	 is	 epidemiological	 evidence	 of	 the	 role	 of	 genetics	 in	 the	 development	 of	 IBD.		Around	 10%	 of	 people	 with	 IBD	 report	 a	 positive	 family	 history.	 	 The	 concordance	between	monozygous	twins	 is	also	moderately	high[24].	 	A	number	of	genetic	studies	have	shown	that	single	genetic	mutations	may	result	in	IBD.		However,	not	all	subjects	with	these	mutations	will	go	on	to	develop	IBD[25,	26].		Hence,	it	is	more	likely	that	IBD	consists	of	several	different	phenotypes,	which	are	affected	by	genetic	and	environmental	factors	to	differing	extents[23].		As	 detailed	 above,	 inflammatory	 bowel	 disease	 is	 likely	 due	 to	 an	 abnormal	 immune	response	 to	 the	 commensal	organisms	of	 the	gut.	 	A	number	of	 genes	 that	have	 been	implicated	 in	 IBD	 play	 a	 role	 in	 this	 response.	 	 For	 example,	 genes	 involved	 in	 the	regulation	of	innate	and	adaptive	immunity	including	IL10,	STAT3	and	JAK2.		CCR6	and	MST1	are	involved	in	regulating	inflammation	and	genes	such	as	ORMDL3	and	IRGM	are	involved	in	the	regulation	of	autophagy[23].		It	 is	 estimated	 that	 more	 than	 400	 species	 of	 bacteria	 exist	 within	 the	 human	intestine[27].		The	microbiota	provides	a	huge	antigen	load	and	is	responsible	for	driving	
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the	mucosal	inflammatory	response.		The	composition	of	the	microbiome	can	be	affected	by	genetic	factors[23].		Paneth	 cells	 exist	 within	 the	 intestinal	 epithelium.	 	 These	 secrete	 a	 number	 of	antimicrobial	peptides	 including	α-defensins	 in	response	to	 inflammation[28].	 	Paneth	cell	 function	 can,	 therefore,	 be	 affected	 by	 environmental	 factors	 that	 result	 in	inflammation	and	can	also	affect	the	composition	of	the	microbiome	as	a	consequence	of	their	function.		Genetic	risk	factors	for	IBD	such	as	NOD2[29]	play	a	role	in	Paneth	cell	functioning[23].		NOD2	 is	 also	 involved	 in	 the	 regulation	 of	 autophagy	 (the	 lysosomsal	 destruction	 of	ingested	 pathogens)[30].	 	 Mutations	 in	 NOD2	 are	 also	 believed	 to	 result	 in	 a	 lack	 of	intestinal	mucosal	tolerance	to	bacteria[31].		All	these	points	suggest	NOD2	plays	a	role	in	 the	 interaction	between	bacteria	and	 the	 intestinal	mucosa	and	may	be	affected	by	environmental	factors[23].		Finally,	highly	secretory	cells	such	as	those	of	the	intestinal	epithelium	are	sensitive	to	ER	(endoplasmic	reticulum)	stress.	 	This	tends	to	be	as	a	result	of	the	accumulation	of	unfolded	or	mis-folded	proteins.		Genes	involved	in	protecting	against	ER	stress	have	also	been	implicated	in	IBD[32].		Environmental	factors	may	affect	the	cellular	response	to	ER	stress.		Given	the	close	link	between	the	gut	microbiome	and	the	intestinal	immune	system,	it	is	hypothesised	 that	 the	 effect	 of	 environmental	 factors	 on	 genetically	 susceptible	individuals	 is	 via	 their	 effect	 on	 the	microbiome[23].	 	 Altered	 composition	of	 the	 gut	
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microbiota	has	been	identified	in	individuals	with	IBD.	A	proportion	of	patients	with	IBD	have	a	reduced	abundance	and	diversity	of	Bacteroidetes,	with	a	maintenance	or	bloom	of	 Proteobacteria	 [33]	 [34].	 	 F	 prausnitzii	 levels	 are	 reduced	 in	 IBD	 and	 low	 levels	 F	prausnitzii	have	been	linked	to	an	increased	risk	of	post-operative	recurrence	in	Crohn’s	disease[35].		In	 summary,	 the	 pathogenesis	 of	 IBD	 is	 a	 complex	 process	 in	 which	 the	 intestinal	microbiota	play	a	role.	 	It	is	likely	that	IBD	arises	in	genetically	susceptible	individuals	when	certain	environmental	factors	are	present.		
1.1.5	 	 Clinical	features		The	 clinical	 features	 of	 both	 ulcerative	 colitis	 and	 Crohn’s	 disease	 are	 determined	 by	disease	location	and	in	the	case	of	Crohn’s	disease,	disease	behaviour.		The	presence	of	blood	with	or	without	mucous	 in	 the	stools	 is	 the	hallmark	 feature	of	ulcerative	colitis.		Onset	of	symptoms	tends	to	be	insidious	and	the	clinical	course	of	UC	is	that	of	periods	of	relapse	and	remission.		Active	disease	of	the	rectum	is	also	associated	with	symptoms	such	as	urgency	and	tenesmus.		Inflammation	proximal	to	this	may	also	lead	to	symptoms	such	as	chronic	diarrhoea	and	abdominal	pain[36].		The	prognosis	of	ulcerative	colitis	has	been	shown	to	be	good	over	the	first	10	years	following	diagnosis	with	a	low	risk	of	colectomy[37].		Crohn’s	 disease	 may	 present	 in	 a	 number	 of	 ways,	 although	 the	 most	 common	presentation	is	that	of	chronic	diarrhoea	[38].	 	Other	features	include	abdominal	pain,	
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weight	 loss	 and	 anaemia.	 	 Crohn’s	 disease	 may	 also	 present	 acutely	 with	 severe	abdominal	pain	due	to	acute	terminal	ileitis[39].				The	transmural	nature	of	the	inflammation	associated	with	Crohn’s	disease	means	it	may	be	complicated	by	strictures,	abscesses	or	fistulating	disease.		The	presence	of	perianal	disease,	a	young	age	at	diagnosis	and	the	need	for	steroids	at	presentation	have	been	shown	 to	 be	 associated	 with	 a	 high	 risk	 of	 disabling	 disease	 within	 five	 years	 of	diagnosis[40].		Inflammatory	bowel	disease	may	be	complicated	by	extra-intestinal	disorders.		These	can	be	 classified	 as	 either	 reactive	 manifestations	 or	 co-existing	 autoimmune	 disorders.		Reactive	 manifestations	 are	 associated	 with	 active	 inflammatory	 bowel	 disease	 and	include	conditions	such	as	arthropathy,	uveitis	and	the	cutaneous	conditions	erythema	nodosum	 and	 pyoderma	 gangrenosum.	 The	 increased	 incidence	 of	 co-existing	autoimmune	disorders	such	as	ankylosing	spondylitis,	autoimmune	thyroid	disease	and	alopecia	 reflects	 a	 common	 susceptibility	 to	 autoimmune	disorders.	 	 Only	 ankylosing	spondylitis	is	specific	to	IBD	and	activity	of	co-exiting	autoimmune	disorders	do	not	tend	to	be	linked	to	activity	of	IBD[41].		In	 addition	 to	 the	 reactive	 skin	 manifestations	 of	 erythema	 nodosum	 and	 pyoderma	gangrenosum,	other	dermatological	conditions	associated	with	IBD	include	vitiligo	and	psoriasis[42].	 	 Cutaneous	 adverse	 effects	 of	medication	may	 also	 occur	 and	 anti-TNF	antibody	induced	psoriasis	is	a	rare	side	effect	of	treatment[43].		
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A	number	of	hepatobiliary	conditions	are	associated	with	IBD.		Typically,	these	are	not	related	 to	 IBD	 activity.	 	 Primary	 sclerosing	 cholangitis	 (PSC)	 is	 the	 most	 common	hepatobiliary	disorder	associated	with	IBD	[44].	 	Small	duct	PSC[45]	and	autoimmune	hepatitis/primary	 sclerosing	 cholangitis	 overlap	 syndrome	 [46]	 have	 also	 been	described	in	patients	with	inflammatory	bowel	disease.		In	 addition	 to	 the	 hepatobiliary	 disorders	 described	 above,	 cholelithiasis	 is	 more	common	 in	 patients	 with	 Crohn’s	 disease[47]	 and	 portal	 vein	 thrombosis	 has	 been	described	as	a	complication	of	IBD	[48].		Abnormal	liver	function	tests	may	also	be	related	to	medication	 and	many	medications	 used	 to	 treat	 IBD	 are	 associated	with	 a	 risk	 of	hepatotoxicity[49].		Severely	 active	 colitis	 may	 be	 complicated	 by	 haemorrhage,	 toxic	 megacolon	 and	perforation.		Patients	with	IBD	are	also	at	higher	risk	of	thromboembolic	complications,	particularly	whilst	their	disease	is	active	and	in	cases	of	pancolitis	[50].		Patients	with	ulcerative	colitis	are	at	increased	risk	of	colorectal	cancer	compared	to	the	general	population.	 	Reported	risk	estimates	are	variable	and,	on	balance,	it	if	felt	that	whilst	 ulcerative	 colitis	 does	 confer	 and	 increased	 risk	 of	 colonic	 cancer,	 the	 risk	 is	probably	lower	than	originally	thought[51].		The	risk	of	colorectal	cancer	is	affected	by	disease	duration	with	a	cumulative	risk	of	2%	at	10	years,	8%	at	20	years	and	18%	at	30	years	reported.		Risk	is	also	affected	by	disease	extent	with	extensive	colitis	associated	with	the	highest	risk	and	distal	colitis	with	an	intermediate	 risk.	 	 Proctitis	 does	 not	 increase	 the	 risk	 of	 colorectal	 cancer	
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development[52].		The	presence	of	co-existing	primary	sclerosing	cholangitis	(PSC)	and	a	family	history	of	colonic	cancer	are	also	associated	with	an	increased	risk[53].			
1.1.6	 	 Management	
	The	 management	 of	 inflammatory	 bowel	 disease	 requires	 coordinated	 input	 from	 a	multi-disciplinary	team	including	gastroenterologists	and	colorectal	surgeons	as	well	as	dietitians	and	specialist	nurses.		Medical	therapies	remain	central	to	the	management	of	IBD.	 	Whilst	long	established	treatments	such	as	steroids	still	have	a	role	in	treatment,	the	development	of	new	 therapies	such	as	biological	 agents	has	greatly	 improved	 the	management	of	IBD	and	its	complications.		
1.1.6.1	 Medical	management	
	Mesalazine	(5-aminosalicylic	acid,	5-ASA)	acts	on	epithelial	cells	affecting	the	release	of	pro-inflammatory	factors	such	as	cytokines	as	well	as	inflammatory	cells.	 	There	are	a	number	of	oral	forms	of	mesalazine.		pH	dependent	release	and	time-controlled	release	preparations	exist.		A	multimatrix	delivery	system	has	also	been	developed.		Drugs	such	as	 balsalazide	 and	 olsalazine	 consist	 of	 mesalazine	 bound	 to	 a	 carrier	 molecule.		Mesalazine	is	then	released	due	to	the	action	of	bacterial	enzymes	within	the	colon[54].		Mesalazine	can	also	be	delivered	topically	in	the	form	of	enemas	or	suppositories.		Whilst	5-ASA	can	be	used	to	induce	remission	in	ulcerative	colitis,	its	main	role	is	in	the	maintenance	of	remission	[3].	 	Long	term	use	of	5-ASAs	has	been	shown	to	reduce	the	
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risk	 of	 colorectal	 cancer[55]	 and	 should	 therefore	 be	 considered	 in	 all	 patients,	particularly	with	extensive	disease.		5-ASAs	have	not	been	shown	to	produce	a	clinically	significant	 improvement	 in	active	Crohn’s	 disease[56],	 nor	 have	 they	 been	 shown	 to	 be	 of	 benefit	 in	 maintaining	remission[57].		Therefore,	the	use	of	5-ASAs	as	first	line	therapy	is	not	recommended	in	Crohn’s	disease	[3]		Corticosteroids	are	of	use	in	moderate	and	severe	flare-ups	of	both	Crohn’s	disease	and	ulcerative	colitis.	 	They	are	not	recommended	for	maintenance	of	remission.	 	Steroids	may	be	administered	parenterally,	orally	or	topically[3].		Oral	 prednisolone	has	 been	 shown	 to	 be	 effective	 in	 inducing	 remission	 in	ulcerative	colitis[58].	 	 It	 is	 recommended	 in	 patients	 with	 moderately	 active	 UC	 that	 has	 not	responded	to	mesalazine.		It	is	recommended	that	a	gradually	reducing	course	is	given	over	an	8-week	period	 in	order	 to	 reduce	 the	 risk	of	 early	 relapse[3].	 	Budesonide,	 a	poorly	absorbed	corticosteroid	with	less	systemic	side	effects,	has	been	shown	to	be	as	effective	 as	 prednisolone	 in	 the	 treatment	 of	 mild-moderate	 ulcerative	 colitis[59].		Topical	steroids	can	be	used	in	UC,	but	have	been	shown	to	be	less	effective	than	topical	5-ASA	preparations[60].		Prednisolone	 has	 been	 shown	 to	 be	 effective	 in	 inducing	 remission	 in	 Crohn’s	disease[61].	 	 However,	 the	majority	 of	patients	 do	 not	 remain	 in	 sustained	 remission	following	 their	 first	 course	 of	 steroids[62].	 	 	 Although	 slightly	 less	 effective	 than	
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prednisolone,	budesonide	is	an	alternative	corticosteroid	in	cases	of	moderately	active	ileocaecal	Crohn’s	disease	in	view	of	the	favourable	side	effect	profile[3].		The	thiopurines:		azathioprine	(AZA)	and	6-mercaptopurine	(6MP)	are	used	in	ulcerative	colitis	and	Crohn’s	disease.		Azathioprine	is	metabolised	to	6-mercaptopurine,	which	is	subsequently	metabolised	to	the	6-thioguanine	nucleotides	(6-TGN).		6-TGN	is	the	active	end	metabolite	of	AZA	and	6MP	and	acts	by	inducing	T-cell	apoptosis[63].		Azathioprine	 should	 be	 considered	 in	 steroid	 dependent	 ulcerative	 colitis	 or	 when	mesalazine	has	failed	or	cannot	be	tolerated[3].	 	However,	the	evidence	to	support	the	use	of	thiopurines	in	UC	is	not	of	high	quality	and	further	research	is	needed[64].		The	evidence	to	support	the	use	of	thiopurines	in	Crohn’s	disease	is	stronger	and	it	has	been	shown	to	be	an	effective	treatment	for	both	inducing	and	maintaining	remission	[65,	66].		Thiopurines	 should	 also	 be	 considered	 in	 steroid	 dependent	 or	 frequently	 relapsing	Crohn’s	disease.		Methotrexate	is	a	cytotoxic	agent	with	anti-inflammatory	properties.		It	has	been	shown	to	be	effective	in	Crohn’s	disease	for	both	induction	and	maintenance	of	remission	[67]	[68].		It	may,	therefore,	be	considered	as	a	second	line	agent	for	the	treatment	of	Crohn’s	disease	in	patients	unresponsive	or	intolerant	of	thiopurines.	 	Evidence	to	support	the	use	of	methotrexate	in	UC	is	not	as	strong.		However,	methotrexate	has	been	shown	to	be	effective	 in	 patients	 unresponsive	 or	 intolerant	 to	 thiopurines[69].	 	 For	 this	 reason	methotrexate	may	also	be	considered	as	a	second	line	therapy	for	maintaining	remission	in	ulcerative	colitis[3].		
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Ciclosporin	 is	a	calcinurin	 inhibitor	 that	may	be	used	as	a	rescue	therapy	(to	avoid	or	defer	colectomy)	in	acute	severe	ulcerative	colitis,	when	standard	treatment	has	failed.		Current	National	Institute	for	Health	and	Care	Excellence	(NICE)	guidelines	recommend	the	 use	 of	 ciclosporin	 in	 these	 cases,	 with	 infliximab	 to	 be	 used	 when	 ciclosporin	 is	contraindicated[70].		However,	whist	cyclosporin	has	been	shown	to	be	effective	in	the	short	term,	there	are	concerns	with	regard	to	toxicity	and	long-term	effectiveness[71].		The	Comparison	of	iNfliximab	and	ciclosporin	in	STeroid	Resistant	Ulcerative	Colitis	Trial	(CONSTRUCT)	is	a	large	randomised	controlled	trial	aimed	at	comparing	ciclosporin	and	infliximab	in	acute	severe	UC[72].		Ciclosporin	has	not	been	shown	to	be	of	use	in	Crohn’s	disease[73].		A	 number	 of	 biological	 agents	 have	 been	 developed	 for	 use	 in	 inflammatory	 bowel	disease.		Biological	therapies	are	antibodies	able	to	block	inflammatory	pathways.		The	anti-TNF	 agents,	 infliximab	 and	 adalimumab	 were	 the	 first	 biological	 agents	 to	 be	established	in	IBD	clinical	practice.		Infliximab	is	a	chimeric	antibody	consisting	of	murine	and	human	components	and	is	administered	via	an	intravenous	infusion.		Adalimumab	is	a	 fully	 humanised	 antibody	 and	 is	 administered	 via	 subcutaneous	 injection[3].	 	More	recently,	 golimumab	 has	 been	 developed.	 	 This	 is	 also	 a	 fully	 humanised	 anti-TNF	antibody	treatment,	administered	subcutaneously	on	a	four	weekly	basis[74].		There	is	good	evidence	to	support	the	use	of	infliximab	and	adalimumab	in	the	treatment	of	 Crohn’s	 disease.	 	 Infliximab	 has	 been	 shown	 to	 be	 effective	 in	 Crohn’s	 disease	unresponsive	to	standard	management[75].		It	has	subsequently	been	shown	to	maintain	remission	in	patients	responsive	to	initial	treatment[76].		Adalimumab	has	been	shown	to	be	effective	both	in	patients	that	have	not	received	previous	biological	agents[77]	and	
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in	those	who	failed	treatment	with	infliximab[78].		It	has	also	been	shown	to	be	effective	in	 maintaining	 remission[79].	 	 Infliximab	 and	 adalimumab	 have	 also	 been	 shown	 to	improve	 fistulating	Crohn’s	disease,	 although	 improvement	 in	non-perianal	 fistulating	disease	was	modest	[80]	[81].		Infliximab	 significantly	 reduces	 the	 90-day	 colectomy	 rate	 in	 acute	 severe	 ulcerative	colitis[82].		It	has	also	been	shown	to	be	effective	in	moderately	active	ulcerative	colitis	that	has	not	responded	to	standard	treatment[83].		Adalimumab	has	also	been	shown	to	be	effective	in	inducing	and	maintaining	remission	in	ulcerative	colitis[84].		Golimumab	has	also	been	shown	to	be	effective	in	inducing	remission	and	as	maintenance	therapy	 for	 ulcerative	 colitis[85,	 86]	 An	 open	 label,	 phase	 4	 trial	 in	 the	 UK	 has	 also	confirmed	it	is	both	efficacious	and	safe	for	the	treatment	of	moderate	to	severe	UC[87].		Infliximab,	adalimumab	and	golimumab	have	been	approved	by	NICE	for	use	in	moderate	to	severe	ulcerative	colitis,	following	failure	of	conventional	therapy	or	if	such	therapies	are	not	tolerated	or	contraindicated	[74].	Infliximab	is	recommended	for	patients	with	steroid	 refractory	 acute	 severe	 colitis	 in	 whom	 ciclosporin	 is	 contraindicated[70].		Infliximab	and	adalimumab	have	been	approved	for	use	in	severely	active	Crohn’s	disease	and	infliximab	has	been	approved	for	use	in	fistulating	Crohn’s	disease[88].		Vedolizumab	 is	 an	 a4b7	 integrin	 inhibitor.	 	 It	 blocks	a4b7	 integrins	 on	 gut-specific	leukocytes,	preventing	the	infiltration	of	leukocytes	into	the	gastrointestinal	submucosa.			It	 is	 administered	by	 intravenous	 infusion.	 	 It	 is	 effective	 in	 inducing	and	maintaining	remission	in	ulcerative	colitis	[89]	and	Crohn’s	disease	[90].		It	is	also	approved	by	NICE	
 33 
for	 use	 in	 moderately	 to	 severely	 active	 ulcerative	 colitis[91]	 and	 in	 moderately	 to	severely	active	Crohn’s	disease	if	an	anti	TNF	treatment	has	failed,	is	not	tolerated	or	is	contraindicated[92].		Ustekinumab	is	a	fully	humanised	monoclonal	antibody	that	blocks	interleukin-12	(IL-12)	 and	 interleukin-23	 (IL-23).	 	 This	 therefore	 inhibits	 IL-12	 and	 IL-23	mediated	 cell	signalling,	 activation	and	cytokine	production	[93].	 	 It	 is	 administered	by	 intravenous	loading	dose	and	then	by	subcutaneous	injection	for	maintenance.		It	has	been	shown	to	be	 efficacious	 in	 the	 induction	 of	 remission	 and	 for	 maintenance	 therapy	 in	 Crohn’s	disease[94]It	 is	 approved	 by	 NICE,	 	 for	 use	 in	moderately	 to	 severely	 active	 Crohn’s	disease	 if	 there	 has	 been	 loss	 of	 response	 to,	 intolerance	 of,	 or	 contraindications	 to	conventional	or	anti-TNF	treatment	[95].		Tofacitinib	 is	an	oral,	small	molecule	 Janus	kinase	(JAK)	 inhibitor.	 	 It	inhibits	all	 Janus	kinases,	 but	 preferentially	 affects	 JAK1	 and	 JAK3.	 	 Phase	 3	 trials	 have	 confirmed	tofacitinib	 to	 be	 effective	 at	 inducing	 and	 maintaining	 remission,	 in	 patients	 with	ulcerative	colitis	compared	to	placebo[96].		It	has	recently	been	approved	by	NICE	for	use	in	 moderately	 to	 severely	 active	 ulcerative	 colitis	 when	 conventional	 treatment	 or	biological	 treatment	 cannot	be	 tolerated,	or	 if	 there	 inadequate	or	 loss	of	 response	 to	these	treatments[97].		There	 is	 some	 evidence	 to	 support	 the	 use	 of	 the	 antibiotics	 ciprofloxacin	 and	metronidazole	as	disease	modifying	agents	in	Crohn’s	disease.		These	antibiotics	have	a	clear	role	in	the	management	of	perianal	sepsis	in	Crohn’s	disease.		However,	they	have	also	been	shown	to	improve	or	induce	remission	in	a	proportion	of	patients	with	perianal	
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fistulae.		Although	not	statistically	significant,	ciprofloxacin	appears	to	be	more	effective	and	 better	 tolerated	 than	 metronidazole	 [98].	 	 Metronidazole	 or	 ciprofloxacin	 are	recommended	as	first	line	therapy	for	pouchitis	(inflammation	of	the	pouch	following	an	ileo-anal	pouch	procedure)[3].		There	is	no	evidence	to	support	the	use	of	antibiotics	as	a	disease-modifying	agent	in	ulcerative	colitis.		Nutrition	is	an	important	aspect	of	IBD	care,	not	least	due	to	the	high	rates	of	malnutrition	in	patients	with	Crohn’s	disease	and	ulcerative	colitis.		There	is	also	evidence	to	suggest	that	an	exclusive	liquid	polymeric	diet	reduces	the	inflammatory	response	and	induces	remission	 in	 Crohn’s	 disease[99].	 	 Exclusive	 enteral	 nutrition	 is	 not	 of	 benefit	 in	ulcerative	 colitis.	 	 The	 probiotic	 VSL3	 is	 effective	 in	 maintaining	 remission	 in	pouchitis[100].		There	is	also	some	evidence	to	support	its	use	in	ulcerative	colitis[101]	although	this	approach	is	not	widely	used.		
1.1.6.2	 Surgical	management		Surgery	is	an	important	aspect	of	IBD	care	and	may	be	required	both	as	an	emergency	and	electively.		Whilst	the	use	of	“rescue	therapy”	in	acute	severe	ulcerative	colitis	may	defer	the	need	for	emergency	colectomy,	many	patients	will	need	surgery	in	the	future.		Sub-total	colectomy	and	end	ileostomy	is	required	in	acute	severe	colitis,	whilst	an	ileo-anal	pouch	procedure	(IPAA)	should	be	considered	in	elective	surgery[3].		The	 risk	 of	 requiring	 surgery	 for	 Crohn’s	 disease	 is	 increased	 over	 time	 following	diagnosis.		Surgery	is	most	likely	in	the	case	of	ileocaecal	disease[102].		A	large	proportion	
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of	 these	 patients	 will	 develop	 recurrent	 disease	 following	 surgery	 although	 will	 not	necessarily	be	symptomatic[103].		
1.1.7	 	 Goals	of	management	 	 	 		The	goal	of	treating	IBD	is	to	induce	and	maintain	remission.		However,	there	is	no	fully	validated	or	internationally	agreed	definition	of	remission.		The	definition	of	remission	depends	on	the	context	in	which	it	is	being	used.		For	example,	remission	in	clinical	trials	is	often	defined	on	the	basis	of	disease	activity	scores,	whereas	remission	at	a	patient	level	may	be	defined	as	improvement	of	symptoms	and	better	quality	of	life[104].		Standard	management	of	IBD	centres	on	control	of	symptoms	with	stepwise	introduction	of	increasingly	potent	medical	therapy.		However,	there	is	increasing	evidence	that	this	approach	does	not	improve	long	term	outcomes[105].		Whilst	 control	 of	 symptoms	 is	 of	 great	 importance	 to	 patients	 and	 will	 affect	 health	related	quality	of	life,	it	has	been	proposed	that	new	targets	for	therapy	are	required	in	order	 to	 prevent	 long-term	 bowel	 damage	 and	 complications.	 	 This	 “treat-to-target”	approach	 is	 based	 on	 the	 management	 of	 other	 inflammatory	 diseases	 such	 as	rheumatoid	arthritis	in	which	inflammation	in	treated	aggressively	in	order	to	prevent	joint	destruction.		Mucosal	healing,	as	defined	by	disappearance	of	ulceration,	has	been	shown	 to	 be	 an	 appropriate	 target	 for	 treatment	 in	 order	 to	 avoid	 long-term	complications	[106]	
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1.1.8	 	 Disease	activity	assessment	options		The	 importance	 of	 achieving	 mucosal	 healing	 and	 deep	 sustained	 remission	 are	increasingly	 recognised.	 	 Measuring	 disease	 activity,	 therefore,	 requires	 several	investigation	modalities	as	well	as	more	traditional	measures	such	as	the	disease	activity	indices.		Whilst	traditional	measures	such	as	disease	activity	indices	play	a	role,	there	is	increasing	 use	 of	 endoscopy	 and	 cross-sectional	 imaging	 as	 well	 as	 non-invasive	biomarkers	such	as	faecal	calprotectin.	
	
1.1.8.1	 Assessment	of	disease	extent,	activity	and	complications		Ileo-colonoscopy	remains	the	gold	standard	test	for	the	diagnosis	of	inflammatory	bowel	disease	as	well	as	for	the	assessment	of	disease	activity	and	extent.		Its	use	is	of	increasing	importance	 with	 regard	 to	 the	 need	 to	 assess	 mucosal	 healing	 and	 is	 often	 a	 key	investigation	 when	 initiating	 or	 withdrawing	 treatments	 such	 as	 biological	 agents.		Whilst	ileo-colonoscopy	has	excellent	diagnostic	properties	it	is	an	invasive	investigation	with	some	associated	risks.		It	will	also	miss	non-intestinal	pathology	[107].		Endoscopic	 scores	 have	 been	 developed	 in	 order	 to	 standardise	 the	 reporting	 of	endoscopic	 findings.	 	 The	 Crohn’s	 Disease	 Endoscopic	 Index	 of	 Severity	 (CDEIS)	 is	 a	complicated	 scoring	 system	which	 is	 mainly	 used	 in	 clinical	 trials[108].	 	 The	 Simple	Endoscopic	Score	for	Crohn’s	Disease	(SES-CD)	is	a	simplified	score,	suitable	for	routine	clinical	practice[109]	and	correlates	well	with	the	CDEIS[110].		The	Rutgeerts	score	can	be	used	to	grade	post	operative	recurrence	of	the	distal	 ileum	and	has	been	shown	to	predict	clinical	recurrence[103].	
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	A	number	of	endoscopic	scores	exist	for	use	in	UC	and	a	systematic	review	has	recently	been	undertaken[111].		Both	the	endoscopic	component	of	the	Mayo	score[112]	and	the	UC	endoscopic	index	of	severity[113]	have	been	shown	to	be	reliable	scoring	systems.		Small	bowel	capsule	endoscopy	(SBCE)	may	be	used	for	the	diagnosis	of	Crohn’s	disease.		However,	whilst	diagnostic	yield	is	high,	detected	changes	may	not	be	specific	to	Crohn’s	disease	and	there	is	no	means	of	obtaining	histological	specimens	[107].		Cross	sectional	imaging	also	plays	a	role	in	the	diagnosis	and	assessment	of	inflammatory	bowel	disease.		Ultrasound	(US)	is	quick,	cheap	and	does	not	involve	radiation.		It	is	of	use	for	examining	the	colon	and	terminal	ileum.		Results	may	be	affected	by	factors	such	as	obesity	and	are	dependent	on	operator	expertise[114].		Computed	 Tomography	 (CT),	 on	 the	 other	 hand,	 is	 a	 well-established	 and	 readily	available	investigation	modality.	 	CT	has	a	high	sensitivity	and	specificity	for	detecting	intestinal	 Crohn’s	 disease	 [115].	 	 It	 also	 allows	 the	 detection	 of	 extra-intestinal	complications	such	as	collections.	 	The	significant	disadvantage	of	CT	is	the	associated	radiation	dose,	which	is	of	importance	given	the	young	age	of	some	patients	as	well	as	the	potential	need	for	repeated	imaging.		CT	is	also	widely	used	in	the	management	of	ulcerative	colitis,	again	to	determine	disease	extent	and	detect	complications	such	as	perforation.		Although	some	studies	have	shown	correlation	of	CT	features	of	colitis	with	endoscopic	severity	scores	[116,	117],	endoscopy	
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remains	 the	 first	 line	 investigation	 for	assessing	disease	activity	 in	UC.	 	CT	 should	be	utilised	in	cases	such	as	impassable	strictures	or	when	complications	are	suspected[118].		Magnetic	resonance	imaging	(MRI)	of	the	small	bowel	is	now	becoming	more	available.		MRI	allows	visualization	of	the	GI	tract	without	overlapping	bowel	loops.		It	also	allows	real	time	functional	imaging	as	well	as	detection	of	extra-intestinal	complications.		More	importantly,	 MRI	 does	 not	 involve	 the	 use	 of	 radiation[119].	 	 Whilst	 CT	 and	 MRI	enterography	have	comparable	sensitivity	and	specificity	for	diagnosing	Crohn’s	disease	[115],	 MRI	 pelvis	 is	 the	 modality	 of	 choice	 for	 assessing	 pelvic	 disease	 [107].	 	 MR	colonography	has	been	reported	[120],	but	is	not	widely	used.		Biomarkers	are	also	of	use	for	measuring	disease	activity	of	inflammatory	bowel	disease	and	have	the	benefit	of	being	non-invasive	and	therefore	more	acceptable	to	patients.		C-reactive	protein	(CRP)	is	an	acute	phase	protein	and	a	routinely	available	blood	test.		It	can	 be	 used	 as	 a	 measure	 of	 disease	 activity.	 	 In	 the	 case	 of	 Crohn’s	 disease,	 it	 is	particularly	useful	in	patients	with	high	levels	of	CRP	at	diagnosis.		In	these	patients	it	is	a	sensitive	marker	of	disease	activity	as	well	as	a	predictor	of	relapse	[121].		More	recently,	interest	has	turned	to	the	use	of	faecal	biomarkers	such	as	calprotectin	and	 lactoferrin.	 	 Both	 have	 been	 shown	 to	 be	 able	 to	 detect	 colonic	 and	 ileo-colonic	disease,	but	not	Crohn’s	disease	confined	to	the	small	bowel[122].		Serial	measurement	of	faecal	calprotectin	can	be	used	to	monitor	disease	activity.		A	meta-analysis	has	shown	it	to	be	able	to	predict	disease	relapse	in	patients	with	quiescent	disease[123].	 	Faecal	biomarker	levels	have	also	been	shown	to	return	to	normal	in	patients	with	endoscopic	response	to	treatment[124].	
 39 
In	summary,	whilst	ileo-colonoscopy	is	the	gold	standard	investigation	for	the	diagnosis	of	Crohn’s	disease,	other	investigation	modalities	are	important	particularly	for	detecting	complications	such	as	collections	or	fistulae.		There	is	increasing	evidence	to	support	the	use	of	non-invasive	biomarkers.	 	Investigation	selection	should	be	based	on	individual	patient	need.	
	
1.1.8.2	 Disease	activity	indices		A	number	of	disease	activity	scores	exist	for	use	in	IBD.		These	measure	clinical	and	or	endoscopic	data.		It	has	been	acknowledged	that	a	simple	disease	activity	index	for	use	in	routine	clinical	care	is	need.		However,	with	the	exception	of	the	Truelove	and	Witts	score	for	ulcerative	colitis	[125],	these	activity	indices	are	not	used	routinely	and	their	main	use	is	in	clinical	trials	[126].		Instruments	used	in	ulcerative	colitis:		Disease	activity	indices	used	in	ulcerative	colitis	can	be	further	classified	as	those	based	on	 clinical	 and	 biochemical	 parameters,	 endoscopic	 parameters,	 or	 a	 combination	 of	both.		The	Truelove	and	Witts	Severity	Index	was	first	described	in	1955.		It	is	composed	of	6	variables:	 	number	of	stools	per	day,	blood	 in	stools,	 temperature,	pulse,	haemoglobin	and	erythrocyte	sedimentation	rate	(ESR).		Remission	was	defined	as:		1-2	stools	per	day,	lack	of	fever	and	tachycardia,	normal	(or	returning	to	normal)	haemoglobin	and	ESR	and	
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gaining	weight[125].		This	disease	activity	index	is	not	quantitative,	ie	it	does	not	produce	a	score.		Their	definition	of	remission	has	not	been	validated.		The	Powell-Tuck	Index	consists	of	10	variables	and	scores	range	from	0-20.		Remission	is	 defined	 as	 a	 score	 of	 0	 and	 improvement	 an	 increase	 in	 score	 by	 2	 or	more	 above	baseline[127].			The	 Simple	 Clinical	 Colitis	 Activity	 index	 incorporates	 6	 variables:	 	 bowel	 frequency	during	the	day,	bowel	frequency	during	the	night,	urgency	of	defaecation,	blood	in	the	stools,	 general	 well-being	 and	 extra-colonic	 manifestations.	 	 Scores	 range	 from	 0-19[128].		A	cut	off	value	of	less	than	2.5	correlates	with	patient	defined	remission	and	a	reduction	 in	 score	 by	 1.5	 points	 or	 more	 correlates	 with	 patient	 defined	 significant	improvement[129].		Endoscopic	 disease	 activity	 indices	 have	 been	 subject	 to	 a	 recent	 systematic	 review.		Many	of	these	indices	have	not	been	validated.		However,	the	endoscopic	component	of	the	Mayo	score	as	well	as	the	UC	endoscopic	index	of	severity	(UCEIS)	have	been	shown	to	be	valid[111].		The	endoscopic	component	of	the	Mayo	score	describes	the	rectal	mucosa	using	a	4-point	scale	(0-inactive	disease,	1-mild	disease	erythema	loss	of	vascular	pattern	mildly	friable,	2-moderate	 disease	 marked	 erythema	 absent	 vascular	 pattern	 marked	 friability,	 3-severe	 disease	 spontaneous	 bleeding	 ulceration	 [112].	 	 It	 has	 been	 shown	 to	 be	 both	reliable	and	 responsive[130].	 	 It	has	also	been	 shown	 to	 correlate	with	health	 related	quality	of	life[131].	
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The	UC	endoscopic	index	of	severity	consists	of	3	components:	vascular	pattern,	bleeding	and	erosion/ulceration.		Potential	scores	range	from	0	to	11[113].		The	UCEIS	has	been	shown	to	have	 favourable	psychometric	characteristics.	 	Score	components	have	been	shown	to	correlate	with	a	global	rating	of	endoscopic	severity.		The	UCEIS	is	also	to	have	satisfactory	intraobserver	and	interobserver	reliability[132].		A	number	of	disease	activity	indices	used	in	UC	incorporate	clinical	and	endoscopic	data.		These	include	the	Mayo	score	and	the	Sutherland	Index.		The	Mayo	score	consists	of	4	variables:		stool	frequency,	rectal	bleeding,	sigmoidoscopy	findings	 and	 a	 physician’s	 global	 assessment	 (PGA).	 	 Scores	 range	 from	 0	 to	 12.	 	 In	addition	 to	 these	 variables	 a	 patient	 functional	 assessment	 is	 determined	 in	 order	 to	inform	the	physician’s	global	assessment.		Complete	response	is	defined	as:		normal	stool	frequency,	no	rectal	bleeding,	patient	generally	well	and	normal	endoscopic	findings.		The	PGA	score	must	also	be	0.		A	partial	response	is	defined	as	an	improvement	in	the	PGA	score	 in	 association	 with	 an	 improvement	 in	 at	 least	 one	 clinical	 parameter	 and	 an	absence	of	deterioration	in	any	clinical	parameter.	 	The	Mayo	score	and	its	definitions	have	not	been	validated[112].		These	definitions	have	been	modified	in	subsequent	trials.		Clinical	remission	as	defined	by	a	score	of	2	or	less	and	no	individual	sub-score	of	more	than	one	has	been	 shown	 to	 correlate	with	 significant	 improvement	 in	health	 related	quality	of	life[133].		Finally,	 the	 Disease	 Activity	 Index	 (Sutherland	 Index)	 consists	 of	 4	 variables:	 	 stool	frequency,	rectal	bleeding,	mucosal	appearance	and	physician’s	rating	of	disease	activity.		Scores	range	from	0	to	12	[134].		The	Sutherland	score	has	not	been	validated.		However,	
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a	 score	 of	 less	 than	 2.5	 points	 has	 been	 shown	 to	 correlate	 with	 patient	 defined	remission[129].		 	Instruments	used	in	Crohn’s	disease:		The	Crohn’s	disease	activity	index	(CDAI)	consists	of	eight	variables:		number	of	liquid	stools,	extent	of	abdominal	pain,	general	wellbeing,	extra-intestinal	symptoms,	the	need	for	 anti-diarrhoeal	 drugs,	 abdominal	 masses,	 haematocrit	 and	 body	 weight.	 	 The	variables	are	weighted	and	scores	range	from	0	to	approximately	600.		This	instrument	has	been	validated	as	a	measure	of	disease	activity	in	Crohn’s	disease.		A	cut	off	value	of	150	has	been	shown	to	define	remission	with	90%	of	patients	with	scores	below	this	being	 rated	 as	 “very	well”	by	assessing	physicians.	 	A	 cut	off	 value	of	450	or	more	 is	consistent	with	severely	active	disease[135].		Of	note,	parts	of	the	CDAI	score	are	based	on	 a	 symptom	 diary	 covering	 the	 preceding	 7	 days	 and	 therefore,	 the	 CDAI	 is	 not	amenable	to	use	in	day-to-day	clinical	care.		The	 Harvey	 Bradshaw	 index	 is	 a	 simpler	 disease	 measure	 consisting	 of	 5	 variables:		general	 well	 being,	 abdominal	 pain,	 number	 of	 liquid	 stools	 daily,	 the	 presence	 of	abdominal	mass	and	the	presence	of	complications.		A	score	of	less	than	5	is	consistent	with	remission,	5	to	7-mild	disease,	8	to	16-moderate	disease	and	more	than	16-severe	disease[136].		The	Harvey	Bradshaw	index	is	not	designed	to	be	completed	in	full	by	the	patients	since	the	variable	“abdominal	mass”	requires	clinical	examination.	Other	 clinical	 indices	 include	 the	Organization	Mondial	de	Gastro-enterologie	 (OMGE)	index[137]	and	the	Cape	Town	index[138].		These	indices	have	been	shown	to	correlate	with	each	other	[139].	
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The	CDAI	is	not	an	appropriate	index	for	use	in	patients	with	active	fistulating	disease	since	 the	 presence	 of	 fistulae	 contributes	 a	 relatively	 small	 number	 of	 points	 to	 the	overall	 score[140].	 	 The	 perianal	 disease	 activity	 index	 (PDAI)	 has	 been	 designed	 to	measure	disease	activity	in	patients	with	perianal	Crohn’s	disease.		There	are	5	variables:		discharge,	 pain,	 restriction	 of	 sexual	 activity,	 type	 of	 perianal	 disease	 and	 degree	 of	induration[141].		At	present	there	are	no	identified	cut	off	values.		
1.2	 	 Patient	reported	outcome	measures		A	patient	reported	outcome	measure	(PROM)	may	be	defined	as	a	series	of	questions	that	patients	 are	 asked	 in	 order	 to	measure	 their	 views	 on	 their	 own	health.	 	 A	 PROM	 is	designed	to	measure	health	or	health	related	quality	of	life,	rather	than	satisfaction	or	experience	of	health	care[1]		Traditionally,	measurement	of	quality	of	healthcare	has	relied	on	clinical	measures	such	as	complication	rates	or	mortality.		However,	it	has	been	increasing	recognised	that	since	our	primary	aim	is	to	improve	our	patients’	health,	measuring	change	in	health	from	our	patients’	perspective	is	an	important	outcome	measure	in	clinical	trials	and	an	important	measure	of	quality	within	health	systems.	
	
1.2.1	 	 Content	of	patient	reported	outcome	measures	
	 	 	PROMs	measure	the	patient’s	subjective	experience	of	health	and/or	the	consequences	of	illness.		The	content	of	PROMs	is	varied	and	an	individual	PROM	may	measure	one	or	several	aspects	of	health	status.		Content	may	be	grouped	into	dimensions.		Commonly	
 44 
included	dimensions	include	physical	functioning	(eg	physical	activity,	activities	of	daily	living),	specific	symptoms	(eg	pain,	fatigue),	overall	assessment	of	health,	psychological	wellbeing	 (eg	 anxiety,	 depression),	 social	 wellbeing	 (eg	 social	 contact,	 undertaking	leisure	 activities),	 cognitive	 functioning	 (eg	 concentration,	 memory),	 role	 activities	(employment),	personal	constructs	(eg	life	satisfaction)	and	satisfaction	with	health	care	(Figure	3).		
Figure	3	Dimensions	assessed	by	patient	reported	outcome	measures[142]	Dimension	 Example	Physical	function	 Mobility,	physical	activity,	ADLs	Symptoms	 Pain,	fatigue,	diarrhoea	Global	judgements	of	health	Psychological	well-being	 Anxiety,	depression,	self-esteem	Social	well-being	 Family	relations,	leisure	activities,	social	contact	Cognition	 Alertness,	concentration,	memory	Role	activities	 Employment,	household	management	Personal	constructs	 Life	satisfaction,	stigma,		Satisfaction	with	care	ADLs-activities	of	daily	living		
1.2.2	 	 Types	of	instrument		There	are	a	number	of	different	types	of	patient	reported	outcome	measures.		Most	can	generally	 be	 described	 as	 either	 “disease	 specific”	 or	 “generic”.	 	 Disease	 specific	instruments	are	designed	for	use	in	a	specific	condition.		For	example,	the	inflammatory	
 45 
bowel	disease	questionnaire	(IBDQ)	is	an	IBD	specific	measure	of	health	related	quality	of	life[143].		The	most	important	advantage	of	using	a	disease	specific	measure	is	that	it	is	 more	 likely	 to	 detect	 clinical	 important	 change	 over	 serial	 measurements[144].		However,	 disease	 specific	 instruments	 cannot	 be	 used	 to	 compare	 health	 status	 in	respondents	with	different	conditions	or	with	a	healthy	general	population	sample[142].		Generic	measures	 are	 instruments	 that	 have	 been	 intentionally	 designed	 to	measure	several	aspects	of	health	status	and	can	therefore	be	applied	to	many	different	diseases.		They	may	also	be	used	to	compare	treatment	effects	between	different	groups	of	patients.		Generic	 measures	 can	 also	 be	 used	 to	 measure	 health	 status	 in	 general	 population	samples	 and	 therefore	 generate	 “normal	 values”	 to	 which	 study	 data	 can	 be	compared[142].		An	example	of	a	generic	instrument	that	has	been	validated	for	use	in	IBD	is	the	SF-36	questionnaire.		The	SF-36	consists	of	8	dimensions	covering	broad	areas	such	as	“physical	functioning”,	“social	functioning”	and	“energy/vitality”[145].			Generic	 measures	 are	 more	 likely	 to	 detect	 unexpected	 changes	 in	 health	 status.		However,	 they	 do	 lack	 sensitivity	 and	 therefore	 are	 less	 likely	 to	 be	 able	 to	 detect	clinically	important	change	over	time	[142].		Another	important	and	distinct	type	of	PROM	is	the	utility	measure.		Utility	measures	are	used	to	measure	an	individual’s	preference	for	particular	health	outcomes[146].		Utility	measures	may	employ	techniques	such	as	standard	gamble	or	time	trade	off	in	order	to	obtain	 information	 on	 respondent	 preferences.	 	 Standard	 gamble	 technique	 involves	providing	the	 individual	with	the	option	of	a	certain	health	state	or	a	gamble	that	 the	health	state	may	be	better	or	worse.	 	The	respondent	 is	asked	for	 the	probability	of	a	
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better	outcome	that	would	make	them	indifferent	between	staying	in	the	certain	health	state	 or	 gambling	 on	 the	 alternative	 state.	 	 The	 time	 trade	 off	 technique	 asks	 the	individual	 the	amount	of	 time	(eg	 life	years)	 they	would	give	up	 in	order	to	achieve	a	better	health	state[147].		Alternatively,	utilities	may	be	derived	via	an	indirect	method.		An	individual’s	reported	health	measure	is	obtained	in	the	usual	manner	(for	example	a	questionnaire).			Scores	are	then	weighted	using	valuations	previously	obtained	from	an	appropriate	population	sample	 to	 produce	 a	 utility	 index.	 	 An	 example	 of	 this	 is	 the	 EuroQol:	 EQ-5D	questionnaire[148].		Utility	measures	have	a	number	of	advantages.		They	provide	a	single	value,	rather	than	a	number	of	responses,	 that	reflects	 the	respondent’s	preferences	or	values	regarding	their	health.		Utility	measures	can	be	used	to	generate	quality-adjusted	life	years	(QALYs)	and	can	be	used	for	use	in	cost-utility	analysis.		Utility	measures	involving	methods	such	as	standard	gamble	and	time	trade	off	technique	are	often	time	consuming	and	poorly	understood	by	respondents.		Data	is	therefore	often	obtained	 via	 interview	 rather	 than	 self	 completed	 questionnaire.	 	 This	 increases	 the	burden	both	on	participant	and	researcher[142].		The	use	of	indirect	methods	to	derive	utility	measures,	such	as	with	the	EuroQol	questionnaire,	avoids	these	problems[148].		Disease–specific	and	generic	PROMs	are	associated	with	advantages	and	disadvantages.		It	 is	 recommended	 that	both	generic	 and	disease-specific	 instruments	are	 included	 in	trials.		This	allows	the	collection	of	data	relevant	to	the	condition	under	investigation	and	
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detection	 of	 clinically	 important	 change,	 whilst	 ensuring	 unexpected	 effects	 are	 also	identified	[149].		
1.2.3	 	 Criteria	for	the	assessment	of	PROMs	
	When	assessing	a	patient	reported	outcome	measure	the	following	properties	should	be	considered:	 	 appropriateness,	 reliability,	 validity,	 responsiveness,	 precision,	interpretability,	acceptability	and	feasibility[142].		Appropriateness	refers	to	whether	the	instrument	has	the	appropriate	content	to	address	the	aims	of	the	trial	in	which	it	will	be	used.		Both	the	patient	group	and	the	content	of	potential	 instruments	 must	 be	 assessed	 in	 order	 to	 ensure	 the	 most	 appropriate	instrument	is	chosen	[149].		A	further	means	of	ensuring	appropriate	outcome	measures	are	used	is	to	include	at	least	one	disease	specific	measure	and	one	generic	measure[150].		As	 detailed	 above,	 this	 strategy	 is	 to	 increase	 the	 likelihood	 of	 capturing	 anticipated	effects	as	well	as	unanticipated	effects	[142].		Reliability	refers	 to	whether	an	 instrument	 is	 free	 from	random	error.	 	There	are	two	components	of	reliability:		reproducibility	and	internal	consistency.		Reproducibility	assesses	whether	similar	results	are	obtained,	on	repeated	testing,	in	a	stable	or	unchanged	group	of	participants.		It	is	measured	by	test-retest	reliability	-	the	amount	 of	 correlation	 between	 initial	 score	 and	 a	 subsequent	 assessment.	 	 Most	investigators	will	 choose	 a	 time	 frame	 of	 2	 -14	 days	 between	 tests.	 	 This	 is	 trade-off	
 48 
between	 the	 risk	 of	 recollection	 bias	 and	 the	 potential	 for	 change	 in	 clinical	condition.[151]		Although	 often	 used,	 correlation	 coefficients	 have	 the	 potential	 to	 exaggerate	reproducibility.	 	Therefore,	measurement	of	intra-class	correlation	coefficients	(ICC)	is	more	appropriate.		ICC	determines	the	amount	of	variability	that	is	due	to	true	differences	in	individuals	vs	the	amount	due	to	variability	in	measurement	[142].			Internal	 consistency	 can	 also	 be	 used	 to	measure	 the	 reliability	 of	 questionnaires	 in	which	a	number	of	items	are	used	to	measure	the	same	construct.		Internal	consistency	refers	to	whether	individual	items	measuring	the	same	construct	correlate.		This	inter-correlation	 of	 items	within	 a	 domain	 is	 commonly	 determined	 using	 Cronbach	 alpha	statistic.		Whilst	a	high	Cronbach	alpha	statistic	signifies	internal	consistency,	a	very	high	alpha	 statistic	 may	 indicate	 redundancy	 of	 some	 items[142].	 	 Therefore,	 it	 is	recommended	that	Cronbach	alpha	values	should	be	over	0.7,	but	no	more	than	0.9	[152].		Validity	 is	 an	 assessment	 of	 whether	 an	 instrument	 measures	 the	 construct	 it	 was	designed	to	measure.		It	can	be	categorised	further	as:	content	validity,	face	validity	and	construct	validity.		Face	 and	 content	 validity	 are	 qualitative	measures.	 	 Face	 validity	 is	 an	 assessment	 of	whether	 an	 instrument	 appears	 to	 be	 measuring	 the	 construct	 in	 question.	 	 Content	validity	 refers	 to	 whether	 all	 components	 of	 the	 subject	 to	 be	 tested	 are	 adequately	covered	by	the	instrument[153].		
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Construct	validity	is	a	quantitative	measure	of	whether	an	instrument	is	able	to	measure	what	 it	 is	designed	 to	measure.	 	 It	 involves	 correlating	 instrument	scores	with	 scores	from	other	measures	 that	 are	 known	 to	 or	 hypothesised	 to	measure	 the	 construct	 in	question[142].	 	 Rather	 than	 a	 single	 observation,	 several	 variables	 should	 be	 used	 to	prove	construct	validity[154].				Construct	 validity	may	 also	 be	 measured	 using	 convergent	 and	 discriminant	 validity	[155].	 	 This	 requires	 hypothesising	 that	 a	measure	will	 correlate	 strongly	with	 some	variables	and	weakly	with	others.		Correlations	are	expected	to	be	strongest	with	closely	related	variables	and	weakest	with	those	not	closely	related[142].		An	instrument	must	also	possess	responsiveness	-	the	ability	to	detect	changes	over	time.		Responsiveness	can	be	assessed	in	a	number	of	ways.		The	first	is	the	calculation	of	effect	size.		Effect	size	is	calculated	by	dividing	the	change	in	mean	score	from	baseline	to	follow	up,	by	the	standard	deviation	of	the	baseline	scores.		Effect	sizes	can	be	used	for	assessing	relative	size	of	change.		An	effect	size	of	0.2	is	considered	small	where	as	an	effect	size	of	0.5	and	more	than	0.8	are	considered	medium	and	large	respectively[156].		Alternatively,	the	standardised	response	mean	can	be	calculated.		This	differs	from	effect	size	 in	 that	 the	 denominator	 is	 the	 standard	 deviation	 of	 the	 change	 in	 scores[157].		Furthermore,	 for	 calculation	 of	 the	 modified	 standardized	 response	 mean,	 the	denominator	is	the	standard	deviation	of	the	change	in	scores	in	stable	patients[158].		Receiver-operating	characteristics	(ROC)	can	also	be	used	to	assess	responsiveness.		This	method	requires	the	existence	of	a	gold	standard	test	for	detecting	whether	a	true	change	
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in	clinical	condition	has	occurred.		Sensitivity	(the	true	positive	rate)	is	plotted	against	1-specificity	 (the	 false	 positive	 rate)	 to	 produce	 a	 ROC	 curve.	 	 Of	 note,	 calculation	 of	sensitivity	and	specificity	of	an	 instrument	requires	 identification	of	a	change	 in	score	(between	two	visits)	that	is	considered	a	“positive	result”	i.e.	indicates	a	change	in	clinical	condition.		The	area	under	the	ROC	curve	indicates	the	instruments	responsiveness.		If	ROC	curves	are	 plotted	 for	 variously	 selected	 cut	 off	 scores,	 the	 optimal	 cut	 off	 score	 can	 be	identified[159].		Floor	and	ceiling	effects	may	affect	the	responsiveness	of	a	questionnaire.		These	occur	when	questionnaire	design	or	wording	results	in	respondents	not	being	able	to	report	improved	health	state	(ceiling	effect)	of	worsened	health	state	(floor	effect).		Responsiveness	may	also	be	affected	by	the	distribution	of	baseline	scores.		If	most	items	within	a	domain	are	easily	obtainable,	then	a	large	change	in	score	could	occur	despite	only	a	small	real	improvement[142]		Precision	 is	 the	 ability	 of	 a	 measure	 to	 make	 a	 number	 of	 distinctions.	 	 Hence,	 an	instrument	that	can	only	distinguish	between	two	health	states	lacks	precision,	whereas	one	which	can	distinguish	between	many	health	states	is	precise	[160].		Interpretability	 refers	 to	 how	meaningful	 the	 score	 obtained	 from	 an	 instrument	 is.		Minimal	clinically	important	difference	(MCID)	may	be	used	to	assess	interpretability.		
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A	PROM	must	also	possess	acceptability,	ie	is	it	acceptable	to	patients?		Acceptability	is	important	 in	order	 to	 ensure	high	 completion	 rates.	 	 Acceptability	may	 be	 proven	 by	measuring	completion	rates	and	the	time	to	complete	questionnaires	[142].		Finally,	feasibility	must	also	be	considered.		This	refers	to	the	burden	on	clinical	staff	and	researchers.	 	 For	 example,	 directly	 administering	 a	 questionnaire	 will	 have	 a	 higher	burden	on	staff	than	a	postal	questionnaire.[142]	
	
1.3	 	 PROMs	and	the	National	Health	Service	
	There	has	been	a	significant	shift	in	approach	to	health	policy	over	the	last	few	years.		The	government	 report,	 “High	Quality	Care	 for	All”,	 by	Lord	Darzi	was	published	 in	2008.		Based	on	a	year	 long	 review	of	 the	NHS,	 the	 report	 sets	out	 the	government’s	 aim	 to	improve	 quality	 of	 care.	 	 It	 is	 an	 extensive	 report	 covering	many	 aspects	of	 the	NHS.		However,	it	is	the	measurement	of	healthcare	quality	that	is	most	relevant	to	PROMs.		By	improving	the	ability	to	measure	quality	within	the	NHS,	it	is	felt	that	staff	will	have	the	means	to	develop	quality	improvement	strategies.		The	 report	 defines	 quality	 of	 care	 in	 terms	 of	 patient	 safety,	 patient	 experience	 and	effectiveness	 of	 care.	 	 The	 report	 recommends	 that	 effectiveness	 of	 care	 should	 be	measured	in	a	number	of	ways	including	traditional	indicators	such	as	complication	rates	and	 survival	 rates.	 	 However,	 it	 also	 states	 that	 patient	 reported	 outcome	measures	should	 also	 be	 used	 in	 order	 to	 ensure	 quality	 of	 healthcare	 is	 measured	 from	 the	patients’	perspective	[161].		
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A	further	white	paper,	“Equity	and	excellence:		liberating	the	NHS”	was	published	in	2010.		This	document	set	out	proposed	changes	to	the	NHS	including	improving	patient	choice,	patient	 involvement	 in	 decision-making	 and	 the	 empowerment	 of	 clinicians	 to	make	decisions	 at	 a	 local	 level	 rather	 than	 being	managed	 by	 government.	 	There	was	 also	emphasis	on	improving	healthcare	quality.		Again,	the	need	to	capture	patient	reported	data	 was	 recognised	 as	 well	 as	 the	 need	 for	 improved	 data	 reporting	 and	transparency[162].		Following	on	from	this	the	NHS	Outcomes	Framework	was	developed	in	order	to	provide	a	 national	 overview	 of	 healthcare	 performance.	 	 It	 is	 the	 primary	 accountability	mechanism	between	the	government	and	the	NHS	and	one	of	the	strategies	to	improving	healthcare	quality.		Indicators	 fall	within	 five	 domains	 of	 outcomes	 that	 the	NHS	 should	 aim	 to	 improve.		These	domains	are:		preventing	people	for	dying	prematurely,	enhancing	quality	of	life	in	people	with	long	term	conditions,	helping	people	to	recover	from	episodes	of	ill	health	or	following	injury,	ensuring	that	people	have	a	positive	experience	of	care,	and	treating	and	caring	for	people	in	a	safe	environment	and	protecting	then	from	avoidable	harm.		Each	domain	 contains	 a	 small	 number	 of	 “overarching	 indicators”	 as	 well	 as	 a	 number	 of	improvement	 areas.	 	 For	 example,	 within	 the	 NHS	 Outcomes	 Framework	 2014/15	domain	“Enhancing	quality	of	life	for	people	with	long	term	conditions”,	the	overarching	indicator	 is	 “Health-related	 quality	 of	 life	 for	 people	 with	 long	 term	 conditions”.		Improvement	areas	include:		“ensuring	people	feel	supported	to	manage	their	condition”	and	“improving	functional	ability	in	people	with	long	term	conditions”[163]		
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The	 “Mandate	 to	 the	NHS”	 is	published	by	 the	government	each	year.	 	The	objectives	within	the	mandate	are	set	around	these	five	domains	and	therefore,	the	NHS	Outcomes	Framework	is	used	to	assess	whether	the	objectives	have	been	met	[163].		Routine	 collection	 of	 patient	 reported	 outcome	measures	has	 been	mandatory	within	NHS	England	since	2009[164].		At	present,	all	hospitals	undertaking	elective	hernia,	knee,	hip	and	varicose	vein	surgery	are	collecting	PROMs	data.		There	is	ongoing	work	in	order	to	extend	the	PROMs	programme	to	cover	more	conditions	such	as	mental	health,	cancer	and	long	term	conditions	such	as	asthma[1].			Utility	 measures,	 a	 form	 of	 patient	 reported	 outcome	 measures,	 are	 used	 for	 cost-effectiveness	analysis.	 	The	National	 Institute	 for	Health	and	Care	Excellence	(NICE)	 is	responsible	for	the	appraisal	of	healthcare	interventions.		Recommendations	are	based	on	both	clinical	evidence	and	cost-effectiveness	analysis.		Quality	 adjusted	 life	 years	 (QALYs)	 are	 the	 preferred	 outcome	 measure	 of	 cost	effectiveness	used	by	NICE	for	health	 intervention	appraisal.	 	QALYs	combine	data	on	length	of	life	and	the	values	placed	on	various	levels	of	quality	of	life.		The	lowest	possible	value	of	a	QALY	is	0	(health	rating	is	as	bad	as	being	dead)	and	the	highest	is	1	(good	health	for	1	year).		The	EQ-5D	utility	index	is	the	preferred	utility	index	for	calculation	of	QALYs	[165].		When	comparing	a	new	treatment	to	an	existing	one,	the	incremental	cost-effectiveness	 ratio	 can	be	 calculated	which	 reflects	 the	extra	 cost	 associated	with	one	gained	QALY	[166].		
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“Cost	per	QALY”	values	are	used	by	NICE	to	help	assess	whether	an	intervention	is	good	value	for	money	and	therefore	to	be	recommended.		If	an	intervention	is	estimated	to	cost	less	than	£20000	per	QALY	it	is	judged	to	be	cost	effective.		If	over	£20000,	other	evidence	such	as	the	whether	there	is	a	possibility	that	quality	of	life	data	has	been	mis-captured,	should	be	considered	before	recommendations	are	made.		If	an	intervention	costs	more	than	£30000	per	QALY,	there	must	be	increasingly	strong	evidence	to	support	the	use	of	the	treatment	in	order	for	it	to	be	recommended[167].		Whilst	these	thresholds	are	not	backed	 by	 evidence,	 they	 are	 a	 means	 for	 NICE	 to	 use	 economic	 evidence	 to	 make	decisions	with	regard	to	limited	resource	allocation[1].		
1.3.1	 	 The	use	of	PROMs	in	the	management	of	chronic	disease	 		Chronic	diseases	are	becoming	an	increasing	burden	on	health	services	and	account	for	a	large	proportion	of	NHS	spending.	 	It	is	estimated	that	the	care	of	patients	with	long	term	conditions	accounts	for	70%	of	the	total	health	and	social	spending	in	England[168].		Chronic	conditions	do	not	commonly	lead	to	death	and	can	be	managed	on	a	long-term	basis,	often	requiring	ongoing	treatment	and	monitoring.		However,	long	term	conditions	have	 been	 shown	 to	 affect	 quality	 of	 life[169].	 	 Therefore,	 improving	 or	maintaining	quality	of	life	is	a	key	goal	in	this	patient	group.		The	development	of	systems	to	measure	quality	of	life	of	patients	with	chronic	diseases	is	therefore	required.		As	detailed	above,	the	 quality	 of	 life	 of	 patients	 with	 long	 term	 conditions	 is	 a	 component	 of	 the	 NHS	Outcomes	Framework[163].		The	use	of	PROMs	to	measure	effective	management	of	chronic	diseases	is	challenging.		In	contrast	to	elective	surgical	care,	in	which	there	is	a	clear	intervention	at	a	single	point	
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in	time,	chronic	diseases	are	complex,	may	co-exist	with	other	disorders	and	may	involve	multiple	specialities	and	multiple	interventions	over	time[170].		The	Department	of	Health	commissioned	a	pilot	study	to	determine	the	feasibility	of	the	routine	 collection	 of	 patient-reported	 outcome	measures	 for	 long-term	 conditions	 in	primary	 care.	 	 The	 following	 6	 chronic	 conditions	 were	 included:	 	 asthma,	 chronic	obstructive	pulmonary	disease	(COPD),	diabetes,	epilepsy,	heart	failure	and	stroke.[170].		The	 study	 was	 conducted	 by	 post	 in	 general	 practice	 and	 included	 around	 4500	participants.		The	primary	aim	of	the	study	was	to	investigate	the	feasibility	of	collecting	PROMs	 in	 long-term	 conditions.	 	 The	 change	 in	 EQ-5D	 scores	 between	 visits	 was	 a	secondary	endpoint.		The	questionnaire	pack	sent	to	potential	respondents	contained	a	generic	PROM	and	a	disease-specific	 PROM	 (specific	 to	 their	 conditions).	 	 The	 included	 instruments	were	chosen	on	the	basis	of	extensive	 literature	review	of	PROMs	used	 in	chronic	diseases.		Overall,	there	was	a	38.4%	questionnaire	return	rate.	 	71%	of	those	who	returned	the	initial	questionnaire	agreed	to	complete	a	follow	up	assessment.	 	This	response	rate	is	similar	to	other	primary	care	based	surveys[171]	and	indicates	collection	of	PROMs	in	this	patient	group	is	feasible.		Interestingly	there	was	no	change	in	health-related	quality	of	 life	 (as	measured	 using	 the	 EQ-5D	 questionnaire)	 between	 baseline	 and	 follow-up	questionnaire	(one	year	later).	 	This	raises	questions	with	regard	to	optimal	follow	up	interval	as	well	as	instrument	choice	if	chronic	diseases	are	incorporated	into	the	current	NHS	PROMs	programme.		
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1.3.2	 	 PROMs	currently	used	in	the	National	Health	Service		A	small	number	of	patient	reported	outcome	measures	have	been	incorporated	into	the	NHS	Outcomes	Framework	and	it	is	planned	for	further	PROMs	to	be	used	in	the	future.		Within	domain	2,	“Enhancing	quality	of	life	for	people	with	long-term	conditions”,	health	related	quality	of	life	is	measured	using	the	EQ-5D[172].	 	This	is	obtained	from	the	GP	survey,	which	includes	the	EQ-5D	questionnaire.		The	EQ-5D	questionnaire	is	a	widely	used	generic	patient	reported	outcome	measure.		It	consists	 of	 2	 parts:	 	 the	 EQ-5D	 descriptive	 system	 and	 a	 visual	 analogue	 scale.	 	 The	descriptive	system	consists	of	5	dimensions:		mobility,	self-care,	usual	activities,	pain	and	discomfort	 and	anxiety	and	depression.	 	Each	response	 is	 scored	between	1	and	3	 (1	indicates	 no	 problem	 and	 3	 indicates	 severe	 problems).	 	 These	 numbers	 are	 then	expressed	as	a	5-digit	code.		The	visual	analogue	scale	(VAS)	is	a	vertical,	thermometer	scale	 ranging	 from	 0	 (worst	 imaginable	 health	 state)	 to	 100	 (best	 imaginable	 health	state).		The	EQ-5D	descriptive	system	can	be	converted	to	a	summary	utility	index	using	value	sets[172].		Improving	health	related	quality	of	life	of	people	with	dementia	 is	an	 indicator	within	domain	2	of	 the	NHS	 outcomes	 framework.	 	 Research	 is	 currently	 underway	 into	 the	possibility	of	using	a	quality	of	life	measure	on	a	routine	basis	in	patients	with	dementia.		If	 a	 suitable	 instrument	 is	 identified	 this	 may	 also	 be	 incorporated	 in	 the	 Outcomes	Framework[173].		
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“Total	health	gain	as	assessed	by	patients	for	elective	procedures”	is	an	indicator	within	domain	3	of	the	NHS	Outcomes	Framework	(“Helping	people	to	recover	from	episodes	of	ill	 health	 or	 following	 injury”).	 	 The	 NHS	 PROMs	 programme	 collects	 data	 related	 to	elective	hip	and	knee	replacement	surgery,	elective	hernia	repair	and	elective	varicose	vein	surgery.		However,	as	the	PROMs	programme	develops,	PROMs	related	to	additional	elective	procedures	may	be	included.		The	 instruments	 currently	used	 in	 the	PROMs	programme	 include	 the	EQ-5D[172]	as	described	above,	the	Aberdeen	varicose	vein	questionnaire	(AVVQ)[174],	the	Oxford	hip	score	(OHS)[175]	and	the	Oxford	knee	score	(OKS)[176].		All	patients	complete	the	EQ-5D	before	and	after	surgery	as	well	as	the	appropriate	procedure	specific	instrument.		The	Aberdeen	varicose	vein	questionnaire	consists	of	13	questions	related	to	subjects	such	as	pain,	swelling	and	interference	with	daily	activities.		Overall	scores	range	from	0-100[174].	 	The	Oxford	hip	and	knee	scores	contain	12	questions	related	to	pain,	 joint	movement	and	ability	to	undertake	daily	activities.		Scores	range	from	0-48[175,	176].		There	 is	 ongoing	work	with	 regard	 to	 the	 incorporation	of	 patient	 reported	outcome	measures	 following	 elective	 psychological	 therapies,	 stroke	 and	 trauma	 into	 the	 NHS	Outcomes	Framework[173]		The	National	Cancer	Survivorship	Initiative	(NCSI)	was	launched	in	2007.		Its	aim	was	to	improve	the	health	and	quality	of	life	of	people	who	had	survived	cancer[177].		
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As	part	of	this	initiative,	the	Department	of	Health	undertook	a	study	of	the	quality	of	life	of	 cancer	 survivors	 [178].	 	 Quality	 of	 life	 was	 measured	 using	 the	 EQ-5D	questionnaire[172],	 the	 Social	 Difficulties	 Inventory[166]	 and	 cancer	 site-specific	questions	extracted	from	the	relevant	Functional	Assessment	of	Cancer	Therapy	(FACT)	questionnaires	 (http://www.facit.org/FACITOrg).	 	 This	 study	 provided	 important	information	with	regard	to	the	quality	of	life	of	people	with	cancer,	which	has	informed	recent	recommendations	by	the	NCSI.	 	 It	also	 identified	a	high	response	to	the	survey	indicating	the	routine	capture	of	patient	reported	data	using	PROMs	is	both	feasible	and	acceptable	in	this	population.		The	National	Cancer	Survivorship	 Initiative	 recommends	 the	 routine	use	of	PROMs	 in	order	to	collect	patient	reported	data	in	many	aspects	of	cancer	care	including	symptoms,	quality	of	life,	patient	concerns	and	unmet	needs[177].		
1.3.3	 Potential	uses,	benefits	and	disadvantages	of	using	PROMs	in	the	NHS		The	potential	use	for	PROMs	within	the	NHS	is	wide	ranging.	 	Firstly,	patient	reported	data	available	to	patients	might	allow	them	to	make	informed	decisions	on	whether	they	wish	to	receive	a	certain	treatment	and	where	they	would	like	it	to	be	done[1].		Patient	surveys	have	confirmed	that	factors	such	as	“impact	on	health	as	a	result	of	treatment”	is	an	 important	 factor	when	 choosing	 a	 hospital[179].	 	 It	 is	 hoped	 that	 the	NHS	PROMs	programme	will	facilitate	patient	choice.	 	However,	a	large	survey	of	NHS	patients	has	revealed	 that	 only	 a	 small	 proportion	 sought	 performance	 data	 when	 deciding	 on	 a	hospital	for	treatment[180].		
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PROMs	data	will	be	of	great	use	in	managing	clinical	quality	in	hospitals.		Data	will	allow	local	benchmarking	against	other	hospitals	as	well	as	national	targets.		As	detailed	above,	patient	reported	data	are	an	important	aspect	of	the	NHS	Outcomes	Framework.	PROMs	data	are	likely	to	be	incorporated	into	trusts’	annual	quality	accounts[1].		PROMs	are	also	likely	to	be	used	by	health	care	commissioners.		PROMs	may	be	used	to	monitor	the	performance	of	existing	care	providers	or	provide	incentives	via	linkage	of	payment	to	defined	PROMs	scores.	 	PROMs,	and	specifically	utility	measures	may	also	inform	commissioners	with	regard	to	obtaining	good	value	for	money[1].		Finally,	PROMs	may	be	of	use	at	the	individual	clinician	level	and	may	help	with	clinical	decision-making.	 	 	 Serial	patient	 reported	data	 could	be	 recorded	 in	order	 to	monitor	response	to	interventions	or	treatments[181].		PROMs	may	be	used	to	screen	for	certain	conditions	(for	example	depression)	and	a	certain	score	prompt	earlier	follow	up[182].	Completion	of	PROMs	may	serve	to	reassure	patients	that	their	views	are	of	importance	and	may	also	serve	to	highlight	issues	that	would	otherwise	not	have	been	covered	during	a	consultation[183].		PROMs	data	are	subjective	and	are	affected	by	a	patient’s	view.				This	is	the	purpose	of	PROMs,	 but	 it	 highlights	 that	 PROMs	 should	 not	 be	 used	 in	 isolation	 when	 making	decisions.		PROMs	are	not	a	replacement	for	traditional	clinical	measures,	but	should	be	used	in	conjunction	with	them.		
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Conditions	such	as	dementia,	stroke,	learning	difficulties	and	illiteracy	present	a	problem	with	regard	to	capturing	patient	reported	data[1].		However,	a	number	of	PROMs	have	been	designed	to	be	completed	by	caregivers	such	as	parents[184].		
1.4	 	 The	use	of	PROMs	in	inflammatory	bowel	disease	
	
1.4.1	 	 Current	instruments	used	in	IBD		A	number	of	IBD	specific	patient	reported	outcome	measures	have	been	developed[143,	185,	186],	mainly	for	use	in	clinical	trials.		Of	these,	only	the	Inflammatory	Bowel	Disease	Questionnaire	 has	 undergone	 extensive	 psychometric	 evaluation.	 It	 is	 the	 most	commonly	 used	 IBD	 specific	 PROM	 and	 is	 a	 measure	 of	 health-related	 quality	 of	 life	designed	for	use	in	clinical	trials.		It	consists	of	32	questions	within	4	domains	(gastro-intestinal	 symptoms,	 systemic	 symptoms,	 emotional	 function	 and	 social	 function).		Response	options	are	on	a	7-point	Likert	scale	with	1	indicating	a	severe	problem	and	7	indicating	no	problem.		Hence	a	low	IBDQ	score	indicates	poor	health	related	quality	of	life[143].	 	 It	has	been	widely	validated	 for	use	 in	many	countries	 including	the	United	Kingdom[187].		The	Short	Inflammatory	Bowel	Disease	Questionnaire	(SIBDQ)	was	developed	in	order	to	provide	a	measure	of	quality	of	life	feasible	for	use	in	day-to-day	clinical	practice.		It	is	composed	of	10	questions	taken	from	the	original	IBDQ.		Whilst	this	has	been	shown	to	be	a	 valid	and	 reliable	 instrument[188],	 it	has	not	been	widely	established	 in	 routine	clinical	practice.		
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A	small	number	of	generic	patient	reported	outcome	measures	have	been	validated	for	use	in	inflammatory	bowel	disease.		Of	these	the	EQ-5D	is	widely	used	generic	measure	of	health	status.	 	The	EQ-5D	questionnaire	has	been	tested	in	many	diseases	including	IBD	and	has	been	shown	to	be	valid[189,	190].		Again,	the	use	of	these	generic	measures	has	not	crossed	over	into	clinical	practice.		
1.4.2	 	 The	need	for	IBD	specific	PROMs	for	use	in	clinical	practice		The	 first	 UK	 national	 IBD	 audit	 was	 undertaken	 in	 2006.	 	 A	 total	 of	 212	 hospitals	submitted	data.	 	This	audit	identified	a	large	variation	in	the	care	provided	to	patients	with	IBD.		For	example,	only	33%	of	hospitals	had	a	dedicated	gastroenterology	(medical	or	surgical)	ward	and	44%	of	sites	did	not	have	a	IBD	specialist	nurse[191].		Following	on	from	this,	the	IBD	Standards	Group	was	formed	and	subsequently	published	“Quality	Care:	 	Service	Standards	 for	 the	healthcare	of	people	who	have	Inflammatory	Bowel	Disease	(IBD)”	in	2009.	The	aim	of	this	document	was	to	ensure	safe,	effective	and	consistently	high	standards	for	people	with	IBD.		This	comprehensive	guideline	outlines	six	standards	related	to	the	care	of	patients	with	IBD:		 High	quality	clinical	care	–	the	provision	of	high	quality	care	via	a	multidisciplinary	approach.		 Local	delivery	of	care	–	the	provision	of	local	secondary	care	services	as	well	as	the	development	of	shared	care	protocols	with	general	practice.		 	
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Maintaining	 a	 patient-centred	 service	 –	 care	 should	 be	 patient-centred	 and	responsive	to	individual	needs.		Patients	should	be	able	to	make	choices	related	to	their	treatment.		 Patient	education	and	support	–	Patients	should	be	well	informed	with	regard	to	their	condition	and	provided	information	on	the	services	available	to	them.		 Information	technology	and	audit	 –	A	register	of	 all	patients	with	 IBD	must	be	kept,	 a	 database	 should	 be	 developed	 and	 the	 IBD	 team	 should	 participate	 in	regular	audit.		 Evidence	based	practice	and	research	–	High	level	training	should	be	provided	to	all	members	if	the	IBD	team	[192].		The	Inflammatory	Bowel	Disease	Quality	Improvement	Project	(IBDQIP)	was	established	in	order	to	support	the	implementation	of	the	IBD	Standards.		It	provided	a	web-based	self-assessment	tool	in	order	to	allow	local	IBD	teams	to	benchmark	their	services	against	national	standards.		Participation	improved	overtime	and	IBDQIP	has	now	merged	with	the	National	IBD	Audit[193].		A	further	two	rounds	of	the	national	IBD	audit	have	been	completed	and	round	four	is	in	progress.	 	There	has	been	a	 significant	 improvement	over	a	 relatively	 short	period	of	time.	 	There	has	been	 improvement	 in	a	number	of	areas	such	as	contact	with	an	IBD	nurse	during	admission	and	a	reduction	on	mortality	associated	with	ulcerative	colitis.		
 63 
However,	 there	 remains	 room	 for	 improvement	 in	 some	 areas.	 	 For	 example,	 the	collection	of	stool	samples	was	reduced	in	the	most	recent	audit	round[194].		Both	the	IBD	audit	programme	and	the	IBD	standards	have	driven	up	the	quality	of	care	provided	to	patients	with	IBD.	 	It	is	hoped	that	the	ongoing	implementation	of	the	IBD	standards	will	 continue	 to	 improve	 IBD	 care	 across	 the	 country.	 	Whilst	 certain	 IBD	standards	can	be	audited	using	traditional	methods,	PROMs	may	have	a	role	to	play	in	the	monitoring	of	these	standards,	particularly	standards	related	to	patient-centred	care.		Additionally,	 PROMs	 may	 also	 play	 a	 role	 in	 routine	 clinic	 care.	 	 Patient	 reported	information	 captured	 using	 PROMs	 might	 serve	 to	 inform	 physician	 and	 patient	decisions.	 	They	may	also	have	a	 role	 in	monitoring	response	 to	 treatment	as	well	 as	aiding	 communication	 between	 patients	 and	 physicians,	 particularly	 with	 regard	 to	identifying	unmet	needs.		Whilst	 a	 small	number	of	 IBD	specific	PROMs	exist,	none	have	become	established	 in	routine	clinical	care.	 	The	majority	of	 these	 instruments	 focus	on	the	measurement	of	health-related	quality	of	life.		The	routine	use	of	PROMs	in	clinical	practice	is	limited	by	a	number	of	factors.	 	There	is	generally	a	lack	of	knowledge	related	to	PROMs	and	their	potential	advantages.		Concerns	with	regard	to	burden	on	the	patient	and	clinical	team	are	also	barriers	to	their	use.		Therefore,	there	is	a	case	for	developing	a	PROM	that	measures	an	aspect	of	health	status	relevant	to	day	to	day	care	of	patients	with	IBD,	rather	than	focusing	solely	on	health-
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related	quality	of	life.		A	PROM	for	use	in	clinical	care	must	also	be	acceptable	to	patient	and	physician	alike	as	well.		Therefore,	 the	aim	of	 this	 study	 is	 to	develop	a	patient	 reported	outcome	 to	measure	“disease	control”	and	for	this	to	be	rapid,	user	friendly	and	applicable	to	routine	clinical	care.		
1.5	 	 Summary		In	summary,	 inflammatory	bowel	disease	 is	a	chronic	disorder	of	 the	gastro-intestinal	tract.	 	It	is	a	disease	predominantly	of	the	western	world	and	the	incidence	of	Crohn’s	disease	is	continuing	to	rise.	 	The	pathophysiology	is	complex	and	most	likely	due	to	a	genetically	determined	abnormal	immune	response	to	the	commensal	organisms	within	the	GI	 tract.	 	 Clinical	 features	 are	 varied	 and	 determined	 by	 disease	 type,	 extent	 and	behaviour.	 	 Medical	 management	 remains	 a	 central	 component	 to	 IBD	 care	 and	 the	development	 of	 new	 treatments	 such	 as	 biological	 agents	 has	 improved	 treatment	options.	 	 Endoscopy	 remains	 the	 gold	 standard	 investigation	 modality,	 but	 other	investigation	modalities	as	well	as	disease	activity	indices	play	a	role.		Patient	 reported	outcome	measures	allow	 the	measurement	of	health	 status	 from	 the	patient’s	 perspective.	 	 PROMs	 are	 increasingly	 recognised	 as	 an	 important	 outcome	measure	within	clinical	trials	as	well	as	quality	measures	for	health	care	systems.		PROMs	may	be	generic	or	disease	specific.		Utility	measures	are	a	distinct	type	of	PROM	and	are	used	 in	 cost-utility	 analysis.	 	 It	 is	 recommended	 that	 the	 psychometric	 properties	 of	patient	reported	outcome	measures	are	determined	in	order	to	validate	the	instrument.		
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Appropriateness,	 reliability,	 validity,	 responsiveness,	 precision,	 interpretability,	acceptability	and	feasibility	should	be	reported.		Changes	in	health	policy	have	resulted	in	the	need	to	incorporate	the	use	of	PROMs	into	the	 National	 Health	 Service.	 	 Routine	 collection	 of	 patient	 reported	 data	 has	 been	mandatory	for	NHS	trusts	undertaking	certain	elective	surgical	procedures	since	2009.		There	 is	ongoing	work	to	determine	whether	 it	 is	 feasible	 to	collect	PROMs	data	 from	other	patient	groups	such	as	those	with	chronic	diseases.		The	reporting	of	PROMs	data	is	a	component	of	the	NHS	Outcomes	Framework	and	utility	measures	are	used	by	the	National	 Institute	 for	 Health	 and	 Clinical	 Excellence	 (NICE)	 when	 assessing	 cost	effectiveness	of	healthcare	interventions.		The	National	IBD	audit	identified	a	significant	variation	in	the	quality	of	care	received	by	patients	 with	 IBD	 across	 the	 UK.	 	 Following	 on	 from	 this	 the	 IBD	 Standards	 were	developed	in	order	to	standardise	and	improve	care.		PROMs	could	play	an	important	role	in	the	measurement	of	IBD	care	from	the	patient’s	perspective	allowing	benchmarking	with	the	IBD	standards.		Moreover,	an	IBD	PROM	may	also	serve	to	aid	clinical	decision-making	and	improve	communication	between	patients	and	their	healthcare	team.		Whilst	a	small	number	of	 IBD	specific	 instruments	exist,	 the	majority	 focus	on	health-related	quality	of	life.		To	date,	none	have	become	established	in	routine	clinical	care.		This	study	aims	 to	develop	and	validate	a	novel	patient	 reported	outcome	measure	of	 IBD	“control”	 for	use	 in	 the	routine	care	of	patients	with	 inflammatory	bowel	disease.	 	We	hypothesised	that	it	should	be	possible	to	create	a	short,	simple,	pragmatic	questionnaire	by	 drawing	 upon	 the	 existing	 literature	 for	 both	 “generic”	 and	 “condition-specific”	
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PROMs	and	seeking	patient	views	on	content	and	format.		Given	the	challenges	for	PROMs	in	 gaining	 traction	 in	 routine	 settings,	 our	 design	 criteria	 would	 place	 emphasis	 on	generating	a	simple	tool	that	offers	a	rapid	assessment	of	overall	health	status	in	IBD.		
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Chapter	2	Literature	review	
	
2.1	 	 Introduction	
	There	has	been	increasing	interest	in	the	measurement	of	patient	reported	data	in	IBD	over	 the	 last	 10-20	 years.	 	 IBD	 specific,	 as	well	 as	 generic	 patient	 reported	 outcome	measures	 have	 been	 developed,	most	 commonly	 to	measure	 health-related	 quality	 of	life[143,	185,	195].		However,	instruments	designed	to	measures	other	aspects	of	health	status	 have	 also	 been	 developed[196-198].	 	Whilst	 PROMs	 are	most	 commonly	 used	within	clinical	research,	there	is	a	drive	to	bring	their	use	into	clinical	practice	[161].		As	yet,	they	have	not	become	established	within	this	role	for	inflammatory	bowel	disease.		The	 primary	 aim	 of	 this	 chapter	 was	 to	 review	 current	 patient	 reported	 outcome	measures	 for	use	 in	adults	with	 IBD.	 	A	secondary	aim	of	 the	 literature	review	was	to	determine	whether	the	construct	of	‘control’	of	IBD	had	been	used	in	the	development	of	previous	PROMs.		Our	goal	was	to	use	the	existing	literature	to	guide	the	development	of	a	novel	instrument.	
	
2.2	 	 Methods	
	A	literature	search	was	undertaken	of	the	PubMed	database	using	the	following	search	terms:	 	 [“inflammatory	 bowel	 disease”	 OR	 “IBD”	 OR	 “Crohn’s	 disease”	 OR	 “ulcerative	colitis”]	 AND	 [“patient	 reported	 outcome	 measure”	 OR	 “PROM”	 OR	 “control”	 OR	“questionnaire”].		Articles	published	up	to	and	including	September	2013	were	included.		Non-English	 language	 articles	were	 excluded.	 	 Further	 PubMed	 searches	 of	 identified	
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outcome	measure	 names	 were	 undertaken.	 	 Review	 article	 reference	 lists	 were	 also	screened	for	additional	instruments.		For	 each	 PROM,	 information	was	 extracted,	 if	 possible,	 on	 the	 following:	 instrument	name,	details	of	domains	and	individual	items,	item	scoring	method,	and	summary	score	system.	 	 Evidence	 for	 testing	 of	 the	 psychometric	 properties	 in	 patients	 with	inflammatory	bowel	disease	was	extracted	and	summarised.		
2.3	 	 Results	–	description	of	patient	reported	outcome	measures	
	A	total	of	10492	references	were	identified.		81	relevant	articles	were	identified	of	which	9	related	to	the	paediatric	population	and	were	therefore	excluded.		These	articles	related	to	27	IBD	specific	instruments	(the	majority	of	which	measure	health-related	quality	of	life)	and	5	generic	instruments	validated	for	use	in	IBD.	 	No	instruments	were	focused	specifically	 on	 the	 construct	 of	 disease	 ‘control’,	 confirming	 the	 novel	 nature	 of	 our	proposed	new	PROM.		Inflammatory	bowel	disease	questionnaire	(IBDQ)	and	its	adaptations		
• Inflammatory	Bowel	Disease	Questionnaire	(IBDQ)[143]	
• Extended	Inflammatory	Bowel	Disease	Questionnaire	(IBDQ-36)[199]	
• UK-IBDQ[195]	
• Short	Inflammatory	Bowel	Disease	Questionnaire	(SIBDQ)[188]	
• IBDQ	shorted	to	nine	items	(IBDQ-9)[200]		
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Other	measures	of	health-related	quality	of	life		
• Rating	Form	of	IBD	Patient	Concerns	(RFIPC)[185]	
• Short	Health	Scale	(SHS)[201]	
• Cleveland	Clinic	Questionnaire[202]	
• Edinburgh	IBD	Quality	of	Life	Questionnaire	(EIBDQ)[203]	
• Household	Member	Quality	of	Life	Questionnaire	(HHMQoL-IBD)[204]	
• Social	Impact	of	Chronic	Conditions-IBD	(SICC-IBD)	[205]	
• Cleveland	Global	Quality	of	Life	Instrument	(CGQL)[206]		Measures	of	other	aspects	of	health	status		
• Health	Status	Scales[186]	
• Burden	of	Symptoms	“feeling	thermometer”[207]	
• IBD	Self-efficacy	Scale	(IBD-SES)[197]	
• Numeric	Rating	Scale[208]		Measures	of	patient	satisfaction	with	healthcare		
• Treatment	Satisfaction	Questionnaire	for	Crohn’s	Disease	(TSQ-C)[198]	
• Quality	of	Care	Through	the	Patient’s	Eyes	IBD	(QUOTE-IBD)[209]					
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Measures	of	patient	knowledge		
• Crohn’s	and	Colitis	Knowledge	Score	(CCKNOW)[210]	
• Knowledge	Questionnaire	(KQ)[211]	
• Crohn’s	and	Colitis	Pregnancy	Knowledge	Score	(CCPKnow)[212]	
• Short	measure	of	patient	knowledge[213]		Measures	of	work,	productivity	and	disability		
• Work	Productivity	and	Activity	Impairment	in	Crohn’s	Disease	(WPAI:CD)[196]	
• Crohn’s	Disease	Perceived	Work	Disability	Questionnaire	(CPWDQ)[214]	
• Inflammatory	Bowel	Disease	Disability	Index[215]	
• Inflammatory	Bowel	Disease	Disability	Score	(IBD-DS)[216]		Generic	instruments	validated	for	use	in	IBD		
• EuroQol	(EQ-5D)[172]	
• Short	Form-36	(SF-36)[145]	
• 15D	Questionnaire[217]	
• Morisky	Medication	Adherence	Scale	(MMAS-8)[218]	
• Functional	Assessment	of	Chronic	Illness	Therapy-Fatigue	(FACIT-F)[219]		
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2.3.1	 	 Disease	specific	measures	
	
2.3.1.1	 	 	 	 	 	 	 	 	The	Inflammatory	Bowel	Disease	Questionnaire	and	its	adaptations
	 	The	most	widely	 used	 disease-specific	 instrument	 is	 the	 inflammatory	 bowel	 disease	questionnaire	(IBDQ)	[143].		The	IBDQ	measures	the	health-related	quality	of	life	of	IBD	patients.		Originally	developed	and	validated	in	Canada,	it	has	also	been	validated	in	many	other	 countries	 and	 languages[187,	 220,	 221].	 	 It	 has	 also	 been	 validated	 for	 use	 in	patients	following	ileal	pouch	anal	anastomosis	for	ulcerative	colitis[222,	223].		The	instrument	consists	of	32	questions	within	4	domains	(gastro-intestinal	symptoms,	systemic	symptoms,	emotional	function	and	social	function).		Response	options	are	on	a	7-point	 Likert	 scale	with	 1	 indicating	 a	 severe	 problem	 and	 7	 indicating	 no	 problem.		Hence	a	low	IBDQ	score	indicates	poor	health	related	quality	of	life[143].		The	IBDQ	has	also	been	modified	further	to	produce	an	extended	version	(The	IBD	quality	of	 life	 questionnaire)[199],	 the	 short	 inflammatory	 bowel	 disease	 questionnaire	(SIBDQ)[188],	the	IBDQ-9	[200]	and	the	UK-IBDQ	[195].		The	extended	IBDQ	contains	36	questions.		This	extended	instrument	was	developed	to	be	self-administered	by	patients	with	stable	 IBD	being	managed	within	the	outpatient	setting.		The	additional	questions	were	derived	by	splitting	some	of	the	original	questions	into	several	shorter	questions	as	well	as	the	identification	of	further	important	concerns	by	a	group	of	patients.		It	must	be	noted	that	although	this	instrument	has	been	used	to	
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compare	 controls	 to	 IBD	 patients,	 there	 are	 no	 data	 with	 regard	 to	 psychometric	properties	[199].		The	short	inflammatory	bowel	disease	questionnaire	(SIBDQ)	was	developed	for	use	in	routine	clinical	practice.		It	consists	of	10	questions	taken	from	the	original	32-item	IBDQ.		Items	 for	 inclusion	 were	 selected	 using	 regression	 analysis	 techniques[188].	 	 An	alternative	shortened	form,	the	IBDQ-9,	has	also	been	described.		Nine	items	for	inclusion	were	identified	using	Rasch	analysis	of	the	36	item	extended	IBDQ	(IBDQ-36).		Scores	for	the	 IBDQ-9	are	obtained	by	adding	the	9	responses	together	and	then	converting	this	value	to	a	scale	from	0-100[200].		The	UK-IBDQ	 is	 based	on	 the	original	 IBDQ	having	 been	modified	 in	 order	 to	 change	wording,	remove	questions	and	simplify	response	options.		The	UK	IBDQ	consists	of	30	questions	within	5	domains	(gastro-intestinal	I,	gastrointestinal	II,	systemic	symptoms,	emotional	function	and	social	function).		Response	options	range	from	1-4	as	opposed	to	1-7,	with	low	scores	again	indicating	poor	quality	of	life[195].		
2.3.1.2									Other	disease	specific	measures	of	health-related	quality	of	life		The	Rating	Form	for	IBD	Patient	Concerns	(RFIPC)	was	designed	in	order	to	measure	the	worries	 and	 concerns	 of	 patients	 with	 inflammatory	 bowel	 disease.	 	 The	 instrument	contains	25	items.		Responses	are	on	a	visual	analogue	scale	(VAS)	ranging	from	0-100	with	0	representing	“no	problem”	and	100	representing	“a	great	deal”.		It	was	designed	to	be	self-administered[185].		
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A	number	of	other	disease	specific	instruments	have	been	developed	to	measure	health	related	quality	of	life.		However,	they	are	not	widely	used.		The	Short	Health	Scale	is	a	4-item	questionnaire	originally	developed	for	use	in	ulcerative	colitis.	 	The	4	items	were	designed	 to	 cover	 4	 dimensions	 of	 health	 status:	 	 symptom	 burden,	 social	 function,	disease	 related	worry	 and	 general	well	 being.	 	 Responses	 are	 on	 a	 0-100	mm	 visual	analogue	scale	and	the	domain	scores	are	presented	rather	than	a	total	score[201].		The	Cleveland	Clinic	questionnaire,	another	measure	of	quality	of	life,	was	designed	to	be	used	 by	 patients	 “functioning	 in	 society”	 and	 therefore	 emphasis	 was	 placed	 on	measuring	effects	on	activities	of	daily	living	rather	than	medical	or	psychological	aspects	of	 health	 status.	 	 The	 questionnaire	 consists	 of	 47	 questions	 within	 4	 domains:		functional/economic,	social/recreational,	affect/life	in	general	and	medical/symptoms.	2	 questions	 are	 open	 ended	 and	 the	 remaining	 questions	 are	 answered	 on	 a	 5-point	Likert	scale.		This	questionnaire	was	also	used	by	the	authors	to	develop	a	quality	of	life	index.		The	index	consists	of	18	questions	selected	from	the	original	questionnaire	using	univariate	analysis	of	responses[202].		The	Edinburgh	Inflammatory	Bowel	Disease	(EIBDQ)	was	specifically	designed	to	be	both	user	 friendly	 and	 practical.	 	 It	 consists	 of	 15	 questions.	 	 Response	 options	 are	 either	yes/no	or	a	little/moderately/severely[203]		A	 questionnaire	 has	 also	 been	 developed	 to	measure	 the	 quality	 of	 life	 of	 household	members	of	people	with	IBD.		It	is	a	14-item	questionnaire.		The	questions	are	organised	into	2	domains:		daily	living	activities	and	mental	health.		Responses	are	recorded	on	a	7-point	Likert	scale[204].	
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The	 Social	 Impact	 of	 Chronic	 Conditions-Inflammatory	 Bowel	 Disease	 (SICC-IBD)	questionnaire	was	designed	to	measure	the	effect	of	IBD	on	social	aspects	of	quality	of	life	 (social	morbidity).	 	 Originally	 validated	 for	 use	 in	 ulcerative	 colitis,	 the	 SICC-IBD	consists	of	8	questions.		Each	question	consists	of	2	parts.		The	first	relates	to	“disruption	of	life”	and	is	answered	either	yes	or	no.		If	answered	positively,	the	second	part	of	the	question,	which	relates	to	“severity	of	disruption”	is	completed.		This	is	recorded	on	a	5-point	 Likert	 scale	 ranging	 from	 “extremely”	 to	 “not	 at	 all”.	 	 A	 SICC-IBD	 score	 can	 be	derived	from	the	questionnaire.	 	This	 is	a	weighted	sum	of	 items	answered	positively.		Hence,	a	low	score	represents	a	low	level	of	social	morbidity	[205].		The	Cleveland	Global	Quality	of	Life	 (CGQL)	 instrument	was	originally	developed	and	validated	to	measure	health	related	quality	of	life	in	patients	following	ileo-anal	pouch	procedures	 (IPPA)[206].	 	 It	 has	 since	 been	 validated	 for	 use	 in	 patients	with	 Crohn’s	disease[224].		The	CGQL	instrument	is	a	short	questionnaire	consisting	of	3	items:		current	quality	of	life,	current	quality	of	health	and	current	energy	level.		It	is	designed	to	be	self-completed	and	respondents	are	asked	to	rate	each	item	between	0-10	with	0	indicating	worst	state	and	10	indicating	best	state.		These	scores	are	summed	and	then	divided	by	30	to	produce	a	CGQL	utility	score[206]		
2.3.1.3	 Measures	of	other	aspects	of	health	status	
	The	 Ulcerative	 Colitis	 and	 Crohn’s	 Disease	 Health	 Status	 Scales	 were	 developed	 to	measure	 health	 status.	 	 Health	 status	 is	 described	 as	 a	 concept	 that	 incorporates	 a	
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patient’s	 perception	 of	 illness,	 functional	 status,	 psychological	 factors	 and	 disease	activity.		Multiple	regression	analyses	were	performed	in	order	to	determine	the	components	of	the	final	health	status	scales.		In	order	to	ensure	the	scales	were	easy	to	interpret,	variable	weights	were	used	to	produce	potential	scores	ranging	from	0-100.		The	resultant	health	status	scale	for	UC	consists	of	9	components	to	which	a	constant	is	added	to	produce	the	final	value.		The	scale	for	Crohn’s	disease	consists	of	10	variables	and	does	not	require	the	addition	of	a	constant	value[186].		An	instrument	consisting	of	simple	visual	analogue	scales	has	been	developed	to	measure	the	burden	of	Crohn’s	disease	and	 its	 treatment,	on	patients.	 	 It	 consists	of	2	 “feeling	thermometers”	ranging	from	0	(death)	to	100	(perfect	health).		The	first	scale	relates	to	burden	due	to	disease.		Respondents	are	instructed	to	place	a	“C”	on	the	thermometer	to	indicate	current	health	and	a	“P”	on	the	same	scale	to	indicate	perceived	health	in	the	absence	of	symptoms	related	to	Crohn’s	disease.	 	The	difference	between	these	values	represents	symptom	burden.		The	second	scale	is	related	to	treatment	associated	burden.		As	before,	patients	are	asked	to	place	a	“C”	on	the	scale	to	indicate	current	health.	 	They	are	asked	to	place	a	“P”	to	represent	their	perceived	health	if	all	aspects	related	to	treatment	could	be	stopped.		The	difference	 between	 the	 two	 values	 indicates	 treatment	 burden.	 	 This	 instrument	 is	designed	to	be	self-completed	and	can	be	undertaken	rapidly	and	therefore	be	used	in	the	clinical	setting[207].	
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A	questionnaire	to	determine	self-efficacy	in	IBD	has	been	developed[197].		Self-efficacy	has	been	 shown	 to	affect	health	outcomes	 in	other	 chronic	diseases	 [225]	and	 it	was	therefore	hypothesised	that	it	would	also	have	an	effect	on	patients	with	inflammatory	bowel	disease.		The	Inflammatory	Bowel	Disease	Self-Efficacy	Scale	(IBD-SES)	consists	of	29	items	within	4	domains	(managing	stress	and	emotions,	managing	medical	care,	managing	symptoms	of	disease	and	maintaining	remission).		Answers	are	recorded	on	a	10-point	Likert	scale	with	1	anchored	at	“not	sure	at	all”	and	10	at	“totally	sure”.		Hence,	a	low	score	indicates	low	self-efficacy	and	vice	versa	[197].		A	simple,	numeric	rating	scale	has	been	developed	to	measure	overall	health	status	and	general	well	being	in	IBD.		It	has	been	designed	to	be	self-completed	and	to	be	used	by	patients	with	both	Crohn’s	disease	and	ulcerative	colitis.		It	is	a	horizontal	11-point	scale	ranging	from	0	(“as	bad	as	being	dead”)	to	10	(“perfect	health”).		It	is	a	rapidly	completed	and	convenient	tool,	that	can	give	an	indication	of	overall	health	status	from	the	patient’s	perspective[208].	
	
2.3.1.4		 Measures	of	patient	satisfaction	with	healthcare	
	The	treatment	satisfaction	questionnaire	for	Crohn’s	disease	(TSQ-C)[198]	was	designed	to	measure	patient	satisfaction	with	medical	therapy	in	people	with	Crohn’s	disease.		The	TSQ-C	was	developed	through	adaptation	of	an	existing	satisfaction	questionnaire	used	in	gastro-oesophageal	reflux	disease	[226].		
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The	 questionnaire	 consists	 of	 32	 items	 within	 6	 domains:	 	 symptoms,	 satisfaction,	expectations,	“physician	relationships”,	bother	and	cost.	 	Response	options	range	from	“very	strongly	agree”	 to	“very	strongly	disagree”	and	are	recorded	on	a	6	point	Likert	scale[198].		The	QUOTE	(quality	of	care	through	the	patient’s	eyes)	questionnaires	measure	quality	of	healthcare	 from	the	patient’s	perspective	and	are	designed	to	be	self-administered.		They	have	been	designed	to	explore	the	importance	patients	convey	to	particular	aspects	of	care,	the	performance	of	the	healthcare	service	used	as	well	as	the	combined	effect	of	both	importance	and	performance	(termed	the	“quality	impact”	and	calculated	using	the	importance	and	performance	scores)[227].		A	 series	 of	 questionnaires	 exist	 for	 use	 in	 a	 number	 of	 specific	 diseases	 including	inflammatory	 bowel	 disease[209].	 	 Each	 questionnaire	 consists	 of	 10	 core	 generic	questions	in	addition	to	disease	specific	items.	 	The	QUOTE-IBD	consists	of	10	generic	questions	and	13	IBD	specific	items[209]	
	
2.3.1.5	 	 Measures	of	patient	knowledge	
	Providing	patient	education	is	an	important	aspect	of	chronic	disease	management	and	is	a	recommended	standard	of	 IBD	care	 in	 the	UK[192].	 	 It	has	been	shown	that	patient	education	 positively	 affects	 compliance	 with	 treatment	 and	 long	 term	 health	outcome[228].		
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The	Crohn’s	and	Colitis	Knowledge	Score	(CCKNOW)	is	a	self-administered	questionnaire	designed	to	measure	patient	knowledge	related	to	IBD	and	its	treatment.		It	contains	24	multiple	choice	questions	related	to	1)	general	IBD	knowledge,	2)	medication,	3)	diet	and	4)	complications	related	to	IBD.		All	but	2	of	the	questions	relate	to	IBD	in	general	and	can	therefore	be	answered	by	patients	with	either	ulcerative	colitis	or	Crohn’s	disease.		Each	correct	answer	yields	one	mark	with	no	negative	marking.		Therefore,	scores	range	from	0-30	[210].		The	CCKNOW	has	been	used	to	assess	patient	knowledge	in	a	number	of	surveys[229,	230].		The	 Knowledge	 Questionnaire	 (KQ)	 is	 a	 similar	 questionnaire	 for	 the	 assessment	 of	patient	knowledge	of	IBD[211].		A	patient	knowledge	questionnaire	related	to	pregnancy	and	IBD	has	also	been	developed	and	validated[212].		However,	these	instruments	have	not	been	used	as	extensively	as	the	CCKNOW	questionnaire.		The	instruments	described	above	are	used	to	assess	patient	knowledge	over	a	wide	range	of	areas.		More	recently,	a	short	outcome	measure	for	determining	patient	knowledge	has	been	developed.		It	was	designed	to	cover	knowledge	of	disease	risk	and	severity	only.		It	consists	of	10	questions	with	8	 related	 to	 the	 risk	of	developing	 IBD	and	2	 related	 to	factors	that	may	affect	severity	of	IBD.		It	has	been	shown	to	be	a	rapid	and	acceptable	measure	of	patient	knowledge[213].	
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2.3.1.6		 Measures	of	work,	productivity	and	disability		Inflammatory	bowel	disease	results	in	a	significant	economic	burden	and	costs	are	both	direct	medical	costs	as	well	as	indirect	costs,	as	a	result	of	loss	of	productivity[231].		The	Work	Productivity	and	Activity	 Impairment	Questionnaire	 (WPAI)	measures	 time	missed	from	work	as	well	as	work	and	activity	impairment	due	to	health	problems	[232].		The	WPAI	has	been	modified	for	use	in	a	number	of	chronic	diseases	[233,	234]	including	Crohn’s	disease	(WPAI:CD)[196].		The	WPAI:CD	questionnaire	consists	of	6	questions	relating	to	work	and	activity	over	the	preceding	7	days.		The	questions	cover	aspects	such	as	employment	status,	hours	missed	due	 to	 Crohn’s	 disease,	 hours	missed	 due	 to	 other	 reasons,	 hours	worked,	 degree	 to	which	 work	 productivity	 was	 affected	 (scale	 0-100)	 and	 degree	 to	 which	 regular	activities	 were	 affected.	 	 The	 overall	 score	 is	 expressed	 as	 a	 percentage	 of	impairment/productivity	loss.	High	scores	indicate	greater	impairment	[196].		Chronic	diseases	such	as	 IBD	may	also	 result	 in	 “work	disability”:	 	 the	partial	or	 total	inability	 to	 perform	work	 activities.	 	 The	 Crohn’s	 Disease	 Perceived	Work	 Disability	Questionnaire	 (CPWDQ)	was	developed	 in	order	 to	measure	work	disability	 from	 the	patient’s	perspective.		The	CPWDQ	consists	of	2	domains:		clinical	determinants	of	work	impairment	(containing	11	questions)	and	social	determinants	of	work	impairment	(5	questions).		Responses	are	
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recorded	on	a	4-point	Likert	scale.		Potential	scores	range	from	0-64	with	higher	scores	indicating	worse	perceived	disability[214].		It	 was	 recognised	 that,	 in	 contrast	 to	 other	 chronic	 diseases[235],	 patient	 reported	outcome	measures	of	disability	in	IBD	were	lacking[236].		Therefore,	a	disability	index	for	 use	 in	 IBD	 was	 developed	 [215].	 	 This	 index	 is	 based	 on	 an	 ICF	 (International	Classification	of	Functioning,	Disability	and	Health)	core	set	for	IBD[237].		The	 IBD	 Disability	 Index	 is	 designed	 to	 be	 competed	 via	 interview.	 	 It	 consists	 of	 28	questions.	 	 The	 majority	 of	 which	 are	 answered	 on	 a	 5-point	 Likert	 scale	 (1=no,	5=extreme).		There	are	also	a	number	of	symptoms-based	questions	such	as	number	of	liquid	stools	and	presence	of	arthritis	or	arthralgia[215].		A	second	disability	related	instrument,	the	inflammatory	bowel	disease	disability	score	(IBD-DS)	has	also	been	developed.		This	was	also	based	on	the	ICF	checklists	for	disability	and	 functioning,	 as	well	 as	 literature	 review	and	a	 survey	of	 experts.	 	 It	 consists	of	7	domains:		demographics,	mobility,	gastro-intestinal	related	problems,	self-care,	major	life	activities,	mental	health	and	interaction	with	the	environment.		There	are	49	questions;	the	 majority	 of	 questions	 are	 answered	 on	 a	 5-point	 Likert	 scale	 and	 a	 0-10	 visual	analogue	scale.		Higher	scores	indicate	more	significant	IBD	related	disability[216].		
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2.3.2	 Generic	 instruments	 that	 have	 been	 validated	 for	 use	 in	
inflammatory	bowel	disease	
	 There	are	a	number	of	generic	measures	of	health-related	quality	of	life	that	have	been	validated	 for	 use	 in	 inflammatory	 bowel	 disease.	 	 	 The	 EQ-5D	 questionnaire	 was	developed	by	the	EuroQol	group	-	a	multidisciplinary,	multinational	group	of	experts,	in	order	to	measure	health	related	quality	of	 life[172].	 	 It	consists	of	2	parts:	 	the	EQ-5D	descriptive	system	and	a	visual	analogue	scale.		The	descriptive	system	consists	of	5	dimensions:		mobility,	self-care,	usual	activities,	pain	and	discomfort	and	anxiety	and	depression.		Each	response	is	scored	between	1	and	3	(1	indicates	 no	 problem	 and	 3	 indicates	 severe	 problems).	 	 These	 numbers	 are	 then	expressed	as	a	5-digit	code.		The	visual	analogue	scale	(VAS)	is	a	vertical,	thermometer	scale	 ranging	 from	 0	 (worst	 imaginable	 health	 state)	 to	 100	 (best	 imaginable	 health	state).		The	EQ-5D	descriptive	system	can	be	converted	to	a	summary	 index	using	value	sets.		These	values	sets,	or	weightings,	have	been	derived	in	various	countries	using	the	EQ-5D	VAS	 valuation	 technique	 or	 the	 time	 trade	 off	 (TTO)	 technique.	 	 These	 are	 generally	derived	using	a	sample	of	the	general	population.		The	EQ-5D	is	widely	used	and	has	been	translated	into	many	languages[238].		The	Short	Form-36	(SF-36)	survey	is	another	widely	used	generic	instrument.		Originally	designed	for	use	in	the	Medical	Outcomes	Study,	it	also	measures	health	related	quality	of	 life[145].	 	 It	 consists	 of	 36	 items	 within	 8	 domains:	 	 physical	 functioning,	 role	
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limitations	 due	 to	 physical	 health	 problems,	 bodily	 pain,	 social	 functioning,	 general	mental	 health,	 role	 limitation	 due	 to	 emotional	 problems,	 vitality	 and	 general	 health	perceptions.		The	 scales	 can	 be	 used	 to	 produce	 two	 summary	 scores:	 	 the	 physical	 component	summary	 (PCS)	 and	 the	 mental	 component	 summary	 (MCS)[145].	 	 The	 SF-36	 was	originally	validated	in	the	United	States	of	America[239]	and	has	since	been	validated	in	the	 UK[240].	 	 The	 SF-36	was	 revised	 in	 1996.	 	 The	main	 adjustment	was	 to	 5-point	response	options[241].		The	15D	questionnaire	 is	 a	 generic	 instrument	 for	 the	measurement	of	health-related	quality	of	life.		It	consists	of	15	dimensions	which	each	contain	1	question.		Dimensions	include:	 	 breathing,	mental	 function,	 speech,	 vision,	mobility,	 usual	 activities,	 vitality,	hearing,	eating,	elimination,	sleeping,	distress,	discomfort/symptoms,	sexual	activity	and	depression[217].		Responses	produce	a	15D	profile	that	can	then	be	converted	to	a	single	index	using	value	sets.	 	It	must	be	noted	that	the	value	sets	available	are	based	on	the	Finnish	population[242].		The	Morisky	Medication	Adherence	Scale	(MMAS-8)	is	a	generic	tool	designed	to	measure	medication	adherence.		It	consists	of	8	questions,	the	majority	of	which	require	a	yes	or	no	answer.		The	final	question	has	5	response	options.		A	total	score	is	produced	and	on	the	basis	of	this,	respondents	can	be	classified	as	low,	medium	or	high	adherers	(<6	=low,	6-7=medium,	8=high)[218].		It	has	been	validated	for	use	in	patients	with	inflammatory	bowel	disease[243].		
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The	FACIT-fatigue	questionnaire	(FACIT-F)	is	a	measure	of	fatigue[219].		It	is	a	subscale	of	the	Functional	Assessment	of	chronic	Illness	Therapy	general	questionnaire	(FACIT-G)-a	measure	of	health-related	quality	of	life[244].		Initially	developed	to	measure	fatigue	associated	with	anaemia,	it	has	since	been	validated	for	use	in	the	general	population	as	well	as	a	number	of	chronic	diseases	including	IBD[245].		The	FACIT-F	questionnaire	consists	of	13	questions	that	are	answered	on	a	5-point	Likert	scale.		Total	scores	can	range	from	0	to	52	and	lower	scores	are	associated	with	higher	levels	of	fatigue[219].	
	
2.4	 Results	-	Psychometric	properties	of	PROMs	used	in	IBD	
	Criteria	 for	 the	 assessment	 of	 patient	 reported	 outcome	 measures	 have	 been	recommended[142]	 and	 are	 described	 fully	 in	 chapter	 1.	 	 Furthermore,	 eight	 key	attributes	 of	 outcome	measures	have	 been	 defined.	 	 These	 are:	 	measurement	model	(measurement	characteristics),	burden	(time	to	administer),	alternative	forms,	cultural	and	language	adaptations,	reliability,	validity,	responsiveness	and	interpretability[246]		
2.4.1	 Disease	specific	measures	of	quality	of	life	including	the	IBDQ	and	
its	adaptations			The	 IBDQ	 has	 been	 shown	 to	 have	 good	 test-retest	 reliability	 with	 co-efficient	 of	variations	ranging	from	0.06-0.15	(bowel	domain	0.07,	systemic	domain	0.15,	emotional	domain	0.11,	social	function	0.06)	reported	in	its	original	descriptive	study[143].		This	has	 been	 echoed	 in	 subsequent	 validation	 studies.	 	 High	 intra-class	 correlation	
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coefficients	 (ICC)	 across	 all	 domains	 have	 been	 reported	 in	 patients	 stable	 at	 follow	up[187,	247].		A	study	validating	the	IBDQ	in	the	UK	population	has	reported	similar	ICCs	(0.73-0.93)	for	individual	domains[187].		Internal	consistency	has	also	been	shown	to	be	good	(Cronbach’s	alpha	0.72-0.89	for	individual	domains)[187].		The	UK	IBDQ,	a	modified	version	of	the	original	IBDQ,	has	also	been	shown	to	be	reliable	(ICC	0.73	to	0.93,	Cronbach	alpha	0.78	to	0.86)[195].		Similarly	the	Short	Inflammatory	Bowel	Disease	Questionnaire	(SIBDQ)	remains	reliable	despite	its	shortened	length:		test-retest	correlation	was	good	(r=0.65)	and	internal	consistency	was	high	(Cronbach	alpha	0.78)[188].	 	Finally,	 the	testing	of	 the	 IBDQ-9	has	shown	good	correlation	of	scores	 in	stable	 patients	 at	 follow	up	 and	 high	 ICCs	 indicating	 test-retest	 reliability.	 	 However,	Cronbach	 alpha	 statistic	 was	 very	 high	 (UC-0.95,	 CD-0.91)	 [200]	 indicating	 possible	redundancy	of	included	items.		Original	validation	of	the	rating	form	for	IBD	patient	concerns	(RFIPC)	has	also	proven	test-retest	 reliability.	 	 Test-retest	 reliability	was	 high	 (test-retest	 correlation	 0.87	 for	overall	sumscore)[185].		Subsequent	studies	have	confirmed	this	in	Crohn’s	disease	(test-retest	 correlation	 0.90,	 ICC	 0.91)[248]	 and	 ulcerative	 colitis	 (test-retest	 correlation	0.87)[249].	 	 	 Cronbach	 alpha	 statistics	 were,	 again,	 very	 high	 (CD	 0.96[248],	 UC	0.95[249]).		The	 Short	 Health	 Scale	 has	 been	 shown	 to	 be	 reliable	 in	 Crohn’s	 disease[250]	 and	ulcerative	colitis[201]	with	good	test-retest	correlation,	and	good	 internal	consistency	(Cronbach	alpha	0.85)	[251].		
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There	 is	 some	 evidence	 to	 support	 the	 reliability	 of	 the	 remaining	 quality	 of	 life	instruments.		However,	this	is	less	comprehensive	than	that	presented	above	and,	in	most	cases,	relates	to	the	original	descriptive	study.			IBDQ	scores	have	been	shown	to	correlate	with	other	related	measures	such	as	patient	global	assessment	(r=0.36	to	0.52)[143].		Subsequent	full	validation	of	the	IBDQ	in	a	large	clinical	trial	of	patients	with	Crohn’s	disease	revealed	it	to	correlate	well	with	the	Crohn’s	disease	activity	index	(r=-0.67,	p<0.0001)[133]	and	relevant	domain	scores	of	a	generic	measure	of	health	status	(SF-36,	r=0.45	to	0.840)[187].		The	UK-IBDQ	has	also	been	shown	to	correlate	with	the	SF-36[195]	and	the	SIBDQ	with	relevant	disease	activity	indices[252].		The	IBDQ-9	correlates	well	with	the	IBDQ-36	from	which	it	is	derived	(r=0.91)	and	also	with	disease	activity	indices[200].		The	 IBDQ	 has	 also	 been	 shown	 to	 be	 able	 to	 discriminate	 between	 patient	 groups	(differing	 disease	 activity	 as	 defined	 by	 CDAI	 scores	with	 significantly	 different	mean	scores	between	groups,	p<0.001	ANOVA).			Significantly	different	IBDQ	scores	have	been	demonstrated	 between	 ulcerative	 colitis	 patients	 in	 remission	 and	 with	 active	disease[253].	 	 Similarly,	 the	 UK-IBDQ,	 SIBDQ	 and	 IBDQ-9	 have	 also	 been	 shown	 to	possess	discriminant	validity[188,	195,	200].		Regression	analysis	has	indicated	that	RFIPC	scores	are	related	to	disease	activity	and	generic	wellbeing	instruments[185].		RFIPC	scores	of	patients	with	Crohn’s	disease	have	been	shown	to	correlate	with	domain	scores	of	the	IBDQ,	the	short	health	scale	(SHS)	and	generic	 questionnaires[248].	 	 Correlation	 of	 RFIPC	 scores	 of	 patients	 with	 ulcerative	
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colitis	with	a	patient	reported	visual	analogue	scale	of	general	wellbeing	and	the	Sickness	Impact	Profile	(SIP,	a	generic	measure	of	health	status)	has	also	been	reported	[249].	The	RFIPC	correlates	poorly	with	traditional	measures	of	disease	activity,	but	this	is	not	unexpected	as	worries	and	concerns	of	patients	are	not	necessarily	related	to	current	disease	activity[248].		The	 Cleveland	 Clinic	 Questionnaire	 has	 also	 been	 shown	 to	 correlate	 with	 related	components	of	the	SIP	(Sickness	Impact	Profile)	questionnaire.		It	has	been	shown	to	be	able	to	distinguish	between	its	4	test	groups	(Crohn’s	disease	surgical,	Crohn’s	disease	non-surgical,	ulcerative	colitis	surgical,	ulcerative	colitis	non-surgical)	[202].		Some	of	the	components	of	the	health	status	scales	correlated	strongly	with	the	Crohn’s	disease	activity	index	(CDAI)[186].		The	 Short	 Health	 Scale	 item	 responses	 correlate	 with	 domain	 scores	 of	 other	 health	related	quality	of	 life	scores	(IBDQ,	SF-36,	RFIPC,	psychological	general	well-being)	 in	patients	 with	 Crohn’s	 disease[250]	 and	 ulcerative	 colitis[201].	 	 Scores	 from	 the	remaining	 instruments	have	also	been	 shown	to	 correlate	either	with	disease	activity	scores	or	other	patient	reported	measures.		The	 RFIPC	 has	 been	 show	 to	 possess	 discriminant	 validity.	 	 Mean	 sum-scores	 from	patients	with	active	disease	and	disease	in	remission	have	been	shown	to	be	significantly	different[248,	 249].	 	 This	 has	 also	 been	 shown	 to	 be	 the	 case	 with	 the	 Short	 Health	Scale[250],	house	hold	member	measure	(HHMQoL-IBD)[204]	and	the	Social	Impact	of	Chronic	Conditions	(SICC-IBD)[205].	
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The	 original	 validation	 study	of	 the	 IBDQ	 showed	 that	mean	 IBDQ	 scores	 changed	 in	patients	with	a	change	in	clinical	condition.		This	was	statistically	significant	for	bowel,	systemic	and	emotional	domains.[143].		The	difference	in	scores	of	patients	with	clinical	change	 over	 the	 standard	 deviation	 of	 the	 difference	 in	 scores	 of	 stable	 patients	was	greater	than	1	for	all	domains	indicating	responsiveness.			A	subsequent	validation	study	calculated	 large	 effect	 sizes	 for	 patients	 relapsing	 (UC	 1.70,	 CD	 8.04)	 and	 patients	entering	remission	(UC	-1.88,	CD	-1.81)	again	indicating	the	IBDQ	is	responsive	to	clinical	change[254].		The	 responsiveness	 ratios	 (mean	 change	 in	 scores	 of	 patients	 experiencing	 a	 change	divided	by	standard	deviation	of	the	scores	of	stable	patients)	of	sum-scores	and	domain	scores	for	bowel	function	1,	bowel	function	2	and	social	function	of	the	UK-IBDQ	were	all	greater	than	half	a	standard	deviation	in	stable	patients	indicating	responsiveness	[195].		SIBDQ	scores	of	patients	with	ulcerative	colitis	have	been	shown	to	change	significantly	in	patients	experiencing	a	change	in	disease	status[252].		The	IBDQ-9	is	also	responsive.		Median	scores	were	shown	to	change	in	patients	experiencing	relapse	and	the	effect	size	was	large	(UC-2.67,	CD	-5.29).		Whilst	the	RFIPC	has	been	shown	to	be	responsive	to	clinical	change	in	a	study	of	patients	with	Crohn’s	disease	(responsiveness	ratio	0.84)[248],	other	studies	have	not	been	able	to	prove	responsiveness	[185,	249].		Significant	changes	to	SHS	scores	have	been	shown	in	patients	experiencing	change	in	clinical	status	(CD:		responsiveness	ratio	1.06-1.98[250],	UC	0.45-1.95[201].		Effect	size	
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was	moderate	to	large	for	patients	with	improving	symptoms,	but	only	small	to	moderate	in	patients	with	deteriorating	symptoms	[251].		The	Cleveland	Global	Quality	of	Life	measure	(CGQL)	has	been	shown	to	be	responsive	in	patients	 following	 restorative	 proctocolectomy	 (significant	 change	 in	median	 score	 in	patients	 experiencing	 clinical	 change)[206]	 and	 in	 patients	 with	 Crohn’s	 disease	(significant	change	in	median	scores	following	surgery)[224].		Minimal	 clinically	 important	 difference	 (MCID),	 that	 is	 the	 smallest	 change	 in	 score	perceived	as	beneficial	 to	patients,	 is	 a	measure	of	 interpretability[255].	 	A	 change	 in	overall	IBDQ	score	of	between	16	and	30	points	has	been	shown	to	correspond	to	relapse	(as	 defined	 by	 CDAI	 score)	 or	 change	 in	 therapy	 by	 the	 physician[133].	 	 Regression	analysis	of	data	obtained	from	patients	with	Crohn’s	disease	treated	with	infliximab	has	estimated	cut	off	values	for	the	IBDQ.		An	IBDQ	score	of	170	or	more	suggests	clinical	remission	(as	defined	by	a	CDAI	score	of	150	or	less).		A	change	in	score	of	32	or	more	points	suggests	response	(as	defined	by	a	change	in	CDAI	score	of	-70	to	-100)[256].		The	MCID	of	the	short	IBDQ	is	9	points	which	corresponds	to	a	change	of	the	CDAI	of	100	points[188].		There	are	no	reported	data	on	minimal	clinical	important	difference	for	the	remaining	disease	specific	measures	of	quality	of	life.		
2.4.2	 	 Disease	specific	measures	of	other	aspects	of	health	status		There	are	limited	data	with	regard	to	the	reliability	of	these	instruments.		The	IBD	self-efficacy	scale	(IBD-SES)	has	been	shown	to	have	excellent	test-retest	correlation	of	scores	
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at	follow	up	(r=0.9).		However,	Cronbach	alpha	was	very	high	(0.96)	indicating	possible	item	redundancy[197].		Cronbach	alpha	values	for	the	health	status	scale	scores	ranged	from	0.59-0.84	and	hence	the	internal	consistency	of	the	components	of	the	health	status	scale	is	acceptable	to	good.		Test-retest	reliability	has	not	been	reported[186].		Excellent	correlation	of	the	2	“health	status”	questions	within	the	burden	of	symptoms	“thermometer”	 measure	 has	 been	 shown	 and	 this	 is	 an	 indicator	 of	 internal	consistency[207].	 	There	are	no	reported	reliability	data	related	to	the	numeric	rating	scale[208].		A	number	of	components	of	the	health	status	scales	correlate	with	CDAI	scores[186].		NRS	(numeric	rating	scale)	scores	have	also	been	shown	to	correlate	with	CDAI	as	well	as	HBI	scores[208].		Burden	of	symptoms	“thermometer”	scores	also	correlates	with	HBI	scores	as	well	as	short	IBDQ	scores[207].		IBD-SES	and	NRS	scores	have	been	shown	to	correlate	IBDQ	scores[197,	208].		Hence,	there	is	evidence	to	support	the	construct	validity	of	these	instruments.		There	is	little	evidence	with	regard	to	the	responsiveness	of	the	above	instruments	and	none	related	to	interpretability.		
2.4.3	 Disease	specific	measures	of	patient	satisfaction	with	healthcare	
	The	 QUOTE	 questionnaire	 has	 been	 shown	 to	 have	 test-retest	 reliability	 with	 high	correlation	between	scores	at	baseline	and	follow	up	(4	week	interval)[209].		Cronbach	
 90 
alpha	statistics	for	the	treatment	satisfaction	questionnaire	(TSQ-C)	ranged	from	0.63-0.94[198].		TSQ-C	 scores	 have	 been	 shown	 to	 correlate	 with	 related	 subscale	 scores	 of	 the	IBDQ[198].		In	contrast,	the	QUOTE	questionnaire	has	not	been	shown	to	correlate	with	health	 related	 quality	 of	 life[257].	 	 Scores	 do,	 however,	 correlate	 with	 related	 visual	analogue	scale	(VAS)	scores[209].		The	TSQ-C	has	also	been	shown	to	correlate	with	the	Crohn’s	Work	Activity	Impairment	Index	(CWAII).		It	can	also	discriminate	between	different	patient	groups	(defined	by	the	number	of	flare	ups	over	the	last	year	and	by	disease	activity)	with	significantly	different	scores	between	these	groups[198].		There	 is	 no	 evidence	with	 regard	 to	 the	 responsiveness	 and	 interpretability	 of	 these	instruments.		
2.4.4	 	 Disease	specific	measures	of	patient	knowledge	
	The	CCKNOW,	Knowledge	Questionnaire	 (KQ)	and	CCPKNOW	have	 all	been	 shown	 to	have	 very	 high	 Cronbach	 alpha	 statistics	 (>0.90)[210-212].	 	 The	 short	 measure	 of	knowledge	 has	 been	 shown	 to	 have	 good	 internal	 consistency	 (Cronbach	 alpha	0.73)[213].	 	 There	was	 high	 correlation	 of	 Knowledge	 Questionnaire	 scores	 between	baseline	 and	 4-week	 follow-up	 indicating	 test-retest	 reliability[211].	 	 Test-retest	reliability	has	not	been	reported	for	the	remaining	knowledge	questionnaires.	
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The	CCKNOW,	CCPKNOW	and	short	measure	of	knowledge	have	been	shown	to	be	able	to	 discriminate	 between	 groups	 of	 respondents	 with	 different	 levels	 of	 knowledge.		Significantly	 different	 scores	 were	 observed	 between	 medical,	 nursing	 and	administrative	staff[210,	212,	213].	 	CCPKNOW	and	short	measure	of	knowledge	have	also	 been	 shown	 to	 correlate	with	 CCKNOW	 scores	 indicating	 construct	 validity[212,	213].		Receiver	operating	characteristics	(ROC)	curve	analysis	has	been	used	to	identify	cut-off	scores	for	the	CCPKNOW	questionnaire.		A	score	of	14	indicates	a	very	good	knowledge	of	 IBD	 (sensitivity	94%,	 specificity	95%)	and	a	 score	of	8	 indicates	 “at	 least	 adequate	knowledge”	(sensitivity	78%,	specificity	70%)[212].		Interpretability	data	have	not	been	reported	 for	 the	 remaining	 knowledge	 instruments.	 	 Responsiveness	 has	 not	 been	reported	for	any	of	the	knowledge	questionnaires.		
2.4.5	 	 Disease	specific	measures	of	work,	productivity	and	disability		Whilst	 initial	 validation	 studies	 of	 the	 WPAI:CD	 (Work	 Productivity	 and	 Activity	Impairment	 in	 Crohn’s	 disease	Questionnaire)	 did	 not	 prove	 it	 to	 be	 reliable,	 a	more	recent	validation	has	shown	that	WPAI:CD	scores	were	similar	at	2	to	4	week	follow	up	of	 stable	 patients.	 	 Intraclass	 coefficients	were	 higher	 than	 0.7	 for	 all	domains	 of	 the	questionnaire[214].		The	CPWDQ	(Crohn’s	Perceived	Work	Disability	Questionnaire)	and	the	IBD	Disability	index	have	also	been	 shown	 to	be	 reliable	as	evidenced	by	non-significant	 changes	of	scores	at	 follow	up	(clinically	stable	patients)	and	high	ICCs	(0.89	 in	both	cases)	[214,	
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258].	 	 Analysis	 of	 the	 IBD-DS	 (IBD	 Disability	 score)	 has	 shown	 good	 repeatability	 of	scores	between	first	and	second	questionnaires	(Bland-Altman	analysis)[216].		Cronbach	alpha	 statistics	 have	 been	 reported	 for	 the	 CPWDQ	 (0.89)[214],	 IBD	 Disability	 Index	(0.94)	[258]	and	IBD-DS	(0.826	to	0.938)[216].		All	 instrument	 scores	 have	 been	 shown	 to	 correlate	 with	 disease	 activity	 indices.		WPAI:CD	and	CPWDQ	scores	correlate	with	Harvey	Bradshaw	Index	(HBI)	scores	[214]	[258]	 [259],	 Disability	 Index	 scores	 correlate	with	 CDAI	 scores	 (Crohn’s	 disease)	 and	partial	Mayo	scores	(ulcerative	colitis)	[258]	and	IBD-DS	scores	also	correlate	with	CDAI	scores[216].		The	WPAI:CD,	CPWDQ	and	IBD-DS	also	correlate	with	measures	of	health	related	quality	of	life[214,	216].			The	WPAI:CD	is	able	to	discriminate	between	patients	in	“best	health”	and	“worst	health”	(using	cut	off	values	of	the	CDAI,	IBDQ	and	SF-36	to	define	health	status).		Significantly	different	mean	scores	were	observed	between	these	groups[196].		Significantly	different	IBD	Disability	Index	scores	were	observed	between	IBD	patients	and	controls	[258].		Reduction	of	WPAI:CD	score	has	been	shown	to	be	larger	in	patients	entering	remission	compared	to	those	that	did	not.		In	addition,	effect	sizes	for	patients	that	failed	to	enter	remission	were	small,	but	were	moderate	to	large	in	patients	that	did	enter	remission	(0.54-1.02)[196].		This	indicates	the	WPAI:CD	is	responsive	to	clinical	change.			Significant	difference	 in	 IBD	 disability	 index	 scores	 of	 patients	 experiencing	 a	 change	 in	 clinical	condition	has	also	been	reported	[258].		Again,	this	indicates	it	is	responsive.		There	are	no	data	with	regard	to	responsiveness	for	either	the	CPWDQ	or	the	IBD-DS.		
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Minimally	important	difference	(MID)	values	for	the	WPAI:CD	have	been	estimated	using	data	from	the	PRECiSE	1	trial.		Change	in	WPAI:CD	scores	of	over	7%	may	be	considered	to	represent	substantial	change	in	workplace	productivity[260].		Cut-off	values	for	IBD	Disability	index	scores	have	been	derived	using	ROC	curve	analysis.		A	value	of	more	than	2.5	identified	controls	(sensitivity	94%,	specificity	79%)	[258].		
2.4.6	 	 Generic	instruments	validated	for	use	in	IBD	
	 	The	EQ-5D	has	been	validated	for	use	in	IBD.		Test-retest	reliability	has	been	shown	to	be	good.		In	patients	reporting	no	change	in	condition	at	follow	up,	agreement	of	answers	was	be	good	(Kappa	statistic	0.6-1.0).		The	ICC	for	the	EQ-5D	VAS	score	was	0.89[189].		A	subsequent	 larger	 study	 has	 also	 shown	 test-retest	 reliability	 of	 the	 EQ-5D.	 	 Again,	agreement	of	responses	to	the	descriptive	system	was	good	(Kappa	statistic	0.39-1.00).		The	ICC	for	the	EQ-5D	VAS	was	0.77	and	the	EQ-5D	index	0.89[190].		Internal	consistency	has	not	been	reported.		ICCs	for	the	dimension	scores	of	the	SF-36	ranged	between	0.56	and	0.92.		There	were	similar	 scores	 at	 baseline	 and	 follow	 up	 in	 stable	 patients	 in	 most	 cases.	 	 However,	differences	in	scores	were	only	statistically	different	in	2	dimensions	(ulcerative	colitis	patients:		physical	functioning	and	bodily	pain).		Internal	consistency	was	adequate	for	all	 dimensions	 in	 both	 Crohn’s	 disease	 and	 ulcerative	 colitis	 (Cronbach’s	 alpha	 0.72-0.91)[261].		Test-retest	reliability	has	been	determined	for	the	FACIT-F	questionnaire.		The	ICC	was	0.81	for	all	IBD	patients	with	stable	symptoms	at	follow	up	(assessments	were	completed	
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within	180	days).		Cronbach	alpha	statistic	was	very	high	for	ulcerative	colitis	and	Crohn’s	disease	groups[245].		This	may	indicate	item	redundancy.				Reliability	of	the	15D	questionnaire	and	the	MMAS-8	in	IBD	has	not	been	reported.		EQ-5D	 VAS	 scores	 correlate	 with	 disease	 activity	 indices	 for	 Crohn’s	 disease	 (r=-0.65[189],	r=-0.69[190])	and	ulcerative	colitis	(r=-0.71[189],	r=-0.67[190]).		The	EQ-5D	index	also	correlates	with	disease	activity[189,	190]).	 	Discriminative	validity	has	also	been	shown:	 	response	 levels	of	 the	EQ-5D	items	were	significantly	higher	 in	patients	with	active	disease.	 	However,	 as	expected	 for	a	generic	measure,	 a	 ceiling	effect	was	noted	for	the	EQ-5D	descriptive	system	and	the	EQ-5D	index[189].		Correlation	with	 related	 domains	 of	 other	measures	 has	 been	 shown.	 	 There	 is	 good	correlation	between	the	EQ-5D	VAS	and	the	general	health	domain	of	SF-36	(r=0.64),	the	overall	IBDQ	score	(r=0.73)	and	most	of	the	SF-36	and	IBD	sub-scores	[189].		The	SF-36	questionnaire	correlates	moderately	with	disease	activity	in	ulcerative	colitis	(r=-0.23	to	 -0.53)[262].	 	 It	has	also	been	shown	to	have	good	discriminative	ability	 in	IBD[261].				The	15D	questionnaire	correlates	strongly	with	total	IBDQ	scores	(r=0.733,	p<0.001)	and	frequency	of	IBD	symptoms.		It	is	also	able	to	discriminate	between	active	and	inactive	disease,	with	mean	scores	differing	significantly[263].		
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The	Morisky	Medication	Adherence	Scale	(MMAS-8)	has	been	shown	to	correlate	with	other	indicators	of	medication	adherence	(continuous	single	medication	availability	and	mean	possession	interval).	 	Low	adherers	(as	defined	by	previously	set	cut-off	values)	had	lower	indicators	of	medication	adherence	as	compared	to	medium	adherers;	medium	adherers	 had	 lower	 scores	 than	 high	 adherers.	 	 There	 was	 a	 significant	 difference	between	these	3	groups	(ANOVA	p<0.001).		Harvey	Bradshaw	Index	(HBI)	scores	were	also	statistically	different	between	these	3	groups.		Lower	scores	were	associated	with	the	high	adherer	group	and	higher	scores	with	the	low	adherer	group[243].		FACIT-F	 scores	 correlate	with	 disease	 activity	 indices	 (CD:	 	HBI	 r=-0.49	 p<0.001,	UC:		SCCAI	 r=-0.59,	 p<0.001).	 	 Scores	 also	 correlate	 with	 inflammatory	 markers	 and	haematocrit	in	ulcerative	colitis	patients,	but	not	those	with	Crohn’s	disease.		Significantly	different	 means	 scores	 were	 observed	 when	 comparing	 IBD	 patients	 with	 control	respondents	from	the	general	population	(38.9	vs	43.6,	p<0.001)[245].		EQ-5D	VAS	scores	have	been	shown	to	change	significantly	in	IBD	patients	with	a	change	in	health	 status	as	determined	by	a	 transition	question[189,	190].	 	Changes	 in	EQ-5D	index	scores	have	also	been	shown	in	patients	with	improved	health	(if	not	already	in	remission).		Standardised	response	means	(SRM)	were	large	in	all	subgroups	of	patients	with	 the	exception	of	 those	already	 in	 remission	 reporting	an	 improvement	 in	health	status[190].		The	 responsiveness	 of	 SF-36	 was	 adequate	 for	 most	 domains,	 although	 Guyatt’s	responsiveness	statistic	values	were	generally	low	(-0.18	to	-0.5	for	ulcerative	colitis	and	-0.14-	-0.63	for	Crohn’s	disease).		Values	were	lowest	for	the	“role-physical”	domain[261].		
 96 
A	 trial	 involving	 patients	 with	 ulcerative	 colitis	 identified	 large	 effect	 sizes	 for	 the	physical	component	score	(PCS,	1.21)	and	the	physical	functioning	sub-score	(1.89)[262]		Significant	 change	 in	FACIT-F	 scores	has	been	 shown	 to	be	associated	with	 change	 in	clinical	condition	determined	by	a	physician	global	assessment[245].		Significant	change	in	 FACIT-F	 score	 has	 also	 been	 observed	 in	 patients	 entering	 remission	 following	treatment	with	adalimumab[264].		Responsiveness	has	not	been	reported	for	the	15D	questionnaire	or	the	MMAS-8.		Data	 from	 two	phase	 III	 randomised	 controlled	 trials	 of	 certolizumab[265,	 266]	have	been	used	to	estimate	minimal	clinically	important	difference	(MCID)	values	for	the	EQ-5D	VAS	and	 the	SF-36	 for	patients	with	Crohn’s	disease.	MCID	value	estimates	 (using	IBDQ	for	anchor-based	estimates)	were	4.1	for	the	mental	component	summary	(MCS)	and	3.9	for	the	physical	component	summary	(PCS).		The	MCID	estimate	for	the	EQ-5D	VAS	was	9.2	[267].			Estimates	of	meaningful	difference	 for	 the	 components	of	 the	EQ5D	 in	 IBD	have	been	obtained	with	a	regression	model	(by	regression	analysis	using	the	transition	question	for	anchoring).		Improvement	in	the	UK	EQ-5D	index	score	by	0.08	and	the	EQ-5D	VAS	of	11	was	associated	with	patient	perception	of	better	health.		A	fall	in	UK	EQ-5D	index	of	0.11	and	the	EQ-5D	VAS	of	14	was	associated	with	perception	of	worsening	health[190].		
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Cut-off	 values	 have	 been	 determined	 for	 the	 MMAS-8	 questionnaire	 in	 its	 original	validation	study[218].		However,	this	study	relates	to	patients	with	hypertension	and	cut-off	values	have	not	been	determined	for	patients	with	IBD.		Interpretability	 has	 not	 been	 reported	 for	 the	 15D	 instrument	 or	 the	 FACIT-F	questionnaire.		
2.5	 	 Summary	
	There	has	been	increasing	interest	in	the	use	of	patient	reported	outcome	measures	over	the	last	two	decades[161,	162].		A	number	of	instruments	have	been	developed	for	use	in	IBD[143,	185,	196],	but	as	yet	none	have	become	established	in	routine	clinical	care.		A	literature	search	of	the	PubMed	database	identified	27	IBD	specific	instruments,	the	majority	of	which	are	designed	to	measure	health	related	quality	of	life.	 	A	number	of	instruments	 exist	 to	 measure	 other	 constructs	 such	 as	 patient	 satisfaction	 with	healthcare,	patient	knowledge	and	disability.	 	5	generic	outcome	measures	have	been	validated	for	use	in	inflammatory	bowel	disease.		Of	the	disease	specific	instruments,	the	IBDQ[143]	is	the	most	well	established.	 	There	has	been	extensive	work	related	to	its	validation	including	its	translation	into	a	variety	of	languages.		It	has	also	undergone	a	number	of	adaptions	including	shortening	to	for	the	short	IBDQ	(SIBDQ[188]).		It	has	also	been	adapted	to	form	an	Anglicised	version[195].		Other	measures	of	quality	of	life	exist,	although	they	have	not	been	as	comprehensively	validated	as	the	IBDQ.	
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	A	number	of	instruments	have	been	designed	to	measure	other	aspects	of	health	status	such	as	self-efficacy[197]	and	burden	of	symptoms	and	treatment[207].		However,	these	instruments	 have	 not	 been	 validated	 beyond	 their	 original	 descriptive	 studies.		Questionnaires	to	determine	patient	satisfaction	with	healthcare	and	patient	knowledge	are	described.		The	QUOTE	questionnaire[209]	and	the	CCKNOW[210]	questionnaire	are	the	most	established	of	these	instruments.		IBD	results	in	significant	economic	burden[231]	and	the	Work	Productivity	and	Activity	Impairment	Questionnaire[196]	has	been	designed	to	measure	aspects	related	to	this.		A	further	instrument	to	measure	“work	disability”	specifically	(the	partial	or	total	inability	to	perform	work	activities)	 also	exists[214].	 	More	 recently	 there	has	been	a	move	 to	develop	PROMs	to	assess	disability	related	to	IBD.				The	IBD	Disability	index[215]	and	the	 IBD	 Disability	 Score[216]	 are	 both	 based	 on	 ICF	 checklists	 for	 disability	 and	functioning.		A	 number	 of	 generic	 outcome	 measures	 exist.	 	 Both	 the	 EQ-5D	 and	 SF-36	 are	 well	established	and	extensively	used.	 	They	have	 both	been	validated	 for	use	 in	 IBD[189,	261].			Health-related	 quality	 of	 life	 is	 the	most	 common	 construct	measured	 by	 IBD	 related	outcome	measures.		The	IBDQ	is	the	most	established	disease	specific	instrument.		It	has	been	 translated	and	validated	 in	many	 languages	and	 there	 is	 evidence	 to	support	 its	reliability,	 validity,	 responsiveness	 and	 interpretability.	 	 	 A	 number	 of	 other	 disease	specific	measures	do	exist,	but	are	neither	as	widely	used	nor	as	thoroughly	validated.		
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However,	the	majority	are	comprehensive	questionnaires	that	are	too	burdensome	to	be	used	in	routine	clinical	care.		They	are,	therefore,	mainly	of	use	in	clinical	trials.		There	are	favourable	data	related	to	the	use	of	a	small	number	of	generic	measures	in	IBD.		Whilst	some	are	short	and	can	be	completed	rapidly,	the	use	of	generic	measures	in	isolation	 is	 not	 recommended	 as	 they	 may	 lack	 sensitivity	 to	 clinically	 important	change[142].	A	 few	shorter	 IBD	specific	 instruments	exist,	an	example	of	which	 is	 the	short	IBDQ.		However,	none	have	become	established	in	day-to-day	clinical	care.		This	led	us	to	conceive	the	idea	that	for	‘IBD	Control’	to	offer	a	novel	approach	and	find	a	place	in	busy	 routine	settings,	 it	 should	aim	 to	be	a	 short	 and	generic	 instrument	–	 taking	 the	simplicity	 and	 wide	 applicability	 of	 a	 general	 measure	 but	 tailored	 specifically	 for	inflammatory	bowel	disease.				Given	the	recognised	importance	of	the	use	of	PROMs	in	clinical	practice,	there	is	a	need	to	develop	outcome	measures	that	can	be	used	in	routine	clinical	care.		In	order	to	be	of	use	in	this	role,	an	instrument	must	be	rapid	and	easy	to	complete	and	must	not	be	overly	burdensome	to	administer.		The	above	review	of	current	PROMs	highlights	the	need	to	develop	such	instruments.								
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Chapter	3	Methods	
	In	the	present	chapter,	I	describe	the	methods	adopted	for	the	development,	piloting	and	prospective	psychometric	 testing	of	 the	 IBD	Control	questionnaire.	 	The	results	of	 the	development	phase	and	description	of	the	final	instrument	are	reported	in	chapter	4,	and	the	data	relating	to	the	prospective	validation	study	are	presented	in	chapter	5.		
3.1	 	 Development	phase	
	
3.1.1	 	 Questionnaire	specification	
	A	steering	group	was	convened	in	order	to	formulate	a	specification	for	the	IBD	Control	questionnaire.	 	 Steering	 group	members	 included	 2	 Consultant	 Gastroenterologists,	 1	Specialist	Registrar	 in	Gastroenterology	and	2	 IBD	Specialist	Nurses.	 	With	the	aim	of	developing	a	patient	reported	measure	of	control	of	disease	for	use	in	routine	clinical	care	in	mind,	the	group	defined	a	number	of	desirable	and	undesirable	characteristics.		The	details	of	the	specification	are	presented	in	chapter	4	(see	results	section	4.1).		
3.1.2	 	 Literature	review	
	The	 design	 of	 IBD	 Control	 was	 informed	 by	 the	 literature	 review	 of	 existing	 patient	reported	outcome	measures	(PROMs)	used	in	IBD.		The	methods	for	the	literature	review,	and	results,	were	described	in	chapter	2.	My	review	of	the	literature	confirmed	a	wealth	of	existing	knowledge	derived	from	IBD	patients	about	the	impact	of	these	conditions	on	health	and	functional	status,	and	informed	the	identification	of	several	core	domains	that	
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were	 common	 to	 the	 existing	 generic	 and	 disease-specific	 instruments	 (see	 results	section	4.6).	
	
3.1.3	 	 Focus	group	meetings	and	one-to-one	interviews		
3.1.3.1	 	 Research	team	and	reflexivity	
	Focus	 groups	 and	 interviews	 were	 facilitated	 by	 me,	 a	 Gastroenterology	 Specialist	Registrar	undertaking	research	during	an	approved	break	in	clinical	training	for	research	purposes.	 	 My	 qualifications	 at	 the	 time	were	 Bachelor	 of	 Science	 and	MB	BS.	 	 I	 had	undertaken	 the	 required	 “Good	 Clinical	 Practice”	 training.	 	 The	 meetings	 were	 also	attended	by	a	member	of	the	IBD	specialist	nurse	team	who	assisted	with	collection	of	field	notes.	 	 I	had	not	had	contact	with	the	participants	before	the	study.	 	An	 informal	introduction	was	given	to	the	participants	at	the	time	of	meeting	or	interview	as	to	my	role	in	the	research	team	and	the	reason	for	undertaking	the	research.					The	study	was	approved	by	the	NHS	Research	Ethics	Committee	(REC)	and	all	patients	had	received	a	patient	information	leaflet	and	provided	written	informed	consent.		
3.1.3.2	 	 Qualitative	study	design	
	Participants	were	invited	to	take	part	in	the	qualitative	study	in	one	of	two	ways.	 	The	study	was	publicised	at	a	Patient	Education	Day	that	was	run	at	the	recruiting	hospital.		They	were	asked	to	provide	contact	details	 if	 they	were	willing	to	participate	 in	 focus	groups	or	interviews.		Secondly,	patients	were	approached	face-to-face,	during	scheduled	
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clinical	visits	to	the	specialist	nurse	led	clinics.		Again,	they	were	asked	to	provide	their	contact	details	if	they	were	happy	to	participate.		Two	 focus	group	meetings	were	undertaken,	with	6	patient	volunteers	 in	each	group.		One	focus	group	included	patients	with	ulcerative	colitis	and	the	other	included	patients	with	Crohn’s	disease.		13	individual	interviews	were	also	performed.		The	focus	group	meetings	were	held	at	the	recruiting	hospital	and	did	not	coincide	with	the	patients’	routine	clinical	visits.	 	One-to-one	 interviews	were	also	performed	at	 the	recruiting	hospital.	 	These	were	arranged	to	occur	at	the	time	of	clinic	attendance	and	were	performed	in	clinic	either	before	or	after	their	scheduled	clinical	appointment.			The	patients	were	asked	to	discuss	the	concept	of	“control”	of	their	inflammatory	bowel	disease	 and	 particularly	 the	 issues	 that	 they	 felt	 were	 associated	with	 good	 and	 bad	control.		They	were	also	shown	a	number	of	questionnaire	types	and	asked	to	comment	on	these.		Other	issues	discussed	included	ideal	length	of	the	questionnaire	and	when	and	how	they	would	wish	to	complete	 it.	 	 	Field	notes	were	taken	during	and	 immediately	after	the	meetings	and	interviews.		Once	 a	 point	was	 reached	where	 new	 themes	were	 not	 arising	 from	 interviews,	 and	therefore	data	saturation	had	been	reached,	qualitative	data	collection	was	brought	to	a	close.		To	identify	core	domains	and	candidate	items	for	the	questionnaire,	I	undertook	thematic	analysis	of	field	notes	which	included	the	transcription	of	verbatim	patient	quotes.	This	
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was	conducted	deliberately	as	a	top-down	or	theoretical	thematic	analysis,	driven	by	my	researcher-defined	aims.		My	explicit	aims	were:	(a)	To	verify	that	the	themes	expressed	by	our	patients	mapped	to	the	broad	domains	elicited	already	from	the	literature	review	of	PROMs;	(b)	To	confirm	that	these	mapped	onto	the	construct	of	disease	‘control’	from	the	patient	perspective;	(c)	To	identify	any	new	themes	expressed	by	patients	in	relation	to	the	construct	of	IBD	‘control’.		In	analysing	the	data	from	the	interviews	and	focus	groups,	I	broadly	followed	the	six-phase	process	outlined	by	Braun	&	Clarke[268].	 	This	involved:	1)	familiarising	myself	with	the	content	of	all	data	transcripts	to	allow	reflection	on	the	overall	body	of	data.		This	included	making	draft	notes	and	“jotting	down”	initial	impressions.		2)	generating	initial	‘codes’	 within	 the	 field	 notes.	 	 This	 was	 informed	 by	 my	 knowledge	 of	 the	 existing	literature	review.	 	Field	notes	and	verbatim	quotes	were	reviewed	manually.	 	Data	felt	relevant	 to,	 or	 capturing	 something	 interesting	 related	 to	 the	 research	question,	were	coded.	 	 3)	 searching	 for	 themes.	 	 Again,	 this	 process	 was	 informed	 by	 the	 literature	review.		Patient	derived	themes	were	then	mapped	onto	the	candidate	themes	derived	from	the	literature	review.			4)	Reviewing	themes	in	order	to	ensure	that	they	made	sense	in	relation	to	the	design	specification	for	the	PROM.		5)	Defining	final	themes.		This	was	a	final	review	of	the	themes	and	how	they	related	to	each	other.		6)	Write	up	of	final	results	(see	chapter	4	sections	4.3,	4.4	and	4.6).		
	
3.1.4	 	 Questionnaire	development		Literature	review	and	thematic	 analysis	of	 focus	group	and	one	to	one	 interview	data	resulted	 in	 the	 identification	 of	 a	 number	 of	 recurring	 themes.	 	 These	were	 used,	 in	
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conjunction	with	the	previously	defined	questionnaire	specification,	to	select	items	for	inclusion	(see	chapter	4,	section	4.6).		The	draft	questionnaire	was	completed	by	30	patients	in	order	to	test	acceptability.		The	patients	were	also	asked	 to	 comment	on	 the	questionnaire.	 	On	 the	basis	of	 this	pilot	study,	changes	to	layout	and	wording	were	made.		
3.2	 	 Prospective	validation	of	the	IBD	Control	Questionnaire	
	Patients	were	recruited	from	a	single	centre.		This	was	a	large	teaching	hospital	serving	approximately	330	000	people.	 	Patients	were	recruited	at	routine	visits	 to	outpatient	clinics,	drug-monitoring	clinics	and	admissions	to	the	day-case	unit.		Patients	admitted	to	hospital	due	to	inflammatory	bowel	disease	were	also	recruited.		Inclusion	 criteria	 included	 adult	 patients	with	 a	 confirmed	diagnosis	 of	 inflammatory	bowel	disease	based	on	standard	clinical,	endoscopic,	radiological	or	histological	criteria	of	6	months	or	more.		Patients	were	excluded	it	they	did	not	speak	English	or	if	they	had	cognitive	impairment	or	active	psychiatric	disease.		Informed	consent	was	obtained.		Patients	were	asked	to	complete	a	questionnaire	pack	(before	their	consultation	in	the	case	of	outpatients).	 	This	pack	 included	the	IBD	Control	Questionnaire	as	well	as	 the	following	established	outcome	measures:		
The	 UK	 Inflammatory	 Bowel	 Disease	 Questionnaire	 (UK	 IBDQ)	 is	 a	measure	 of	 health-related	quality	of	life	for	use	in	patients	with	IBD.		It	is	an	Anglicised,	modified	version	of	
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the	original	inflammatory	bowel	disease	questionnaire	(IBDQ)	and	has	been	validated	in	the	UK	population.	 	 It	consists	of	32	questions,	each	with	4	response	options[195].	 	 If	more	than	half	of	items	were	missing	from	one	or	more	subdomains,	the	questionnaire	was	 disregarded.	 	 Otherwise,	 missing	 items	 were	 substituted	 with	 the	 mean	 of	 the	remaining	items	within	the	subdomain[269].		
The	EQ-5D	(Euro-Qol,	EQ-5D-3L)	Questionnaire	is	a	generic	measure	of	health	status.		It	consists	 of	 2	 parts:	 	 the	 EQ-5D	 descriptive	 system	 and	 a	 visual	 analogue	 scale.	 	 The	descriptive	system	consists	of	5	dimensions,	which	are	expressed	as	a	5-digit	code.		The	visual	 analogue	 scale	 (VAS)	 is	 a	 vertical,	 thermometer	 scale	 ranging	 from	 0	 (worst	imaginable	health	state)	to	100	(best	imaginable	health	state)[172].	 	The	EQ-5D	utility	index	values	are	calculated	using	available	value	sets.		
The	Hospital	 Anxiety	 and	Depression	 Scale	 (HADS)	 is	 a	 validated	 questionnaire	 for	 the	measurement	 of	 anxiety	 and	 depression.	 	 It	 contains	 14	 questions	within	 2	 domains	(anxiety	and	depression).		Separate	scores	for	each	domain	are	obtained[270].		A	 clinical	 assessment	of	 current	 disease	 activity	was	 undertaken	 by	 a	member	 of	 the	research	team	using	the	following	disease	activity	indices:		
The	Harvey	Bradshaw	Index	(for	patients	with	Crohn’s	disease)	is	an	established,	simple	measure	of	disease	activity.	 	 It	consists	of	5	questions	related	to	symptoms,	signs	and	complications.	 	 A	 score	 of	 less	 than	 5	 indicates	 remission,	 whereas	 a	 score	 over	 16	indicates	severe	disease[136].		
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The	Simple	Clinical	Colitis	Index	Activity	(SCCAI)	(for	patients	with	ulcerative	colitis	and	IBD	unclassified)	is	a	simple	disease	activity	measure	based	on	patient	symptoms[128].		If	 the	patient	was	due	 to	have	a	 clinical	 review	 (eg	 clinic	 appointment),	 the	doctor	or	specialist	 nurse	 in	 clinic	was	 asked	 to	 record	 a	 “Global	 Physician	 Assessment”	 of	 the	patient’s	 current	 disease	 activity	 (remission,	mild,	moderate	 or	 severe)	 and	 whether	disease	activity	had	changed	(better,	 the	same	or	worse).	 	 Information,	with	regard	to	changes	to	treatment	made	as	a	consequence	of	the	clinical	encounter,	was	also	recorded.		Hospital	records	were	also	used	to	obtain	information	with	regard	to	diagnosis,	disease	duration,	disease	extent	and	phenotype.		Previous	hospital	admissions,	surgery	and	co-morbidity	were	also	recorded.		Current	therapies	were	also	documented.		
3.2.1	 Assessment	of	the	psychometric	properties	of	the	IBD	Control	Questionnaire	
	
3.2.1.1	 Acceptability	and	feasibility	
	Ten	patients	were	 timed	whilst	 completing	 the	 IBD	Control	Questionnaire	 in	order	 to	obtain	an	average	completion	time.		All	questionnaires	completed	at	baseline	visits	were	assessed	for	completion,	and	completion	rates	for	individual	questions	were	calculated.		
3.2.1.2	 Reliability	
	Reliability	was	assessed	in	2	groups	of	patients.		In	both	cases,	correlation	of	serial	scores	and	intraclass	correlation	coefficients	were	calculated.	
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	Firstly,	20	patients	were	sent	a	further	questionnaire	pack	(containing	the	IBD	Control	and	UK	IBDQ	questionnaires)	by	post,	2	weeks	after	their	first	questionnaire	completion,	in	order	to	determine	test-retest	reliability.	 	The	IBD	Control	scores	of	stable	patients	were	 compared.	 	 Patients	with	 stable	 disease	were	 defined	 on	 the	 basis	 of:	 	 1)	 their	response	 to	 the	 transition	 question	within	 IBD	 Control	 (Question	 2	 “Over	 the	 past	 2	weeks	have	your	bowel	symptoms	been	getting	worse,	getting	better,	or	not	changed”)	and	2)	no	more	than	a	10-point	change	in	their	total	UK	IBDQ	score.		Secondly,	scores	obtained	from	stable	patients	who	completed	questionnaires	on	more	than	one	occasion	(due	to	multiple	clinic	visits)	were	also	compared.		In	this	case,	stable	patients	were	identified	if	there	was	no	change	in	the	Global	Physician	Assessment.		
3.3.3	 Internal	consistency	
	Internal	 consistency	 was	 assessed	 for	 individual	 questions	 and	 sub-scores	 using	Cronbach	 alpha[271].	 	 Spearman’s	 correlation	 coefficient	 was	 also	 used	 to	 compare	individual	question	responses	and	sub-scores	to	 the	 IBD	Control	visual	analogue	scale	(VAS)	score.		
3.3.4	 Construct	validity	
	There	is	no	“gold	standard”	measure	of	control	of	IBD.		Therefore,	construct	validity	was	determined	by	comparing	IBD	Control	scores	with	scores	of	a	number	of	established	and	validated	measures	using	Spearman’s	correlation.	These	established	measures	included	
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a	 disease	 specific	measure	 of	 health	 related	 quality	 of	 life	 (UK	 IBDQ[195]),	 a	 generic	measure	of	health	status	(EQ-5D[172])	as	well	as	the	Hospital	Anxiety	and	Depression	Scale	 (HADS[270]).	 	 Scores	were	 also	 compared	with	 disease	 activity	 indices	 (Harvey	Bradshaw	Index[136]	and	the	Simple	Clinical	Colitis	Activity	Index[128]).		The	ability	of	the	IBD	Control	Questionnaire	to	differentiate	between	clinically	different	groups	was	 tested	 (discriminant	 validity).	 	 Patients	were	 categorised	 on	 the	 basis	 of	Physician	 Global	 Assessment	 (remission,	mild,	moderate,	 severe).	 	 Mean	 scores	were	compared	using	analysis	of	variance	(ANOVA).		Multiple	variable	linear	regressions	were	performed	in	order	to	identify	patient	factors,	other	than	disease	activity,	independently	associated	with	IBD	Control	scores.		
3.2.1.5	 Responsiveness	
	Responsiveness	was	assessed	in	patients	that	completed	follow	up	assessments	and	that	had	experienced	a	change	in	clinical	condition.		Responsiveness	was	tested	in	two	groups.		In	the	first,	change	in	clinical	condition	was	defined	as	a	change	of	total	UK	IBDQ	score	of	more	than	10	points.		In	the	second,	the	Physician	Global	Assessment	was	used	to	identify	change	in	clinical	state	from	baseline.		Change	scores	were	calculated	(i.e.	the	difference	in	scores	between	visit	1	and	visit	2).		Change	scores	for	the	IBD	Control	were	correlated	with	change	scores	of	the	established	outcome	measures	and	disease	activity	indices.		
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The	following	responsiveness	statistics	were	also	calculated:		
Effect	 size	was	 calculated	 by	 dividing	 the	 difference	 between	 mean	 scores	 between	assessments	by	the	standard	deviation	of	baseline	scores.		
The	standardised	response	mean	(SRM)	was	calculated	by	dividing	the	difference	in	mean	scores	between	assessments	by	the	standard	deviation	of	change	scores.		
The	 modified	 standardised	 response	 mean	 (MSRM)	 was	 calculated	 by	 dividing	 the	difference	 in	mean	 scores	 between	 assessments	 by	 the	 standard	 deviation	 of	 change	scores	 of	 clinically	 stable	 subjects.	 	 No	 change	 in	 Physician	 Global	 Assessment	 and	 a	change	in	UK	IBDQ	score	of	no	more	than	10	points	was	used	to	identify	stable	patients.		
3.2.2	 Definition	 of	 cut-off	 values	 of	 IBD-Control	 scores	 for	 the	 detection	 of	
quiescent	IBD.	
	Patients	were	defined	as	having	quiescent	IBD	if	all	of	the	following	criteria	were	met:		 1. Clinical	remission	defined	by	2	or	more	of	the	following	disease	activity/	patient	reported/physician	 reported	 measures:	 	 simple	 clinical	 colitis	 activity	 index	(SCCAI)	less	than	4	or	Harvey	Bradshaw	Index	(HBI)	less	than	5,	UK-IBDQ	score	of	greater	or	equal	to	90	and	a	Physician	Global	Assessment	of	“remission”.		
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2. The	patient	was	not	receiving	a	course	of	oral	steroids,	antibiotics	(as	a	treatment	for	IBD),	therapeutic	liquid	diet,	induction	with	biological	therapies	or	awaiting	surgery	for	IBD.		 3. The	patient	had	not	answered	“worse”	to	the	transition	question	within	the	IBD	Control	Questionnaire	 (Question	2	–	Over	 the	 last	 two	weeks	have	your	bowel	symptoms	been	getting	worse,	getting	better,	or	not	changed?).		 4. There	had	been	no	escalation	in	treatment	following	consultation	at	the	time	of	questionnaire	completion.		Receiver	operating	characteristic	curve	analysis	was	performed	to	identify	whether	the	IBD	Control	Questionnaire	could	reliably	predict	remission.	 	Given	the	intended	use	to	identify	 patients	 in	 remission,	 emphasis	was	 on	 ensuring	 high	 specificity	 (of	 85%	or	more).		Thus,	aiming	to	minimise	the	risk	of	identifying	a	patient	with	active	disease	as	being	in	a	quiescent	state.		Within	the	cut-off	values	associated	with	specificities	of	85%	or	more,	the	value	with	the	highest	sensitivity	×	specificity	product	was	chosen[129].		
3.4	 Summary	
	A	multi-disciplinary	steering	group	determined	the	key	design	specifications	for	the	IBD	Control	Questionnaire.				Questionnaire	 development	 included	 a	 literature	 review	 of	 current	 patient	 reported	outcome	 measures	 used	 in	 IBD,	 identifying	 key	 domains	 and	 candidate	 items	 to	 be	
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covered	by	the	new	PROM.		Patient	focus	group	meetings	and	one-to-one	interviews	were	undertaken	 to	 confirm	 that	 these	 domains/items	 were	 relevant	 to	 the	 construct	 of	‘disease	 control	 from	 the	 patient’s	 perspective’,	 and	 to	 capture	 any	 new	domains	 not	covered	by	existing	generic	or	disease	specific	instruments.		These	continued	until	data	saturation	was	reached.		Patient	views	from	the	qualitative	work	and	a	pragmatically-defined	specification	for	the	new	PROM	were	used	to	guide	the	development	of	the	IBD	Control	Questionnaire.		This	was	piloted	on	30	patients	and	minor	changes	were	made	following	this.		Prospective	 validation	 occurred	 at	 a	 single	 centre	 with	 an	 established	 IBD	 service.		Patients	completed	the	questionnaire	as	well	as	a	number	of	established	measures	at	the	time	of	a	planned	clinical	encounter	(e.g.	clinic	appointment).	 	Disease	activity	 indices	were	recorded,	as	were	physician	global	assessments	and	changes	to	treatment.		Clinical	staff	blinded	to	responses	to	the	IBD	Control	Questionnaire.				The	 following	 psychometric	 properties	were	 determined	 using	 established	 statistical	methods:		acceptability	and	feasibility,	reliability,	construct	validity	and	responsiveness.		Patients	with	quiescent	disease	were	identified	if	they	met	rigorous	criteria	on	the	basis	of	 disease	 activity	 indices,	 patient	 reported	 measures	 and	 physician	 reported	assessments.		This	was	to	establish	the	potential	for	the	new	PROM	to	reliably	identify	individuals	 with	 optimal	 disease	 control.	 	 Optimal	 disease	 control	 is	 not	 only	 a	 key	therapeutic	goal,	but	a	key	performance	characteristic	for	any	PROM	that	might	be	used	in	 the	 future	 to	 support	 self-directed	 care	 or	 non-face-to-face	 disease	monitoring	 via	
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emerging	e-Health	solutions	such	as	patient	portals	or	apps.	 	Data	 from	these	subjects	were	used	to	identify	cut-off	values	for	the	identification	of	patients	with	quiescent	IBD.	Optimal	 cut	 off	 values	were	 determined	 using	 receiver	 operating	 characteristic	 curve	analysis.																								
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Chapter	4	Results	of	Questionnaire	Development	Phase	
	
4.1	 	 IBD	Control	Questionnaire	specification	
	Our	 steering	 group	 of	 Gastroenterologists	 and	 Specialist	 Nurses	 determined	 the	 key	design	 criteria	 for	 the	 IBD	 Control	 Questionnaire,	 based	 on	 informal	 consensus.	 	 A	number	 of	 desirable	 and	 non-desirable	 properties	were	 identified	 (table	 1).	 	 	 	 It	was	agreed	 that	 in	 order	 to	 be	 included,	 items	 must	 be	 1)	 able	 to	 capture	 the	 patient’s	assessment	of	their	overall	disease	control,	2)	relevant	to	patients	with	both	ulcerative	colitis	and	Crohn’s	disease,	3)	relatively	generic	and	not	focused	on	specific	symptoms,	thus	 ensuring	 the	 questionnaire	 is	 applicable	 to	 all	 patients	 with	 IBD	 regardless	 of	disease	location	and	behaviour.		The	latter	criterion	represented	a	new	approach	to	PROM	development	for	IBD,	since	we	made	an	a	priori	decision	to	avoid	a	lengthy,	itemised	listing	of	individual	gastrointestinal	symptoms.		We	did	not	wish	to	re-invent	a	traditional	multiple	item	health	related	quality	of	life	(HRQoL	tool),	such	as	the	existing	IBD-Q.		We	rather	aimed	to	explore	a	deliberately	broad	and	generic	approach	to	item	selection.		The	PROM	was	intended	to	serve	as	a	rapid	tool	to	capture	overall	control	for	any	patient	with	IBD,	not	to	capture	and	quantify	a	list	of	discrete	symptoms.		We	concluded	that	symptom	assessment	for	patients	with	Crohn’s	disease	and	ulcerative	colitis,	including	those	with	specific	complications	or	post-operative	status,	requires	an	individualised	 symptom	 checklist	 or	 formal	 clinical	 review.	 By	 taking	 this	 “generic”	approach	to	PROM	development	for	IBD,	we	would	be	attempting	to	produce	a	novel	tool	
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that	combined	the	broad	thematic	questions	typical	of	a	generic	instrument	(e.g.	EQ5D)	but	tailored	to	the	specifics	of	IBD.		
Table	1	Questionnaire	specification	
	
Desirable	 Undesirable	
	Short	completion	time	 Lengthy	questionnaire		Suitable	for	use	in	routine	clinical	practice	 Replicates	existing	IBD	questionnaires		Applies	to	all	forms	of	IBD	 Different	 variations	 required	 depending	on	disease	type/location		Measures	 patient	 reported	 “control”	 of	IBD	 Measures	disease	activity	alone	Simple	scorings	system	 Complex	scoring	system		Identifies	patients	in	need	of	intervention	by	the	IBD	team	 	Identifies	 patients	 with	 unmet	 needs	 or	dissatisfaction	with	healthcare	 	Supports	self-management		 	Supports	 service	 improvement	 and	quality	assurance		 			
4.2	 	 Literature	review		A	literature	review	of	existing	patient	reported	outcome	measures	was	performed	and	this	is	reported	in	chapter	2.		A	number	of	disease	specific	and	generic	instruments	were	described	in	the	literature.		On	review	of	these	measures,	a	number	of	common	domains	were	 noted	 within	 the	 instruments.	 Common	 themes	 included	 questions	 related	 to	physical	 symptoms	 such	 as	 bowel	 symptoms,	 abdominal	 pain	 and	 fatigue,	 emotional	impact	and	social	impact	of	symptoms.	
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4.3	 	 Focus	group	meetings	and	one-to-one	interviews	with	patients.		Following	 on	 from	 literature	 review,	 2	 focus	 group	meetings	with	 patient	 volunteers	were	held	-	one	of	patients	with	Crohn’s	disease	and	one	of	patients	with	ulcerative	colitis.		13	one-to-one	interviews	were	also	performed.		Saturation	was	reached	at	this	point	and	no	new	themes	were	identified.		Coding	 of	 field	 notes	 and	 transcribed	 quotes	 identified	 a	 number	 of	 general	 themes.		Firstly,	participants	described	a	number	of	symptoms	that	affected	their	perception	of	whether	their	disease	was	controlled.		A	number	of	these	were	physical	symptoms.		These	symptoms	 were	 both	 disease	 specific	 and	 general.	 	 Other	 emerging	 themes	 were	 of	impact	of	disease	on	mood	and	emotions,	impact	on	day	to	day	activities	and	treatment	concerns	(table	2).		
Bowel	symptoms	and	abdominal	pain		Some	patients	reported	very	specific	symptoms	related	to	their	disease	such	as	perianal	symptoms	 and	 joint	 symptoms.	 	 It	 was	 apparent	 that	 whilst	 these	 symptoms	 were	important	to	individual	patients,	they	would	not	be	appropriate	for	inclusion	in	the	IBD	Control	questionnaire	given	the	aim	for	it	to	be	used	by	all	patients	with	IBD.		Frequency	of	opening	bowels,	urgency	and	the	presence	of	nocturnal	symptoms	were	commonly	 reported	 as	 indicators	 of	 deteriorating	 disease	 control.	 	 Patients	 felt	 that	quantifying	the	number	of	times	they	opened	their	bowels	a	day	was	not	helpful.		Most	patients	 with	 colitis	 reported	 that	 going	 more	 frequently	 was	 associated	 with	 a	
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deterioration	in	disease	control.	 	However,	two	patients	with	Crohn’s	disease	reported	opening	 their	bowels	 less	 frequently	 indicated	 to	them	that	 their	Crohn’s	disease	was	becoming	more	active.		This	highlighted	that	if	the	IBD	Control	instrument	was	to	be	of	use	to	patients	with	all	forms	of	IBD,	items	related	specifically	to	bowel	frequency	should	be	avoided.				Abdominal	pain	and	discomfort	were	 commonly	 reported	by	patients	as	 indicators	of	deteriorating	 control.	 	 Both	 patients	 with	 Crohn’s	 disease	 and	 colitis	 reported	 these	symptoms.		
Fatigue		Fatigue	was	very	commonly	reported	by	patients.		Although	a	number	acknowledged	that	fatigue	was	an	issue	when	their	disease	was	controlled,	it	was	reported	to	become	much	worse	during	active	disease.			It	was	described	as	a	“major	symptom”	(patient	1,	female,	Crohn’s	disease).	 	Another	stated	that	she	“cannot	do	anything	at	all	due	to	tiredness”	(patient	7,	female,	Crohn’s	colitis).		Another	patient	commented	“I	feel	drained	and	unwell	all	the	time	and	I	know	my	colitis	is	flaring”	(patient	16,	female,	ulcerative	colitis).		Other	patients	reported	“I	can’t	do	anything,	can’t	go	out,	can’t	do	simple	tasks”	(patient	18,	 female,	 Crohn’s	 disease)	 and	 “I	 can	 fall	 asleep	 if	 I	 just	 sit	 down	 for	 a	 short	 time”	(patient	20,	male,	ulcerative	colitis).		More	comments	on	this	symptom	included	“I	can’t	be	bothered	to	get	up	and	have	a	bath	in	the	morning”	(patient	23,	male,	Crohn’s	colitis)	and	“I	have	to	sleep	all	day	in	order	to	get	up	for	work	in	the	evening”	(patient	24,	female,	Crohn’s	disease).	
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Difficulty	sleeping	
	A	number	of	patients	reported	that	difficulties	sleeping	occurred	when	their	disease	was	not	controlled.		Sleep	was	reported	to	be	disturbed	due	to	nocturnal	symptoms	with	one	patient	reporting	that	he	could	only	sleep	for	4	hours	a	night.		
Psychological	and	emotional	issues	
	Psychological	 and	 emotional	 issues	 were	 reported	 by	 many	 patients	 as	 indicators	 of	change	in	disease	control.		A	patient	reported	impact	on	others	and	a	lack	of	sympathy	for	other	people	as	indicators	that	her	disease	was	becoming	active.		She	stated	that	when	she	noticed	that	her	symptoms	were	impacting	other	people,	she	realised	her	IBD	was	not	controlled	(patient	1,	female,	Crohn’s	disease).	 	Another	patient	explained	that	she	was	more	“snappy	with	the	children”	during	flares	(patient	22,	female,	Crohn’s	colitis).		Deteriorating	stress	levels	and	mood	were	commonly	reported	during	active	episodes.		One	patient	reported	being	“often	close	to	tears”	and	felt	that	emotional	symptoms	were	just	as	important	as	bowel	symptoms	during	a	flare	up	(patient	7,	female,	Crohn’s	colitis).		
Effect	on	daily	activities	
	This	was	also	a	common	theme	of	problems	reported	by	patients.		Active	symptoms	were	reported	to	affect	home	life,	travel	and	work.		Patients	reported	having	to	plan	carefully	before	going	out.		A	patient	reported	avoiding	driving	during	flare	ups	(patient	22,	female,	Crohn’s	disease).	
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	One	patient	reported	having	to	work	from	home	when	her	disease	was	not	controlled.		She	also	explained	that	she	had	often	had	to	cancel	commitments	and	trips	due	to	her	symptoms	being	active	(patient	18,	 female,	Crohn’s	disease).	 	Another	patient	was	not	able	to	leave	the	house	when	symptoms	were	not	controlled	(patient	1,	female,	Crohn’s	disease).	 	 Another	 reported	 that	 “I	 become	 a	 recluse”	 (patient	 16,	 female,	 ulcerative	colitis).		
Impact	of	treatment	on	perceived	symptom	control	
	Focus	 group	 members	 and	 interviewees	 were	 asked	 whether	 treatment	 concerns	affected	their	perception	of	whether	their	IBD	was	controlled.		One	focus	group	felt	that	concerns	about	side	effects	might	affect	stress	levels	and	therefore	overall	health.		This	was	confirmed	by	a	patient	that	reported	that	she	experienced	side	effects	related	to	her	medical	 treatment	 and	 that	 this	 affected	 her	 general	 wellbeing	 (patient	 16,	 female,	ulcerative	colitis).		Another	patient	reported	similar	side	effects	and	again	reported	that	this	affected	her	generally,	but	did	not	specifically	indicate	to	her	that	her	IBD	was	not	controlled	(patient	22,	female	Crohn’s	disease).	 	Some	patients	did	not	experience	side	effects	and	therefore	did	not	have	strong	concerns	about	medications.							
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Table	2	Themes	identified	following	coding	of	focus	group	meeting	and	interview	field	notes	
	
	
Domain	 Theme	 Codes	
	Physical	 Bowel	symptoms	and	abdominal	pain			 Frequency	of	bowel	movements	Opening	bowels	more	frequently	Opening	bowels	less	frequently	
Urgent	need	to	open	bowels	
How	often	I	go	to	the	toilet	
Nocturnal	symptoms	
Abdominal	pain	
Wind	
Cramps	
Avoiding	food	to	reduce	abdominal	pain	
Reduced	appetite	Fatigue	 Fatigue	is	a	major	symptom	
Can’t	do	anything	due	to	tiredness	
Feel	drained	
Can	fall	asleep	at	any	time	
I	have	to	sleep	all	day	
I	can’t	do	anything	
I	can’t	do	simple	tasks	
Lie	 down	 and	 rest	 as	 soon	 as	 I	 have	 done	
anything	Difficulty	sleeping	 Symptoms	at	night	
Disturbed	sleep	
Only	able	to	sleep	for	4	hours	Social	 Effect	on	daily	activities	 Plan	carefully	before	going	out	
Avoiding	driving	
Having	to	work	from	home	
Cancelling	trips	and	commitments	
I	become	a	recluse	
Not	leaving	the	house	
Have	to	plan	trips	based	on	where	toilets	are	
Doesn’t	go	on	recreational	walks	due	to	lack	of	
toilet	facilities	
Lost	job	because	of	condition	Emotional	 Psychological	and	mood	issues	 Lack	of	sympathy	
Symptoms	impacting	on	others	
Snappy	
Worsening	stress	levels	
Low	mood	
Often	close	to	tears	
Embarrassment	
Takes	over	your	life	
More	emotional	
Cries	a	lot	Treatment	 Impact	 of	 treatment	 of	 perceived	symptom	control	 Concerns	about	side	effects	Side	effects	affecting	general	wellbeing				
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4.4	 Patient	views	on	questionnaire	design	and	format		Patients	were	also	asked	their	views	on	the	design	and	format	of	the	questionnaire.		They	were	shown	some	existing	patient	reported	outcome	measures	such	as	the	UKIBDQ[195]	as	well	as	examples	of	visual	analogue	scales	and	asked	to	comment.		Many	felt	that	completing	a	questionnaire	before	a	clinic	appointment	would	help	guide	the	consultation.		Some	felt	this	could	be	in	the	waiting	room	whilst	others	felt	they	would	prefer	to	complete	it	at	home.		One	focus	group	decided	they	would	be	happy	to	spend	around	5	minutes	completing	a	questionnaire.		However,	another	patient	felt	she	would	be	happy	to	spend	10-15	minutes	doing	so.	 	Some	patients	 felt	 that	 the	questionnaire	should	be	no	longer	than	the	equivalent	of	one	side	of	A4	paper.		With	 regard	 to	 visual	 analogue	 scales	 (VAS),	 patients	 felt	 that	 horizonal	 scales	 were	preferable	 and	 that	 a	 phrase	 at	 either	 end	 of	 the	 scale	 would	 be	 helpful.	 	 It	 was	commented	that	visual	analogues	such	as	“smiley	faces”	were	too	simplistic.		Most	patient	felt	a	combination	of	questions	and	visual	analogue	scales	would	be	optimal	and	some	suggested	the	inclusion	of	a	free	text	box.		Patients	 suggested	developing	a	questionnaire	 that	 could	be	 completed	by	email,	 text	message	or	on	a	website.			One	explained	that	she	would	not	like	to	return	it	by	post.				
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4.5	 	 Questionnaire	design	
	Core	domains	of	“physical”,	“social”,	“emotional”	and	“treatment”	were	identified	on	the	basis	 of	 literature	 review	 and	 the	 above	 qualitative	 data	 (figure	 4).	 	 The	 previously	defined	questionnaire	specification	was	used	to	guide	the	choice	of	broad,	non-specific	questions	to	represent	these	domains.		A	visual	analogue	scale	(VAS)	was	also	included.		This	draft	questionnaire	was	piloted	on	a	sample	of	30	patients.		Following	this,	changes	were	made	to	wording	and	layout.		
Figure	4	Flow	chart	representing	the	development	of	the	IBD	Control	Questionnaire	
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4.5.1	 	 The	IBD	Control	Questionnaire	description	
	The	IBD	Control	Questionnaire	(figure	4.2)	consists	of	5	sections.		It	contains	13	questions	and	a	visual	analogue	scale.		When	completed	on	paper,	it	fills	one	side	of	A4	paper.		Each	question	has	3	response	options.		In	all	but	one	question,	these	options	are	yes,	no	and	 not	 sure.	 	 In	 the	 case	 of	 question	 2	 (“Over	 the	 past	 2	 weeks,	 have	 your	 bowel	symptoms	been	getting	worse,	getting	better	or	not	changed”)	the	response	options	are:		better,	no	change	or	worse.		This	was	included	as	a	‘transition’	question,	to	determine	a	patient’s	sense	of	change	over	time.		Question	responses	are	allocated	a	score	of	0	for	the	least	favourable	response,	1	for	the	intermediate	response	or	not	sure	and	2	for	the	most	favourable	response.		The	scores	are	simply	added	to	produce	a	total	score.		The	IBD	Control	8	sub-score	is	calculated	by	adding	the	scores	of	the	8	questions	within	sections	1	and	3.		The	methodology	for	the	development	of	this	sub-score	is	presented	in	chapter	5.		IBD	Control	Questionnaire	scores	range	from	0	to	26	and	IBD	Control	8	scores	from	0	to	16.	 	Low	scores	indicate	poor	patient	reported	control	of	IBD	and	high	scores	indicate	good	control.		The	visual	analogue	scale	is	a	horizonal	scale	ranging	from	0	to	100.		0	is	labelled	“worst	possible	 control”	 and	 100	 is	 labelled	 “best	 possible”.	 	 Respondents	 are	 asked	 to	 rate	overall	control	of	their	IBD	symptoms	over	the	last	two	weeks.		
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Figure	5	The	IBD	Control	Questionnaire	
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4.6	 	 Summary		The	 IBD	 Control	 questionnaire	 specification	was	 defined	 with	 the	 need	 to	 develop	 a	measure	 for	use	 in	routine	clinical	care	 in	mind.	 	Literature	review	of	existing	patient	reported	 outcome	 measures	 used	 in	 IBD	 was	 performed	 and	 a	 number	 of	 common	themes	were	apparent.		Focus	group	meetings	and	one	to	one	interviews	were	convened	and	patients	described	a	number	of	symptoms	they	related	to	their	IBD	being	controlled.		Thematic	analysis	of	field	 notes	 and	 transcribed	 quotes	 identified	 a	 number	 of	 themes.	 	 These	 included	symptoms	related	to	bowel	function	and	abdominal	pain.		Fatigue	and	difficulty	sleeping	were	also	commonly	reported	issues.		Impact	on	emotional	wellbeing	and	daily	activities	were	also	described.		Effect	of	concerns	about	treatment	on	control	was	also	explored	and	concerns	over	side	effects	of	medications	were	often	raised.		A	draft	questionnaire	was	produced	in	line	with	the	defined	questionnaire	specification	and	included	questions	related	to	the	key	themes	described	by	patients	and	in	the	existing	literature.		It	was	then	a	piloted	on	40	patients	and	minor	changes	to	wording	and	format	were	made.		The	IBD	Control	questionnaire	 is	a	short	questionnaire	consisting	of	13	questions	and	one	visual	analogue	scale	set	within	5	sections.		Each	question	has	3	response	options.		A	total	IBD	Control	score	is	calculated	by	adding	the	scores	of	all	question	responses.		The	IBD	Control	8	sub-score,	the	rationale	for	which	is	described	in	chapter	5,	is	a	total	score	of	responses	to	the	8	questions	within	section	1	and	3	of	the	IBD	Control	Questionnaire.	
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Chapter	5	Prospective	validation	of	the	IBD	Control	Questionnaire		
5.1	 	 Patient	demographics		Patients	were	 recruited	between	March	2011	and	 June	2012.	 	A	 total	of	299	patients	completed	 a	 baseline	 assessment	 (table	 3).	 	 160	 (53.5%)	 patients	 had	 a	 diagnosis	 of	ulcerative	colitis	and	139	(46.5%)	had	a	diagnosis	of	Crohn’s	disease.		The	mean	age	of	patients	completing	baseline	assessment	was	43	(SD	16).		169	(56.5%)	of	patients	were	female	and	130	(43.5%)	were	male.		The	mean	duration	of	disease	was	10	years	(SD	10)	and	this	was	similar	between	the	two	diagnosis	types	(Crohn’s	disease	10	[10],	ulcerative	colitis	9	[10]).		83	 (27.8%)	 patients	 had	 undergone	 surgery	 and	 10	 (3.3%)	 had	 a	 stoma.	 	 27	 (9.0%)	patients	had	perianal	disease.		As	to	be	expected,	more	patients	with	Crohn’s	disease	had	undergone	surgery,	had	a	stoma	or	had	perianal	disease	than	patients	with	ulcerative	colitis.		26	(8.9%)	patients	were	being	treated	with	oral	corticosteroids.		104	(34.8%)	patients	were	 on	 standard	 immunomodulator	 drugs	 (azathioprine,	 6-mercaptopurine	 or	methotrexate)	 and	 38	 (12.7%)	were	 treated	with	 biological	 therapies	 (infliximab	 and	adalimumab).		More	patients	with	Crohn’s	disease	were	treated	with	immunomodulators	(71	vs	33	p=0.001),	biological	therapies	(30	vs	8,	p=0.001)	and	dietary	therapy	(8	vs	0,	p=0.008)	than	patients	with	ulcerative	colitis.		The	frequency	of	steroid	use	was	similar	in	both	disease	type	groups	(10	vs	16,	p=0.107).	
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	The	mean	EQ-5D	utility	index	and	EQ-5D	visual	analogue	scale	score[172]	(measures	of	health	status)	were	0.68	[0.30]	and	65	[23].			There	were	no	significant	differences	in	the	mean	EQ-5D	scores	of	patients	with	Crohn’s	disease	and	ulcerative	colitis	(EQ-5D	utility	index	0.65	vs	0.70	p=0.12,	EQ-5D	VAS	65	in	both	groups).		The	mean	UK-IBDQ	score	(an	IBD	specific	measure	of	health	related	quality	of	life)	was	86	[20].		Again,	there	was	no	significant	difference	in	mean	scores	between	the	Crohn’s	disease	and	ulcerative	colitis	groups	(85	vs	88	p=0.23).		Clinical	disease	activity	was	measured	using	the	Harvey	Bradshaw	Index	(HBI)[136]	for	Crohn’s	disease	and	the	Simple	Clinical	Colitis	Activity	Index[128]	(SCCAI)	for	ulcerative	colitis.		The	mean	HBI	was	5[5]	and	the	mean	SCCAI	was	4	[3].		161	 (61.9%)	 patients	 were	 recorded	 to	 be	 in	 remission	 using	 the	 physician	 global	assessment.	 	 58	 (22.3%)	had	mild	disease,	 30	 (11.5%)	 had	moderate	 disease	 and	 11	(4.2%)	had	severe	disease	at	the	time	of	assessment.		This	distribution	of	disease	activity	is	 in	keeping	with	 the	 fact	 that	most	patients	were	assessed	 in	outpatient	or	day	unit	settings.		138	patients	undertook	a	further	assessment	at	scheduled	follow	up	visits	(table	4).		82	(59.4%)	patients	had	Crohn’s	disease	and	56	(40.6%)	patients	had	ulcerative	colitis.		The	mean	age	of	follow	up	patients	was	41	[15]	and	the	mean	duration	of	disease	was	8	[9].		45	 (32.6%)	 patients	 had	 undergone	 surgery,	 5	 (3.6%)	 patients	 had	 a	 stoma	 and	 20	(14.4%)	patients	had	perianal	disease.	 	Again,	more	patients	with	Crohn’s	disease	had	undergone	surgery,	had	a	stoma	or	had	fistulating	disease	than	patients	with	ulcerative	
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colitis.	 	 16	 (11.6%)	 patients	 were	 on	 oral	 corticosteroids,	 61	 (44.2%)	 were	 on	immunosuppressants	and	29	(21.0%)	were	on	biological	therapies.		The	mean	EQ-5D	utility	index	score	was	0.61	[0.34]	and	mean	EQ-5D	VAS	score	was	0.60	[0.35].	 	 The	 mean	 UK-IBDQ[195]	 score	 was	 83	 [19].	 	 49	 (44.1%)	 patients	 were	 in	remission	on	the	global	physician	assessment,	38	(34.2%)	had	mild	disease,	18	(16.2%)	moderate	disease	and	6	(5.4%)	had	severe	disease.																			
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Table	3	Characteristics	of	patients	at	baseline	(n=299)	
Characteristic	 All	patients	 Crohn’s	 UC	
	
Number	of	cases	 299	 160	 139		
Age,	yrs	 43	[16]	 41	[15]	 46	[16]		
Gender	
-	Male	
-	Female	
	130	(43.5%)	169	(56.5%)	 	68	(57.5%)	92	(42.5%)	 	77	(55.4%)	62	(44.6%)	
Disease	duration,	yrs	 10	[10]	 10	[10]	 9	[10]		
Previous	surgery	
-	Yes	
-	No	
	83	(27.8%)	216	(72.2%)	 	76	(47.5%)	84	(52.5%)	 	7	(5.0%)	132	(95.0%)	
Perianal	disease	(fistula)	
-	Yes	
-	No	
	27	(9.0%)	272	(91.0%)	 	27	(16.9%)	133	(83.1%)	 	0	(0.0%)	139	(100.0%)	
Stoma	present	
-	Yes	
-	No	
	10	(3.3%)	289	(96.7%)	 	8	(5.0%)	152	(95.0%)	 	2	(1.4%)	137	(98.6%)	
Medication	
-	Topical	5-ASA	
-	Topical	steroid	
-	Oral	5-ASA	
-	Oral	corticosteroid	
-Immunosuppressants	
-	Biological	agent	
-	Dietary	therapy	
	36	(12.0%)	9	(3.0%)	177	(59.2%)	26	(8.9%)	104	(34.8%)	38	(12.7%)	8	(2.7%)	
	2	(1.3%)	2	(1.3%)	68	(42.5%)	10	(6.3%)	71	(44.4%)	30	(18.8%)	8	(5.0%)	
	34	(24.5%)	7	(5.0%)	109	(78.4%)	16	(11.5%)	33	(23.7%)	8	(5.8%)	0	(0.0%)	
Disease	Activity	Indices	
-	Harvey-Bradshaw	Index	
-	SCCAI	
	n/a	n/a	 	5	[5]	n/a	 	n/a	4	[3]	
Quality	of	life	questionnaires	
-	EQ-5D	Utility	Score	
-	EQ-5D	Visual	Analogue	Scale		
-	UK-IBD-Q	
	0.68	[0.30]	65	[23]	86	[20]	
	0.65	[0.30]	65	[22]	85	[18]	
	0.70	[0.29]	65	[24]	88	[21]	
Physician	Global	Assessment	
-	Remission	
-	Mild	
-	Moderate	
-	Severe	
	161	(61.9%)	58	(22.3%)	30	(11.5%)	11	(4.2%)	
	80	(60.6%)	37	(28.0%)	11	(8.3%)	4	(3.0%)	
	81	(63.3%)	21	(16.4%)	19	(14.8%)	7	(5.5%)	
	
	
	
	
	
	
	
	
Continuous	variables	expressed	as	mean	[sd]	and	categorical	variables	as	number	(%)	where	appropriate)	
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Table	4	Characteristics	of	patients	assessed	at	follow	up	visits	(n=138)	
Characteristic	 All	patients	 Crohn’s		 UC	
Number	of	cases	 138	 82	 56		
Age,	yrs	 41	[15]	 38	[13]	 45	[16]		
Gender	
-	Male	
-	Female	
	65	(47.1%)	73	(52.9%)	 	36	(43.9%)	46	(56.1%)	 	29	(51.8%)	27	(48.2%)	
Disease	duration,	yrs	 8	[9]	 9	[8]	 8	[9]		
Previous	surgery	
-Yes	
-	No	
	45	(32.6%)	93	(67.4%)	 	43	(52.4%)	39	(47.6%)	 	2	(3.6%)	54	(96.4%)	
Perianal	disease	(fistula)	
-	Yes	
-	No	
	20	(14.5%)	118	(85.5%)	 	20	(24.4%)	62	(75.6%)	 	0	(0.0%)	56	(100.0%)	
Stoma	present	
-	Yes	
-	No	
	5	(3.6%)	133	(96.4%)	 	4	(4.9%)	78	(95.1%)	 	1	(1.8%)	55	(98.2%)	
Medication	
-	Topical	5-ASA	
-	Topical	steroid	
-	Oral	5-ASA	
-	Oral	corticosteroid	
-Immunosuppressants	
-	Biological	agent	
-	Dietary	Therapy	
	11	(8.0%)	5	(3.6%)	82	(59.4%)	16	(11.6%)	61	(44.2%)	29	(21.0%)	5	(3.6%)	
	0	(0.0%)	0	(0.0%)	34	(41.5%)	6	(7.3%)	44	(53.7%)	24	(29.3%)	5	(6.1%)	
	11	(19.6%)	5	(8.9%)	48	(85.7%)	10	(17.9%)	17	(30.4%)	5	(8.9%)	0	(0.0%)	
Disease	Activity	Indices	
-	Harvey-Bradshaw	Index	
-	SCCAI	
	n/a	n/a	 	5	[5]	n/a	 	n/a	5	[4]	
Quality	of	life	questionnaires	
-	EQ-5D	Utility	Score	
-	EQ-5D	Visual	Analogue	Scale		
-	UK-IBD-Q	
	n/a	61	[23]	83	[19]	
	n/a	63	[22]	84	[18]	
	n/a	56	[25]	82	[22]	
Physician	Global	Assessment	
-	Remission	
-	Mild	
-	Moderate	
-	Severe	
	49	(44.1%)	38	(34.2%)	18	(16.2%)	6	(5.4%)	
	27	(44.3%)	26	(42.6%)	6	(9.8%)	2	(3.3%)	
	22	(44.0%)	12	(24.0%)	12	(24.0%)	4	(8.0%)	
 
	
	
Continuous	variables	expressed	as	mean	[sd]	and	categorical	variables	as	number	(%)	where	appropriate)	
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5.2	 Psychometric	properties	of	the	IBD	Control	Questionnaire		
5.2.1	 	 Acceptability	and	feasibility		Acceptability	of	the	IBD	Control	Questionnaire,	or	whether	or	not	the	questionnaire	was	acceptable	to	patients,	was	determined	by	measuring	administration	time	and	response	rates.		10	patients,	aged	between	25	and	64	years	old,	were	timed	completing	the	IBD	Control	Questionnaire.	 	The	average	time	to	complete	 the	questionnaire	was	1	minute	and	15	seconds	(SD	25	seconds).		Completion	times	ranged	from	42	seconds	to	2	minutes	and	1	second.		259	(86.6%)	patients	completed	all	13	questions	within	the	IBD	Control	Questionnaire	and	272	(91.0%)	patients	completed	the	IBD	Control	visual	analogue	scale.		Completion	rates	of	individual	question	items	was	high	and	ranged	from	93.3%	(Q2	“Over	the	past	two	 weeks	 have	 your	 bowel	 symptoms	 been	 getting	 better,	 getting	 worse	 or	 not	changed?”)	 to	99.0%	(Q3a	“In	the	past	 two	weeks	did	you	miss	any	planned	activities	because	of	IBD?”	and	Q3d	“In	the	past	two	weeks	did	you	often	feel	lacking	in	energy?”).		It	 was	 planned	 that	 items	 answered	with	 the	 same	 response	 by	 80%	 or	more	 of	 the	baseline	sample	would	be	removed	from	the	questionnaire.		This	was	due	to	the	fact	that	these	 questions	 would	 be	 unlikely	 to	 have	 the	 necessary	 sensitivity	 to	 differentiate	between	 different	 levels	 of	 symptom	 control.	 	 Exclusion	 of	 these	 questions	 would	therefore	 ensure	 the	 questionnaire	 was	 not	 over	 burdensome.	 	 However,	 no	
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questionnaire	item	was	found	to	fulfil	this	pre-specified	cut-off.		Therefore,	all	question	items	remained	in	the	IBD	Control	Questionnaire.		
5.2.2	 	 Reliability			Reliability	 was	 determined	 using	 two	 methods.	 	 Firstly,	 test-retest	 reliability	 was	assessed.		20	patients	completed	a	questionnaire	2	weeks	following	baseline	assessment.		13	of	these	patients	were	determined	to	have	stable	disease	on	the	basis	of:		1)	stable	UK-IBDQ	 score	 (score	 within	 10	 points	 of	 baseline	 assessment)	 and	 2)	 an	 “unchanged”	response	to	the	transition	question	within	the	IBD	Control	Questionnaire	(Q2	“Over	the	past	 two	weeks	have	your	bowel	symptoms	been	getting	better,	 getting	worse	or	not	changed”).		These	patients	were	therefore	used	to	assess	test-retest	reliability	(table	5A).		There	was	no	statistical	difference	between	IBD	Control	8	or	IBD	Control	VAS	scores	at	baseline	and	2	weeks	later	(p<0.01).		The	mean	difference	in	IBD	Control	8	score	was	-0.45	(SD	1.81)	and	the	mean	difference	in	IBD	Control	VAS	score	was	+2.25	(SD	9.79).		The	intraclass	correlation	co-efficients	(ICC)	were	0.97	for	the	IBD	Control	8	sub-score	(95%	CI	0.90	to	0.99)	and	0.96	for	the	IBD	Control	VAS	score	(95%	CI	0.88	to	0.99).		Secondly,	stable	patients	undertaking	an	assessment	at	a	planned	follow-up	visit	were	identified	 on	 the	 basis	 of	 no	 change	 in	 condition	 reported	 on	 their	 global	 physician	assessment.	 	 32	 patients	 were	 identified,	 and	 the	 mean	 interval	 between	 follow-up	assessments	was	131	days	(table	5B).		
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There	was	no	difference	in	mean	IBD	Control	8	and	IBD	Control	VAS	scores	between	visits	(p<0.01).		The	mean	difference	between	IBD	Control	8	scores	was	0.00	(SD	3.72)	and	the	mean	difference	between	IBD	Control	VAS	scores	was	-0.56	(SD	23.00).		The	ICCs	were	0.87	(95%	CI	0.71	to	0.94)	and	0.81	(95%	CI	0.56	to	0.91)	respectively.	
 
Tables	5A	and	5B	Reliability	of	IBD	Control	summary	scores				A)		Patients	returning	at	2	weeks	(test-retest	group)	
Instrument	score	(scale)	
	
Mean	difference	
(Visit	2	–	Visit	1)	
SD	of	difference	 Intraclass	
Correlation	
(95%	CI)	
IBD-Control-8	sub-score	(0-16)	 -0.45	 1.81	 0.97	(0.90-0.99)	
IBD-Control-VAS	(0-100)	 +2.25	 9.79	 0.96	(0.88-0.99)	
	Notes:	n=13	patients	responding	‘not	changed’	to	the	IBD-Control	transition	question	(‘Over	the	past	two	weeks	have	your	bowel	symptoms	been	getting	worse,	getting	better	or	not	changed’)	and	with	stable	UK-IBD-Q	total	scores	(less	than	10-point	change	between	two	visits).		Two-way	fixed	effects	model	for	consistency,	p<0.001.					B)		Patients	returning	for	a	scheduled	clinic	visit	(routine	care	group)	
Instrument	score	(scale)	 Mean	difference	
(Visit	2	–	Visit	1)	
SD	of	difference	 Intraclass	
Correlation	
(95%	CI)	
IBD-Control-8	sub-score	(0-16)	 0.00	 3.72	 0.87	(0.71-0.94)	
IBD-Control-VAS	(0-100)	 -0.56	 23.00	 0.81	(0.58-0.91)	
	Notes:	 n=32	 patients	with	a	 stable	 (unchanged)	 Physician	 Global	Assessment	 rating	 between	 two	 visits	 (mean	interval	between	visits	131	days).	Two-way	fixed	effects	model	for	consistency,	p<0.001.	
 
	
5.2.3	 	 Internal	consistency		Internal	consistency	of	the	13	question	items	within	the	IBD	Control	Questionnaire	was	assessed	by	Cronbach	alpha	statistic	[271].		Cronbach	alpha	was	0.85	for	the	overall	total	score	(13	questions)	and	0.86	for	the	IBD	Control	8	sub-score.		A	Cronbach	alpha	statistic	of	between	0.7	 and	0.9	 is	desirable	 [272],	 indicating	 the	 IBD	Control	questionnaire	 is	reliable.	
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Responses	to	the	13	categorical	questions	of	the	IBD	Control	Questionnaire	correlated	positively	with	IBD	Control	VAS	scores.		Correlation	coefficients	ranged	from	0.24	to	0.70.		Finally,	the	IBD	Control	8	sub-score	and	IBD	Control	VAS	correlated	positively.		This	was	the	 case	 for	 both	 IBD	 overall	 (r=0.78	 p<0.001)	 as	 well	 as	 Crohn’s	 disease	 (r=0.78,	P<0.001)	 and	ulcerative	 colitis	 (r=0.83,	 p<0.001)	when	 considered	 separately.	 	 These	correlations	 suggest	 that	 both	 individual	 questions	 as	 well	 as	 summary	 scores	 are	measuring	 the	 same	 construct	 (in	 this	 case	 patient	 reported	 control	 of	 IBD)	 This	therefore,	indicates	that	the	questionnaire	possesses	internal	consistency.		
5.2.4	 	 Construct	validity		There	is	no	gold	standard	measure	of	patient	reported	control	of	IBD.		Therefore,	the	IBD	Control	questionnaire	was	compared	to	a	number	of	established	measures	with	which	it	was	hypothesised	there	would	be	correlations.		
5.2.4.1	 Validity	of	individual	question	items		Individual	 questions	 of	 the	 IBD	 Control	 Questionnaire	 correlated	 well	 with	 UK-IBDQ[195]	 scores	 (a	 disease	 specific	 measure	 of	 health	 related	 quality	 of	 life).		Correlation	coefficients	ranged	from	0.24	to	0.70	for	the	total	UK-IBDQ	score.		Individual	item	 scores	 also	 correlated	with	 the	 IBD	 Control	 VAS	 score.	 	 Correlation	 coefficients	ranged	from	0.38	to	0.70	(table	6).		
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Table	6	Correlation	between	individual	question	items	within	the	IBD-Control	Questionnaire	and	the	IBD-
Control-VAS	and	disease-specific	quality	of	life	(UK-IBDQ)	
Item	 Question	 IBD-Control-
VAS	
UK-IBD-QoL	
Q1a	 …	your	IBD	has	been	well	controlled	in	the	past	2	weeks	*	 0.70	 0.63		
Q1b	 …	your	current	treatment	is	useful	in	controlling	your	IBD	*	 0.39	 0.38		
Q2	 …	have	your	bowel	symptoms	better/worse/not	changed	 0.36	 0.24		
Q3a	
Q3b	
Q3c	
Q3d	
Q3e	
Q3f	
…	miss	any	planned	activities	because	of	IBD	*	…	wake	up	at	night	because	of	symptoms	of	IBD	*	…	suffer	from	significant	pain	or	discomfort	*	…	often	feel	lacking	in	energy	(fatigued)	*	…	feel	anxious	or	depressed	because	of	your	IBD	*	...	think	you	need	a	change	to	your	treatment	*	
0.63	0.61	0.64	0.51	0.58	0.60	
0.67	0.67	0.66	0.63	0.70		0.50	
Q4a	
Q4b	
Q4c	
Q4d	
…	would	you	like	to	discuss	alternative	types	of	drug	…	would	you	like	to	discuss	ways	to	adjust	your	own	treatment	…	would	you	like	to	discuss	side	effects	…	would	you	like	to	discuss	new	symptoms	that	have	developed	
0.42	0.33	0.24	0.30	
0.26	0.31	0.29	0.29	
	Item	responses	were	scored	as	0	(worst	option),	1	(intermediate,	e.g.	‘Not	sure’)	or	2	(best	option),	so	a	higher	score	should	indicate	better	disease	control.	Correlation	coefficients	are	expressed	as	Spearman	Rho	values	(p<0.01	in	all	cases).	*Question	items	included	in	the	IBD-Control-8	sub-score	
 	Furthermore,	correlation	between	individual	item	scores	and	generic	measures	of	health	status	was	also	observed	(table	7).		Correlation	coefficients	with	the	EQ-5D	VAS	ranged	from	0.18	to	0.54	and	with	the	EQ-5D	utility	index	ranged	from	0.16	to	0.62.			Correlations	of	 individual	 question	 scores	 with	 the	 global	 physician	 assessment	 of	 disease	 status	(remission,	mild,	moderate	or	severe)	were	also	seen	(values	ranging	from	-0.23	to	-0.48,	p<0.01),	although	correlations	were	weak	(table	8).	
 
 
 
 
 
 
 135 
Table	7	Correlation	between	individual	question	items	within	the	IBD-Control	questionnaire	and	EQ-5D	
VAS	and	EQ-5D	utility	index	(a	generic	measure	of	health	status)	
	
Item	 Question	 EQ5D	VAS	 EQ5D	Utility	index	
Q1a	 …	your	IBD	has	been	well	controlled	in	the	past	2	weeks	*	 0.49	 0.41		
Q1b	 …	your	current	treatment	is	useful	in	controlling	your	IBD	*	 0.29	 0.29		
Q2	 …	have	your	bowel	symptoms	better/worse/not	changed	 0.18	 0.17		
Q3a	
Q3b	
Q3c	
Q3d	
Q3e	
Q3f	
…	miss	any	planned	activities	because	of	IBD	*	…	wake	up	at	night	because	of	symptoms	of	IBD	*	…	suffer	from	significant	pain	or	discomfort	*	…	often	feel	lacking	in	energy	(fatigued)	*	…	feel	anxious	or	depressed	because	of	your	IBD	*	...	think	you	need	a	change	to	your	treatment	*	
0.54	0.47	0.52	0.48	0.54	0.42		
0.52	0.52	0.51	0.56	0.51	0.62		
Q4a	
Q4b	
Q4c	
Q4d	
…	would	you	like	to	discuss	alternative	types	of	drug	…	would	you	like	to	discuss	ways	to	adjust	your	own	treatment	…	would	you	like	to	discuss	side	effects	…	would	you	like	to	discuss	new	symptoms	that	have	developed	
0.25	0.26	0.24	0.23	
0.36	0.16	0.19	0.16	
	Item	responses	were	scored	as	0	(worst	option),	1	(intermediate,	e.g.	‘Not	sure’)	or	2	(best	option),	so	a	higher	score	should	indicate	better	disease	control.	Correlation	coefficients	are	expressed	as	Spearman	Rho	values	(p<0.01	in	all	cases).	*Question	items	included	in	the	IBD-Control-8	sub-score	
 
Table	8	Correlation	between	individual	question	items	within	the	IBD-Control	Questionnaire	and	the	
Global	Physician	Assessment	(remission,	mild,	moderate,	severe)	
	
Item Question	 Global Physician Assessment 
Q1a …	your	IBD	has	been	well	controlled	in	the	past	2	weeks	*	 -0.48 
 
Q1b …	your	current	treatment	is	useful	in	controlling	your	IBD	*	 -0.34 
 
Q2 …	have	your	bowel	symptoms	better/worse/not	changed	 -0.23 
 
Q3a 
Q3b 
Q3c 
Q3d 
Q3e 
Q3f 
…	miss	any	planned	activities	because	of	IBD	*	…	wake	up	at	night	because	of	symptoms	of	IBD	*	…	suffer	from	significant	pain	or	discomfort	*	…	often	feel	lacking	in	energy	(fatigued)	*	…	feel	anxious	or	depressed	because	of	your	IBD	*	...	think	you	need	a	change	to	your	treatment	*	
-0.44 
-0.36 
-0.39 
-0.34 
-0.36 
-0.42 
Q4a 
Q4b 
Q4c 
Q4d 
…	would	you	like	to	discuss	alternative	types	of	drug	…	would	you	like	to	discuss	ways	to	adjust	your	own	treatment	…	would	you	like	to	discuss	side	effects	…	would	you	like	to	discuss	new	symptoms	that	have	developed	
-0.30 
-0.26 
-0.21 
-0.19 
	Item	responses	were	scored	as	0	(worst	option),	1	(intermediate,	e.g.	‘Not	sure’)	or	2	(best	option),	so	a	higher	score	should	indicate	better	disease	control.	Correlation	coefficients	are	expressed	as	Spearman	Rho	values	(p<0.01	in	all	cases).	*Question	items	included	in	the	IBD-Control-8	sub-score	
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Question	3e	of	the	IBD	Control	Questionnaire	(“In	the	past	two	weeks	did	you	feel	anxious	or	depressed	because	of	your	IBD?”)	correlated	with	the	Hospital	Anxiety	and	Depression	Scales	(HADS,	a	patient	reported	outcome	measure	of	anxiety	and	depression	[270]).		The	correlation	 coefficient	 for	 the	 anxiety	 sub-score	 was	 -0.57	 (p<0.001)	 and	 for	 the	depression	subscale	was	-0.62	(p<0.001).				Individual	item	scores	were	also	correlated	with	sub-scores	of	the	UK	IBDQ.		Question	3e	correlated	with	the	“emotional”	sub-score	of	the	UK	IBDQ	(r=-0.68,	P<0.001).		Question	3a	(“in	the	past	two	weeks	did	you	miss	any	planned	activity	because	of	IBD”)	correlated	with	the	“social”	sub-score	(r=-0.64,	p<0.001).		Question	3d	(“in	the	past	two	weeks	did	you	feel	lacking	in	energy”)	correlated	with	the	“systemic	sub-score	(r=-0.68,	p<0.001)	(figure	6).	
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Figure	6	Validity	of	Question	3e	of	the	IBD	Control	Questionnaire	(“In	the	past	two	weeks	have	you	
felt	anxious	or	depressed	because	of	your	IBD?”)	in	relation	to	the	Hospital	Anxiety	and	Depression	
sub-scores.	
	
 
 HADS(A)-Hospital	anxiety	and	depression	scales	anxiety	sub-score,	HADS(D)-Hospital	anxiety	and	depression	scales	depression	sub-score	
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5.2.4.2	 Validity	of	IBD	Control	summary	scores		IBD	Control	8	summary	scores	correlated	positively	with	UK-IBDQ	scores	(figure	7)	and	EQ-5D	scores	(the	EQ-5D	utility	index	score	and	EQ-5D	VAS	score,	generic	measures	of	health	status).		Correlation	coefficients	for	the	UK-IBDQ	scores	were	0.86	(all	IBD),	0.81	(Crohn’s	 disease)	 and	 0.90	 (ulcerative	 colitis).	 	 Correlation	 coefficients	 for	 the	 EQ-5D	utility	score	were	0.70	(all	IBD),	0.68	(Crohn’s	disease)	and	0.67	(ulcerative	colitis)	and	for	the	EQ-5D	VAS	score	were	0.68	(all	IBD),	0.65	(Crohn’s	disease)	and	0.71(ulcerative	colitis)	(table	9).		A	 linear	 regression	 model	 containing	 the	 eight	 items	 of	 the	 IBD	 Control	 8	 sub-score	accounted	for	75%	of	the	variance	in	UK-IBDQ	score	(r	square	0.747).		IBD	Control	scores	were	correlated	with	disease	activity	indices	(the	Harvey	Bradshaw	Index	for	Crohn’s	disease	and	Simple	Clinical	Colitis	Activity	Index	for	ulcerative	colitis).		Since	 a	 high	 IBD	 Control	 score	 indicates	 good	 disease	 control,	 it	 was	 predicted	 that	negative	 correlations	 with	 disease	 activity	 indices	 would	 exist.	 	 Strong	 negative	correlations	were	observed	(Crohn’s	disease:		IBD	Control	8	-0.68,	IBD	Control	VAS	-0.60,	UC:		IBD	Control	8	-0.72,	IBD	Control	VAS	-0.75,	p<0.01).		IBD	Control	scores	also	correlated	negatively	with	“current	disease	activity”	within	the	global	physician	assessment	(GPA).	 	Moderate	negative	correlations	were	observed	for	all	IBD	patients	(IBD	Control	8	-0.58,	IBD	Control	VAS	-0.58,	p<0.01)	and	patients	with	Crohn’s	disease	(IBD	Control	8	-0.45,	IBD	Control	VAS	-0.47,	p<0.01).		The	IBD	Control	
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summary	 scores	 correlated	 highly	 with	 GPA	 in	 patients	 with	 ulcerative	 colitis	 (IBD	Control	8	-0.67,	IBD	Control	VAS	-0.65,	p<0.01)	(table	9).	
 
Table	9	Construct	validity	of	IBD	Control	summary	scores:		Correlation	with	quality	of	life,	health	
status	and	disease	activity	at	baseline	assessment		
	
External	measure	
IBD-Control-8	 IBD-Control-VAS	All	 CD	 UC	 All	 CD	 UC	
UK-IBD-QoL	score	 0.86	 0.81	 0.90	 0.76	 0.65	 0.85		
EQ-5D	Utility	Score	 0.70	 0.68	 0.67	 0.52	 0.50	 0.58		
EQ-5D	VAS	 0.68	 0.65	 0.71	 0.70	 0.69	 0.71		
Physician	Global	Assessment	 -0.58	 -0.45	 -0.67	 -0.58	 -0.47	 -0.65		
Harvey	Bradshaw	Index	 …	 -0.68	 …	 …	 -0.60	 …		
Simple	 Clinical	 Colitis	 Activity	
Index	
…	 …	 -0.72	 …	 …	 -0.75	Correlation	expressed	as	Spearman	Rho	values	(p<0.01	in	all	cases)	
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Figure	7	Construct	validity	of	 IBD	Control	summary	scores:	 	correlation	with	quality	of	life	 (UK-
IBDQ)	
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The	 IBD	 Control	 Questionnaire	 possesses	 discriminant	 validity	 (the	 ability	 to	differentiate	between	clinically	different	patient	groups).		Patients	were	categorised	on	the	basis	of	disease	activity	score	with	the	global	physician	assessment	(remission,	mild,	moderate	and	severe).		Means	scores	were	significantly	different	between	these	groups	for	both	the	IBD	Control	8	and	IBD	Control	VAS	scores	(figure	8).		
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Figure	 8	 Discriminant	 validity	 of	 IBD	 Control	 summary	 scores	 in	 relation	 to	 global	 physician	
assessment	of	disease	activity.			
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Multiple	linear	regression	models	examined	whether	patient	factors	such	as	age,	gender	and	disease	type	were	independently	associated	with	IBD	Control	summary	scores	after	taking	disease	activity	into	account.		There	was	a	strong	association	between	IBD	Control	scores	 and	 disease	 activity	 indices,	 quality	 of	 life	 and	 physician	 global	 assessment.		However,	 no	 additional	 factors	 were	 found	 to	 be	 independently	 associated	 with	 IBD	Control	summary	scores.		
5.2.4.3	 Mapping	of	the	IBD	Control	8	sub-score	to	EQ-5D	utility	index		EQ-5D	health	states	were	converted	to	EQ-5D	single	index	values.		EQ-5D	index	values	are	 country	 specific	value	 sets	and	 allow	 the	 calculation	of	quality-adjusted	 life	years	(QALYs)[273].	 	 EQ-5D	 utility	 index	 values	 correlated	 with	 IBD-Control	 8	 sub-scores	(figure	9).				This	indicates	that	IBD	Control	scores	may	be	used	as	an	estimate	of	utility.		Therefore,	the	IBD-Control	questionnaire,	may	be	used	in	cost-utility	analysis.		
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Figure	9	Validity	of	the	IBD	Control	8	sub-score	in	relation	to	EQ-5D	utility	index	
	
 
 
 
5.2.5	 	 Development	of	the	IBD	Control	8	sub-score		5	categorical	items	were	excluded	from	the	IBD	Control	questionnaire	to	produce	the	IBD	Control	8	sub-score.		Firstly,	the	questionnaire’s	transition	question	(Q2	“Over	the	past	two	 weeks	 have	 your	 bowel	 symptoms	 been	 getting	 better,	 getting	 worse	 or	 not	changed”)	was	not	included	as	it	measures	change	in	IBD	symptom	control,	rather	than	current	IBD	control.		Secondly,	questions	4a	to	4d	had	weaker	correlations	with	the	IBD	Control	VAS	and	UK-IBDQ,	although	the	correlations	were	significant	(table	6).		These	question	items	did	not	contribute	significantly	 to	 the	performance	of	linear	regression	models	predicting	IBD	
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Control	VAS	and	UK-IBDQ.	 	Whilst	not	 included	 in	 the	 IBD	Control	8	sub-score,	 these	questions	did	provide	important	clinical	information	and	were	therefore	retained	in	the	overall	questionnaire.		Question	4d	relates	to	the	development	of	new	symptoms	over	the	preceding	 2	 weeks.	 	 The	 development	 of	 new	 symptoms	 is	 an	 important	 change	 to	capture	 and	may	 be	 used	 to	 prompt	 further	 clinical	 assessment.	 	 This	 question	 also	remained	in	the	questionnaire.		Questions	4a	to	4c	are	related	to	patient	reported	concerns	regarding	treatment.		Again,	this	is	important	 information	to	guide	clinical	management	and	a	positive	response	to	these	items	was	predictive	of	treatment	escalation.	 	67	patients	reported	no	treatment	concerns	(no	positive	response	to	questions	4a	to	4c).	 	Of	these	patients	5	(7.5%)	had	their	 treatment	 escalated.	 	 192	 patients	 recorded	 either	 a	 positive	 or	 indeterminate	response	to	one	or	more	of	the	treatment	concern	questions.		Of	these,	59	(30.7%)	had	their	treatment	escalated	(p<0.001	chi	squared	test;	OR	4.1,	95%	CI	1.7	to	9.8).		
	
5.2.6	 	 Responsiveness		Responsiveness	was	tested	in	the	138	patients	that	completed	serial	questionnaires	and	clinical	assessments.		The	mean	changes	in	IBD	Control	summary	scores	(IBD	Control	8	and	IBD	Control	VAS)	were	correlated	with	the	mean	change	in	scores	of	quality	of	life	and	disease	activity	measures.	 	Correlations	were	significant,	and	ranged	from	0.25	to	0.78.		The	strongest	correlations	were	with	changes	in	UK-IBDQ	score.		
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Responsiveness	statistics	were	also	calculated	(tables	10A	and	10B).		The	effect	size	(ES)	was	calculated	by	dividing	the	difference	in	mean	scores	(between	baseline	and	follow-up	 assessment)	 by	 the	 standard	 deviation	 of	 baseline	 scores.	 	 An	 effect	 size	 of	 0.2	 is	considered	small	where	as	an	effect	size	of	0.5	and	more	than	0.8	are	considered	medium	and	large	respectively[274].		The	effect	size	for	IBD	Control	8	was	1.44	in	patients	with	an	improvement	in	UK-IBDQ	of	more	than	10	points	and	0.99	in	patients	with	a	reduction	in	UK-IBDQ	score	of	more	than	10	points.		The	IBD	Control	8	also	showed	large	effect	size	in	patients	with	a	change	of	more	than	10	points	on	their	UK-IBDQ	score	at	follow	up	visit	(>10	point	improvement	ES	1.09,	>10	point	deterioration	ES	0.90).		When	change	in	clinical	condition	was	defined	by	a	change	of	one	or	more	points	on	the	global	physician	assessment,	the	IBD	Control	8	sub-score	was	also	found	to	be	responsive	(ES	range	from	0.76	to	1.14).		The	standardised	response	mean	(SRM)	was	also	calculated	by	dividing	the	difference	in	mean	scores	by	the	standard	deviation	of	change	in	scores.		The	SRM	for	IBD	Control	8	was	1.17	in	patients	with	a	positive	change	in	UK-IBDQ	score	of	more	than	10	points	and	1.27	in	patients	with	a	negative	change	in	UK-IBDQ	score	of	more	than	10	points.		Again,	SRM	values	were	also	large	for	the	IBD	Control	VAS	in	patients	with	a	more	than	10-point	change	in	UK-IBDQ	score	(>10	point	improvement	SRM	0.9,	>10	deterioration	SRM	0.95).		When	change	in	physician	global	assessment	score	was	used	to	define	change,	the	SRM	values	were	moderate	to	large.		Finally,	modified	standardised	response	means	(MSRM)	were	calculated	by	dividing	the	difference	 in	mean	 scores	 by	 the	 standard	 deviation	 of	 change	 in	 scores,	 in	 clinically	
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stable	patients.		A	clinically	stable	subgroup	of	patients	with	no	change	in	physician	global	assessment	and	with	a	stable	UK-IBDQ	score	(a	change	of	less	than	10	points	between	baseline	and	follow-up)	was	used	for	this	calculation.		The	MSRM	values	were	large	for	both	the	IBD	Control	8	and	IBD	Control	VAS,	whether	change	in	condition	was	defined	by	change	in	UK-IBDQ	score	or	physician	global	assessment.		
Table	10	Responsiveness	statistics	for	the	IBD	Control	summary	scores	
	
	(A)	 IBD-Control-8	sub-score		 	
Criteria	for	change	in	state	
	
	
n	
	
Mean	difference	(sd)	
	
ES	
	
SRM	
	
MSRM	
UK-IBD-QoL	
-	Improved	by	>10	points	
-	No	change	(+/-	10	points)	
-	Deteriorated	by	>10	points	
	19	63	26	
	+5.50	(4.69)	+0.13	(2.02)	-4.92	(3.88)	
	1.44	0.02	0.99	
	1.17	0.06	1.27	
	2.72	0.06	2.44	
Physician	Global	Assessment	
-	Improved	by	≥1	point	
-	No	change	
-	Deteriorated	by	≥1	point	
	27	32	27	
	+4.52	(5.56)	0.00	(3.72)	-3.32	(4.81)	
	1.08	0.00	0.76	
	0.81	0.00	0.69	
	1.22	0.00	0.89		
(B)	 IBD-Control-VAS			 	
Criteria	for	change	in	state	
	
	
n	
	
Mean	difference	(sd)	
	
ES	
	
SRM	
	
MSRM	
UK-IBD-QoL	
-	Improved	by	>10	points	
-	No	change	(+/-	10	points)	
-	Deteriorated	by	>10	points	
	19	63	26	
	+28.21	(31.33)	+0.84	(15.34)	-26.85	(28.20)	
	1.09	0.03	0.90	
	0.90	0.05	0.95	
	1.84	0.05	1.75	
Physician	Global	Assessment	
-	Improved	by	≥1	point	
-	No	change	
-	Deteriorated	by	≥1	point	
	27	32	27	
	+29.55	(31.78)	-0.56	(23.00)	-19.71	(30.53)	
	1.14	0.02	0.76	
	0.93	0.02	0.65	
	1.28	0.02	0.86		Effect	size	(ES)	=	Mean	difference	divided	by	the	SD	of	the	baseline	absolute	scores	for	the	group.	Standardised	Response	Mean	(SRM)	=	Mean	difference	divided	by	SD	of	the	difference	for	the	group.	Modified	SRM	(MSRM)	=	Mean	difference	for	the	group	divided	by	SD	of	the	difference	for	unchanged	patients.  
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5.2.7	 Sensitivity	 and	 specificity	 of	 the	 IBD	 Control	 Questionnaire	 to	 identify	
quiescent	patients		A	subgroup	of	patients	with	quiescent	IBD	at	baseline	assessment	were	identified	on	the	basis	of	 the	 following	criteria:	1)	clinical	remission	as	defined	by	2	or	more	measures	(SCCAI	 <4,	 HBI<5,	 UK-IBDQ	 ≥	 90	 points,	 physician	 global	 assessment	 rating	 of	“remission”),	2)	not	receiving	oral	corticosteroids,	therapeutic	liquid	diet,	induction	with	biological	 therapy	or	awaiting	surgery,	3)	“unchanged”	or	“improved”	response	to	the	transition	 question	 of	 the	 IBD	 Control	 questionnaire	 and	 4)	 no	 decision	 to	 escalate	treatment	at	clinical	review.		Of	these	80	patients,	none	required	subsequent	treatment	escalation.		Receiver	operating	characteristic	(ROC)	analysis	was	undertaken.	 	The	area	under	the	curve	was	0.90	for	the	IBD	Control	8	sub-score	(p<0.001)	and	0.86	for	the	IBD	Control	VAS	(p<0.001)	(figure	10).		This	indicates	both	summary	scores	to	be	highly	accurate	at	detecting	patients	with	quiescent	disease.		A	cut-off	value	for	the	IBD	Control	8	of	13	points	or	more	identified	quiescent	disease	status	with	67.5%	sensitivity	and	90.6%	specificity.		A	cut-off	value	for	the	IBD	Control	VAS	of	85	points	or	more,	identified	quiescent	disease	status	with	64.3%	sensitivity	and	90%	specificity.	Review	of	the	patients	falsely	categorised	to	have	quiescent	disease	(the	“false	positives”)	revealed	that	they	were	all	rated	as	in	remission	or	to	have	mildly	active	disease	on	the	global	physician	assessment.	 	None	of	the	patients	required	a	change	to	their	treatment	at	the	time	of	clinical	assessment.	
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Figure	10	Receiver	operating	characteristic	(ROC)	curves	for	the	IBD	Control	8	sub-score	and	the	
IBD	Control	VAS	
 
5.3	 	 Summary	
	The	IBD	Control	questionnaire	was	prospectively	validated	in	a	sample	of	299	patients	recruited	from	a	single	centre.		It	was	shown	to	have	favourable	psychometric	properties.		The	questionnaire	was	acceptable	to	patients,	as	demonstrated	by	high	completion	rates	(86.6%	patients	 completed	all	13	 items).	 	 It	 could	also	be	 completed	 rapidly	 (average	completion	 time	1	minute	15	[25	seconds])	demonstrating	 that	 it	 is	 feasible	 to	use	 in	routine	clinical	care.		
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Test-retest	reliability	was	present.		The	was	no	significant	difference	in	mean	scores	at	baseline	and	2	week	follow	up,	in	patients	with	stable	disease.		Intra	class	correlation	co-efficients	were	high	for	the	IBD	Control	8	sub-score	(0.97)	and	the	IBD	Control	VAS	(0.96)	indicating	excellent	reliability[275].		Internal	consistency,	another	measure	of	reliability,	was	determined	by	Cronbach	alpha	statistic[271].		Cronbach	alpha	statistics	were	favourable	(0.85	for	IBD	Control	8	and	0.86	for	IBD	Control	VAS).		The	IBD	Control	8	sub-score	and	IBD	VAS	scores	correlated	(r=0.78,	all	IBD),	again	indicating	internal	consistency.		Construct	 validity	was	 determined	 by	 correlating	 scores	with	 a	 variety	 of	 established	patient	reported	outcome	measures	and	disease	activity	indices.		Individual	item	scores	correlated	 with	 UK-IBDQ	 scores,	 EQ-5D	 scores	 and	 global	 physician	 assessment.		Summary	 scores	 (IBD	 Control	 8	 and	 IBD	 Control	 VAS)	 also	 correlated	 with	 these	established	scores	as	well	as	disease	activity	indices.				The	IBD	Control	8	and	IBD	Control	VAS	were	also	shown	to	possess	discriminant	validity,	that	is	an	ability	to	differentiate	between	different	health	states.		Mean	scores	of	patients	categorised	by	global	physician	assessment	(remission,	mild,	moderate	or	severe)	were	significantly	different.		EQ-5D	index	values	(which	can	be	used	to	determine	QALYs)	correlated	with	IBD	Control	8	scores.		Therefore,	the	IBD	Control	8	may	be	of	use	in	cost	utility	studies.		
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The	 IBD	Control	 8	 sub-score	was	 developed	 by	 removing	 categorical	 items	 related	 to	change	in	control,	rather	than	control	(Q2)	and	those	related	to	other	aspects	of	IBD	care	such	as	treatment	(Q4).		Although	significant,	these	item	scores	correlated	less	strongly	with	IBD	Control	VAS	and	established	measure	scores.		The	excluded	items	were	retained	in	the	questionnaire,	however,	as	they	captured	important	patient	reported	information.		A	range	of	responsiveness	statistics	were	calculated.		Clinical	change	was	determined	on	the	basis	of	a	change	in	UK-IBDQ	score	and	the	global	physician	assessment.	Effect	size,	standardised	 response	 mean	 and	 modified	 standardised	 response	 mean	 of	 the	 IBD	Control	8	and	IBD	Control	VAS	were	large.		This	indicated	the	instrument	to	be	responsive	to	clinical	change.		Finally,	the	sensitivity	and	specificity	of	the	IBD	Control	Questionnaire	to	detect	quiescent	disease	 state	 were	 determined.	 	 A	 subgroup	 of	 patients	 with	 quiescent	 disease	 was	identified	on	the	basis	of	multiple	criteria	and	receiver	operator	characteristic	analysis	was	performed.		A	cut	off	value	of	the	IBD	Control	8	of	13	identified	quiescent	patients	with	90.6%	specificity	and	a	cut	of	value	of	the	IBD	Control	VAS	of	85	identified	quiescent	patients	with	90%	specificity.		Therefore,	the	IBD	Control	Questionnaire	and	the	use	of	these	cut	off	values,	may	be	of	use	in	screening	for	patients	with	controlled	disease.							
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Chapter	6	Discussion	
	In	this	chapter	I	discuss	the	results	presented	in	chapters	4	and	5	and	how	they	relate	to	the	aim	of	this	study	to	develop	a	rapid	and	valid	patient	reported	measure	of	IBD	control.		I	 will	 also	 describe	 further	 validations	 and	 uses	 of	 the	 IBD	 Control	 since	 its	 original	development	 as	well	 as	 other	 PROMs	 that	 have	 since	 been	 developed	 for	 use	 in	 IBD.		Finally,	I	will	provide	my	thoughts	on	the	future	role	of	the	IBD	Control	Questionnaire	in	clinical	practice.		
6.1	 	 The	development	and	validation	of	the	IBD	Control	Questionnaire		The	 IBD	Control	Questionnaire	was	designed	with	an	aim	 to	measure	disease	 control	from	 the	patient’s	perspective.	 	Although	a	number	of	PROMs	existed,	none	had	been	incorporated	into	routine	clinical	care.		Therefore,	we	aimed	to	develop	and	then	robustly	validate,	a	concise,	rapid	tool	for	use	in	clinical	practice.		Literature	 review	 identified	 a	number	of	 disease	 specific	 instruments,	many	 of	which	measured	health	related	quality	of	life,	as	well	as	generic	measures	of	health	status.	 	A	number	of	common	themes	or	domains	emerged.		Patient	consultation	on	the	concept	of	“control”,	and	subsequent	thematic	analysis	of	qualitative	data	found	a	number	of	themes	that	could	be	mapped	to	the	overarching	domains	present	in	the	literature	review.		An	additional	domain	related	to	IBD	‘treatment	concerns’	emerged.		Given	the	similarity	of	patient	reported	themes	to	those	within	the	literature,	a	process	of	item	list	generation	followed	by	factor	analysis	and	item	reduction	was	not	performed.		Rather,	a	pragmatic	
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approach	was	adopted,	and	a	small	number	of	deliberately	broad	questions	were	chosen	to	represent	the	identified	themes.				Despite	 this	 approach,	 the	 data	 presented	 in	 chapter	 5	 confirm	 that	 the	 IBD	 Control	Questionnaire	 has	 favourable	 psychometric	 properties.	 	 The	 questionnaire	 has	 been	shown	 to	 be	 acceptable	 to	 patients	 by	 rapid	 average	 completion	 time	 and	 a	 high	questionnaire	completion	rate.	 	Acceptability	is	of	a	particularly	importance,	given	the	aim	for	it	to	become	established	in	day	to	day	clinical	care.		It	 is	 a	 reliable	 measure:	 	 it	 possesses	 internal	 consistency	 (Cronbach	 alpha	 statistic	between	 0.7	 and	 0.9	 for	 both	 summary	 scores)	 and	 test-retest	 reliability	 (intraclass	correlation	 coefficients	 0.97	 for	 IBD	 Control	 8	 and	 0.96	 for	 total	 IBD	 Control	 score).		Construct	validity	was	tested	by	 correlating	scores	with	a	 range	of	 existing	measures.	Scores	correlated	with	measures	of	disease	activity,	patient	reported	outcome	measures	and	physician	assessment.		It	was	also	shown	to	be	responsive	with	large	effect	sizes,	SRM	and	MSRM	values.	 	Cut	off	values	for	identifying	patients	with	controlled	disease	were	also	derived.		Defined	cut	off	values	were	able	to	predict	patients	with	quiescent	disease	with	90%	specificity.			This	comprehensive	psychometric	assessment	of	the	IBD	Control	Questionnaire	indicates	that	it	is	a	valid	tool	for	collecting	patient	reported	data	and	that	it	should	be	easy	to	use	in	routine	clinical	care.		The	strengths	of	this	study	include	the	participation	of	patients	in	 the	 development	 of	 the	 questionnaire,	 which	 is	 recommended	 by	 both	researchers[142]	 and	 the	 US	 Food	 and	 Drug	 Administration	 (FDA)[276].	 	 Its	 strong	psychometric	 properties	 and	 acceptability	 support	 its	 use	 in	 routine	 clinic	 care.	 	 The	
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definition	of	cut-off	values	to	detect	quiescent	disease	further	adds	to	the	benefit	of	using	the	IBD	Control	Questionnaire	in	clinical	practice.		The	use	of	these	cut	of	values	may	be	of	 particular	 use	 in	 settings	 such	 as	 self-management	 programmes,	 non-medical	 led	consultations	and	virtual	consultations.		The	comprehensive	validation	of	this	PROM	not	only	supports	its	use	in	clinical	care,	but	also	pragmatic	clinical	trials.		Furthermore,	IBD	Control	8	scores	correlated	with	EQ-5Q	utility	index	values.		Therefore,	IBD	Control	scores	could	possibly	be	converted	to	a	utility	estimate	and	may	also	be	used	in	health	economic	studies.		Limitations	of	this	study	include	the	self-selection	bias	associated	with	recruiting	patients	to	studies	involving	the	completion	of	questionnaires.	 	However,	the	study	sample	size	was	 large	and	contained	a	range	of	patient	demographics	and	clinical	 features.	 	 It	was	also	a	single	centre	study,	which	may	have	affected	the	ability	to	generalise	these	results	to	other	 subjects.	 	The	majority	of	patients	were	 recruited	 from	outpatient	areas	and	therefore,	only	around	1/5	of	patients	had	moderate	to	severe	disease.		Whilst	it	is	more	likely	 that	 the	 IBD	 Control	 Questionnaire	 will	 be	 used	 in	 outpatient	 or	 remote	management	settings,	further	validation	of	subgroups	such	as	patients	with	more	active	disease,	may	be	of	use.	 	Although	we	included	patients	with	a	history	of	prior	surgery,	case	 numbers	 were	 not	 sufficient	 to	 undertake	 detailed	 analysis	 of	 psychometric	properties	 for	 selected	 sub-groups	 such	 as	 stoma	 patients.	 	 Furthermore,	 the	identification	 of	 patients	 with	 more	 complex	 disease,	 such	 those	 with	 stricturing	 or	penetrating	phenotypes,	may	have	allowed	subgroup	analysis	to	ensure	the	validity	of	the	 IBD	 Control	 Questionnaire	 in	 these	 patient	 groups.	 	 These	 are	 areas	 for	 future	research.	
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6.2	 	 Further	validation	of	the	IBD	Control	Questionnaire		Since	we	published	the	original	paper	describing	the	IBD	Control	Questionnaire,	its	use	in	 routine	 clinical	 care	 has	 been	 reported.	 	 For	 example,	 it	 has	 been	 used	 to	 support	virtual	IBD	clinics	conducted	via	telephone.			Patients	were	invited	to	complete	and	return	a	questionnaire	via	the	post,	followed	by	a	telephone	follow	up.		59%	of	patients	returned	the	 questionnaire	 indicating	 that	 the	 IBD	 Control	 Questionnaire	 was	 acceptable	 to	patients	and	a	feasible	tool	for	use	in	virtual	clinical	contacts	[277].			Electronic	capture	of	the	PROM,	via	an	online	survey	tool,	patient	portal	or	‘apps’	could	further	improve	the	process.		Indeed,	the	IBD	Control	8	sub-score	of	the	IBD	Control	Questionnaire	has	been	tested	for	electronic	capture	in	a	large	web-based	survey.		The	eight	items	were	incorporated	into	the	IBD2020	survey,	an	online	survey	of	patient	satisfaction	and	experiences	of	IBD	care	across	the	UK	and	Europe.		818	UK	participants	completed	the	survey	and	of	these	85.7%	(701)	completed	all	items	of	the	IBD	Control	8.		This	high	completion	rate	suggests	the	questionnaire	is	an	acceptable	tool	for	patients	to	complete	within	an	electronic	survey	–	in	 this	 instance	 the	 IBD-Control-8	 was	 placed	 towards	 the	 end	 of	 a	 lengthy	 online	questionnaire.		Within	 the	 IBD2020	 survey,	 the	 questionnaire	 was	 reported	 to	 have	 favourable	psychometric	properties.		Internal	consistency	was	strong	(Cronbach	alpha	0.82).		Scores	correlated	negatively	with	patient	self-report	disease	activity	in	the	last	year	(-0.68)	and	with	 number	 of	 relapses	 (-0.61).	 	 Mean	 scores	 were	 significantly	 higher	 in	 patients	
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reporting	to	be	in	remission	than	those	reporting	active	disease.		Finally,	the	IBD	Control	8	score	was	confirmed	to	be	of	use	in	screening	for	patients	with	quiescent	disease.	 	A	score	of	more	than	13	points	detected	patients	 in	self-reported	remission	with	88.2%	specificity	and	patients	with	 self-reported	 remission	or	minimally	active	disease	with	95%	specificity[278].		These	data	confirm	the	IBD	Control	8	sub-score	to	be	an	acceptable	and	valid	tool	for	use	by	patients	electronically.		Other	validations,	 including	 for	use	 in	a	virtual	biologics	 clinic,	have	been	 reported	 in	abstract	form[279,	280].		
6.3	 	 Current	use	of	the	IBD	Control	Questionnaire		The	IBD	Registry	(ibdregistry.org.uk)	is	a	UK	wide	repository	of	anonymised	IBD	patient	data,	for	prospective	audit	and	research	purposes.		It	facilitates	local	data	collection	and	can	 provide	 reports	 on	 performance	 compared	 with	 aggregated	 data	 from	 all	contributing	centres.		It	aims	to	drive	improvement	in	clinical	are,	inform	commissioning	and	service	development,	improve	understanding	of	long-term	outcomes	and	to	support	IBD	research.		The	IBD	Control	Questionnaire	is	included	in	the	IBD	Registry	dataset	and,	therefore,	is	being	used	to	record	patient	reported	outcomes	at	a	number	of	centres	in	the	UK.	 	Although	 this	 currently	 requires	manual	 entry	of	questionnaire	 responses	by	clinicians	 into	 the	 relevant	 registry	 data	 fields,	 the	 IBD	Registry	 is	 seeking	 to	 roll-out	patient-facing	electronic	tools	to	capture	the	PROM	in	2019.		The	IBD	Control	Questionnaire	has	been	 integrated	 into	the	Salford	group’s	electronic	patient	portal,	“My	IBD	Portal”.		This	portal	is	a	web-based	system	designed	with	the	aim	
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to	facilitate	IBD	patient	engagement	with	the	management	of	their	condition.		It	provides	a	 range	 of	 facilities	 including	 access	 to	 information	 such	 as	 blood	 results,	 a	means	 to	contact	the	IBD	team	and	an	ability	to	record	patient	reported	information	[281].		Over	700	patients	are	now	using	the	My	IBD	Portal.		It	has	been	shown	to	have	resulted	in	high	satisfaction	 with	 self-management,	 improved	 perceived	 support	 and	 reduction	 in	outpatient	clinic	attendances.		The	portal	has	also	been	adapted	for	integration	with	the	IBD	Registry	[282].		“TrueColours	ulcerative	colitis”	(TCUC),	developed	by	researchers	in	Oxford,	is	another	web-based	programme	and	is	designed	for	use	by	patients	with	ulcerative	colitis.		This	too,	includes	a	number	of	questionnaires	including	the	IBD	Control	8.	 	A	pilot	study	to	determine	 feasibility	 and	 usability	 has	 been	 performed.	 	 95%	of	 patients	 adhered	 to	completing	the	IBD	Control	8	questionnaire	on	a	fortnightly	basis	as	directed[283].		This	study	 illustrated	 that	 patients	 could	 sustain	 electronic	 collection	 of	 PROMs	 at	 regular	(fortnightly)	 intervals	 over	 time,	 although	 we	 would	 advocate	 less	 frequent	administration	of	the	questionnaire	in	routine	practice	to	avoid	survey	fatigue.		The	need	for	value	driven	healthcare	 is	 increasingly	recognised.	 	Measuring	outcomes	that	matter	 to	patients	 is	 important	when	determining	value[284].	 	A	 standard	 set	of	patient-centred	outcome	measures	has	been	developed	through	the	collaboration	of	the	Oxford	 Academic	 Research	 Network	 with	 the	 International	 Consortium	 of	 Health	Outcomes	Measurement	(ICHOM).		It	was	developed	with	the	aim	to	allow	standardised	capture	of	patient	reported	data	in	routine	clinical	practice,	thus	facilitating	value	driven	care.			The	set	of	outcome	measures	
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includes	a	number	of	measures	set	out	within	domains	that	encompass	all	aspects	of	IBD.		The	IBD	Control	8	items	have	been	recommended	for	inclusion	in	the	IBD	Standard	Set,	providing	a	tool	to	capture	data	in	the	domain	related	to	“symptoms,	function	and	quality	of	 life”[285].	 	 A	 number	 of	 translations	 of	 the	 tool	 are	 in	 progress	 for	 non-English	speaking	settings.	IBD	Control	8	has	been	used	to	capture	patient	reported	data	in	a	number	of	published	abstracts[286-288]		
6.4	 	 Other	IBD	related	PROMs	designed	for	use	in	routine	clinical	care	
	During	the	period	of	my	research,	there	was	increasing	interest	in	the	collection	of	patient	reported	 outcome	 data	 in	 order	 to	 facilitate	 routine	 clinical	 care.	 	 For	 example,	 the	Crohn’s	and	Ulcerative	Colitis	Questionnaire	(CUCQ)	is	a	new	measure	of	quality	of	life	and	was	designed	to	be	suitable	for	use	by	outpatients	with	stable	or	mildly	active	disease	as	well	as	patients	with	severe	disease[289].			The	CUCQ-32	is	a	32-item	questionnaire	and	was	developed	along	conventional	lines	as	a	disease-specific	quality	of	life	instrument.		An	overall	score	is	obtained	by	adding	item	scores	together,	with	potential	scores	ranging	from	0-272.		A	high	score	is	associated	with	poor	quality	of	life.		Comprehensive	psychometric	evaluation	was	performed.		The	PROM	was	shown	to	be	reliable:		Internal	consistency	was	present	(Cronbach	alpha	0.88)	and	test-retest	 reliability	was	 also	 proven.	 	 Scores	 correlated	well	 with	 EQ-5D	 and	 SF-12	scores.		Responsiveness	was	also	very	good	(responsiveness	ratio	0.85,	SRM	0.99).		
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Stepwise	regression	analysis	was	performed	in	order	to	identify	items	for	inclusion	in	a	short	version	of	the	questionnaire	(as	a	short	version	might	be	appropriate	for	routine	settings).		8	items	were	identified	that	explained	95%	of	variance	and	these	were	used	to	form	 the	 CUCQ-8	 questionnaire.	 	 This	 shortened	 version	 retained	 favourable	psychometric	properties[289].		The	CUCQ	has	also	been	validated	separately	in	patients	with	severe	IBD.		The	32-item	questionnaire	 again	 had	 good	 psychometric	 properties	 in	 this	 context.	 	 Stepwise	regression	was	performed,	 and	 in	 this	patient	group	16	 items	accounted	 for	>95%	of	variance[290].		A	 simple	 rapid	 measure	 of	 patient	 reported	 symptom	 control,	 the	 IBD-10,	 has	 been	reported	 [291].	 	This	did	not	undergo	 formal	developmental	processes,	or	qualitative	work	with	patients.		The	PROM	was	administered	by	asking	patients	to	verbally	report	how	their	IBD	was,	on	a	scale	of	0	to	10	(with	10	being	the	best).		Scores	were	shown	to	correlate	strongly	with	disease	activity	indices	(Harvey	Bradshaw	Index	 for	 Crohn’s	 disease	 and	 SCCAI	 for	 ulcerative	 colitis).	 	 IBD-10	 scores	were	 also	statistically	different	between	remission	and	active	disease	groups.	 	Receiver	operator	characteristics	analysis	identified	IBD-10	cut	off	values	for	the	detection	of	remission.		A	score	 of	 7	or	more	was	 reported	 to	 predict	 remission	with	 90%	 sensitivity	 and	 75%	specificity.		IBD-10	scores	 correlated	with	 CRP	 in	 patients	with	ulcerative	 colitis,	 but	 not	 Crohn’s	disease.	 	Patients	 requiring	 treatment	escalation	had	 significantly	 lower	 IBD-10	score	
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than	those	that	did	not.		A	cut	off	value	of	<7	was	reported	to	predict	treatment	escalation	with	81%	sensitivity	and	70%	specificity[291].			
6.5	 	 The	role	of	IBD	specific	PROMs	in	clinical	trials		There	is	increased	recognition	that	patient	reported	outcome	measures	should	be	used	to	measure	end	points	 in	clinical	trials.	 	The	Food	and	Drug	Administration	(FDA)	has	published	guidance	on	the	development	and	use	of	PROMs	in	clinical	 trials	 to	support	labelling	 claims[276].	 	 In	 contrast	 to	 traditional	 disease	 activity	 indices,	 it	 was	recommended	 that	 patient	 reported	 outcome	 measures	 used	 in	 clinical	 trials	 were	validated.	 	 The	 FDA	 recommended	 comprehensive	 validation	 and	 at	 the	 time	 of	 the	guidance	no	IBD	specific	PROM	met	these	stringent	requirements[292].		Although	there	are	 a	 number	 of	 IBD	 specific	 outcome	measures	 described	 in	 the	 literature,	 a	 recent	systematic	review	has	identified	that	very	few	have	been	adequately	validated[293].		The	development	and	validation	of	instruments	to	standards	required	by	the	FDA	was	predicted	to	be	a	lengthy	and	complex	process.		It	was	therefore	proposed	that	interim	PROMs	be	designed	in	order	to	allow	clinical	trials	and	therefore	medicines	development	to	 continue.	 	 It	 was	 also	 proposed	 that	 these	 interim	 PROMs	 be	 used	 to	 measure	symptoms,	rather	than	outcomes,	and	to	be	based	on	patient	reported	components	of	existing	disease	activity	indices[292].		PRO-2	and	PRO-3	measures	have	been	derived	from	patient	reported	components	of	the	CDAI	disease	activity	index.		Optimal	cut	off	values	of	individual	diary	card	items	to	detect	remission	(CDAI	score	<150)	were	obtained	and	this	generated	a	2	item	(PRO-2)	and	3	
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item	 (PRO-3)	measure.	 	 These	measures	 were	 subsequently	 tested.	 	 They	 correlated	moderately	with	CDAI	scores	and	were	also	shown	to	be	responsive	[294].		Patient	 reported	 components	 of	 the	Mayo	Clinic	 Score	 (MCS)	 have	 also	 been	 used	 to	generate	interim	patient	reported	measures	for	use	in	ulcerative	colitis.		Again,	receiver	operator	characteristics	were	used	to	determine	cut	off	values	for	the	identification	of	remission	(as	defined	by	a	Mayo	endoscopic	score	of	0	or	less	than/equal	to	1).		Patient	reported	items	alone	or	in	combination	(PRO-2)	were	assessed.		A	PRO	containing	both	patient	reported	items	(rectal	bleeding	and	stool	frequency)	performed	better	than	either	item	in	isolation.		The	area	under	the	curve	(AUC)	was	0.80	for	remission	defined	by	a	Mayo	endoscopy	score	of	0	and	0.90	for	remission	defined	by	a	score	of	less	than/equal	to	1.		Single	patient	reported	items,	items	in	combination	(PRO	-2)	and	PROs	combined	with	endoscopic	score	were	able	 to	differentiate	a	 treatment	effect	 in	most	scenarios.		However,	it	was	noted	that	using	PRO	scores	without	endoscopy	scores	resulted	in	higher	placebo	rates	of	remission[295].		The	Crohn’s	disease	patient	reported	outcomes	signs	and	symptoms	(CD-PRO/SS)	diary	was	 developed	 in	 line	 with	 FDA	 recommendations.	 	 This	 comprehensive	 instrument	consists	 of	 6	 modules:	 	 bowel	 signs	 and	 symptoms,	 abdominal	 symptoms,	 systemic	symptoms,	 coping	 mechanisms,	 daily	 life	 impact	 and	 emotional	 impact.	 	 The	 first	 2	modules,	 bowel	 signs	 and	 symptoms	 and	 abdominal	 symptoms	 form	 the	 CD-PRO/SS	measure.	 	 It	 has	 been	 shown	 to	 have	 adequate	 internal	 consistency	 (Cronbach	 alpha	statistic	0.74	 for	bowel	signs	and	symptoms	and	0.67	 for	abdominal	symptoms).	 	Test	retest	reliability	was	also	evident	with	intraclass	correlation	coefficients	of	more	than	0.8	for	both	modules[296].			
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	The	 Ulcerative	 Colitis	 Patient	 reported	 outcome	 (UC-PRO)	 instrument	 has	 also	 been	designed	in	line	with	the	FDA	guidelines.		Again,	this	consists	of	6	modules.		Modules	1	(bowel	 signs	 and	 symptoms)	 and	 2	 (abdominal	 symptoms)	 form	 the	 UC-PRO/SS	instrument.		The	remaining	modules	are	systemic	symptoms,	coping	strategies,	daily	life	impact	and	emotional	 impact.	 	The	 instrument	was	designed	 for	use	by	patients	with	moderate	to	severe	ulcerative	colitis	in	the	outpatient	setting.		Internal	consistency	of	the	UC-PRO/SS	was	adequate.		Cronbach	alpha	statistic	was	0.8	for	bowel	signs	and	symptoms	and	0.66	for	abdominal	signs.		Test	re-test	reliability	was	evident	with	high	intraclass	correlation	coefficients	(ICC)	for	bowel	signs	and	symptoms	and	 abdominal	 signs	 (0.81,	 0.71).	 	 UC-PRO/SS	 scores	 correlated	 with	 a	 number	 of	established	measures	such	as	the	IBDQ,	partial	Mayo	score	and	a	global	physician	score.		Scores	were	also	able	to	differential	between	groups	based	on	partial	Mayo	score,	global	patient	assessment	and	global	physician	assessment[297].		Both	the	CD-PRO	and	UC-PRO	are	valid	patient	reported	outcome	measures	with	similar	measurement	properties.		They	have	been	designed	in	line	with	FDA	recommendations.		
6.6	 	 Future	areas	for	development	
	Given	the	aim	of	this	research	was	to	develop	at	PROM	for	use	in	routine	care,	future	plans	relate	to	the	establishment	of	its	role	day	to	day	clinical	practice.		With	increasing	burden	on	 outpatient	 clinics	 as	 well	 as	 the	 changing	 needs	 of	 IBD	 patients,	 novel	 means	 to	interact	with	our	patients	are	required.	
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	The	IBD	Control	Questionnaire	could	be	used	to	record	patient	reported	data	for	virtual	reviews	such	as	annual	review	of	biological	treatments.	 	The	ability	of	the	IBD	Control	Questionnaire	 to	predict	patients	 in	 remission	with	high	 specificity,	makes	 it	 an	 ideal	measure	 for	 use	 in	 self-management	 programmes	 for	 patients	 with	 stable	 disease;	particularly	given	recent	advances	in	the	provision	of	web-based	tools	such	as	My	IBD	Portal.		Practical	 applications	 of	 the	 instrument	 to	 support	 care	 decision-making	 should	 be	tested,	ideally	in	a	future	randomised-controlled	trial.		However,	the	adoption	of	PROMs	into	healthcare	is	progressing	rapidly	and	often	without	formal	experimental	testing	of	the	benefits	and	harms	of	using	individual	instruments	for	defined	applications.		At	this	point,	we	do	not	advocate	that	the	IBD	Control	should	be	used	as	a	‘device’	to	influence	self-care	 decisions	 by	 patients.	 	 Rather,	 its	 adoption	 may	 allow	 services	 to	 gather	information	that	compliments	their	existing	assessments.		The	proposed	application	is	for	IBD	Control	to	serve	as	a	‘screening’	tool	–	with	particular	utility	 in	 identifying	patients	who	are	satisfied	that	 their	condition	 is	controlled.	 	 It	 is,	therefore,	ideally	placed	for	the	management	of	patients	in	remission,	possibly	within	a	self-management	programme.	 	Patients	with	sub-optimal	scores,	or	 ‘flags’	 that	suggest	concerns,	 would	 require	 further	 assessment.	 	 In	 the	 emerging	 Digital	 and	 e-Health	landscape	it	is	envisaged	that	the	IBD-Control	could	serve	as	an	initial	screening	tool,	with	supplemental	 questions,	 additional	 PROM	 completion,	 or	 a	 formal	 clinical	 review	triggered	for	patients	indicating	sub-optimal	control.			Hence,	a	patient	with	good	control	(e.g.	 IBD-Control-8	 score	 of	 15)	would	 not	 be	 required	 to	 complete	 additional	 items,	
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whereas	a	patient	indicating	sub-optimal	control	(e.g.	IBD-Contro-8	score	of	10)	might	be	prompted	 to	answer	an	 individualised	set	of	questions	relevant	 to	 their	disease.	 	At	 a	simple	level,	the	supplementary	questions	could	be	akin	to	the	interim	‘PRO-2’	approach	–	 with	 a	 set	 of	 specific	 symptom	 questions	 for	 Crohn’s	 disease,	 ulcerative	 colitis	 or	tailored	 to	 the	 individual	 patient.	 	 These	 are	 all	 areas	 for	 future	 research	 and	development.	 	 The	 developers	 of	 the	 TrueColoursUC	 app	 have	 piloted	 this	 approach,	using	IBD-Control-8	as	the	overall	measure	of	health	status,	combined	with	patient-facing	question	items	for	a	set	of	specific	symptoms	for	ulcerative	colitis.		It	 is	 acknowledged	 that	 IBD	 Control	 scores	 may	 be	 affected	 by	 the	 co-existence	 of	symptoms	related	to	irritable	bowel	syndrome	(IBS).		The	proportion	of	IBD	patients	in	biochemical	 remission	 with	 IBS	 symptoms	 has	 been	 reported	 to	 be	 between	 19.8-27.7%[298].		However,	any	new	symptoms,	regardless	of	cause,	should	prompt	further	review	 in	 order	 to	 exclude	 active	 inflammation.	 	 If	 entering	 patients	 into	 a	 self-management	 programme	 involving	 the	 use	 of	 the	 IBD	 Control	 Questionnaire,	 there	should	be	clear	criteria	for	inclusion.		It	may	be	the	case	that	patients	with	significant	IBS	symptoms	are	not	be	suitable	for	remote	follow	up	in	view	of	the	unpredictability	of	their	symptoms.	 	 Alternatively,	 the	 cut-off	 value	 for	 triggering	 addition	 measures,	 clinical	review	 etc	 could	 be	 adjusted	 for	 patients	with	 IBS.	 	 Again,	 this	 is	 an	 area	 for	 further	investigation.		There	is	also	a	subset	of	patients	with	IBD	who	normalise	their	symptoms	and	“put	up	with”	quite	significant	 issues	such	as	high	stool	 frequency.	 	Again,	 this	may	affect	 IBD	Control	scores.		However,	as	mentioned	above,	if	a	patient	is	adequately	screened	before	being	considered	for	remote	management,	the	risk	of	this,	too,	should	be	minimised.	
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	The	primary	goal	of	this	research	was	to	produce	a	PROM	that	was	tailored	to	the	specific	needs	of	busy,	routine	IBD	services	–	a	simple,	generic	tool	that	would	be	suited	to	all	patients	in	the	service,	regardless	of	disease	type,	severity	or	a	particular	set	of	dominant	symptoms.	 	 	The	questionnaire	 is	meant	 to	 rapidly	establish	a	global	sense	of	disease	control,	 and	 to	 highlight	 specific	 ‘flags’	 for	 attention	 by	 healthcare	 staff.	 By	 explicitly	excluding	a	‘check	list’	of	individual	gastrointestinal	symptoms,	our	generically-focused	development	process	avoided	the	replication	of	a	traditional	HRQoL	instrument.		We	did	not	 seek	 to	 re-invent	 the	 IBD-Q	and	were	aware	 that	 a	number	of	other	groups	were	producing	updated	versions	of	traditional	instruments	for	IBD.					The	endorsement	of	 IBD	Control	by	 ICHOM,	which	 included	 international	 experts	and	strong	patient	representation,	suggests	this	generic	simplicity	has	a	broad	appeal.			It	will	be	interesting	in	future	to	determine	how	the	growing	range	of	PROMs	can	be	used	to	support	patient	care.		Future	strategies	might	deploy	PROMs	individually	to	support	care,	use	specific	combinations	of	different	instruments	according	to	patient	characteristics,	or	use	 electronic	 tools	 to	 capture	 a	 tailored	 sequence	 of	 PROMs	 according	 to	 a	 patient’s	current	 status	 (e.g.	 IBD-Control	 +/-	 individualized	 symptom	 survey	 tool	 +/-	 clinical	assessment).					
	
6.7	 	 Summary	
	The	IBD	Control	Questionnaire	has	been	shown	to	be	a	valid	patient	reported	outcome	measure	of	disease	control	from	the	patient	perspective.		Its	brevity	and	simple	generic	content	make	it	suited	to	use	in	routine	care.		Independent	groups	have	shown	it	can	be	
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deployed	into	routine	settings,	online	electronic	surveys,	patient-facing	apps	and	patient	portals.		Its	 inclusion	 in	 the	 data	 submission	 framework	 for	 the	 UK	 IBD	 Registry	 has	 allowed	feasibility	to	be	established	for	capturing	the	relevant	items	as	part	of	hospital	uploads	to	NHS-Digital’s	 audit	 platform.	 	 This	 sets	 the	 scene	 for	 future	 electronic	 capture.		International	 endorsement	 by	 ICHOM,	 and	 ongoing	 translations	 into	 other	 languages,	suggest	 that	 this	 research	 has	 produced	 an	 instrument	 of	 genuine	 value	 to	 the	international	IBD	community	and	filled	a	gap	in	existing	PROMs.													
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